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Abstract 
Background: Normal human urothelial (NHU) cells can be induced to 
differentiate by inhibition of the EGFR pathway and activation of PPARγ, 
which is considered a master transcription factor (TF) for urothelium. 
Activation of PPARγ results in up-regulation of downstream TFs, amongst 
which ELF3 was identified as the most up-regulated by microarray. Different 
phenotypes of NHU cells (proliferating or differentiated) assessed by 
expression of differentiation markers were found to resemble different types of 
urothelial cancer (UC) cell lines. The hypothesis is that the differentiation status 
in UC cell lines reflects cancer evolution pathways, which are selected to be 
either retained or lost, and define regulatory pathways that UC cells use for 
growth.  
Aim: To understand the role of TFs in regulating urothelial differentiation and 
pathways regulating proliferation in different UC cell lines. 
Results: Knockdown of ELF3 in NHU cells affected the expression of ELF3. 
Functional study also showed an essential role of ELF3 in maintaining an 
effective barrier. Evidence suggested that PPARγ was coincidentally knocked 
down in some cells. Over-expression of ELF3 demonstrated increased ELF3 
transcript, but had no effect on phenotype. 
A UC cell line (5637) with low expression of differentiation markers resembled 
non-differentiated NHU cells. When maintained in medium without serum, 
5637 cells relied on PPARγ and GSK3β pathways for growth. By contrast, 
UMUC9 cells, which resembled differentiated NHU cells, could not proliferate 
when serum or other growth factors were removed.  
NHU cells or UC cells maintained in different media (± serum) demonstrated 
different expressing patterns of PPARγ transcripts and protein isoforms.  
Conclusions: ELF3 was important in regulating differentiation in NHU cells 
and may affect the expression of other TFs, but was not alone sufficient to 
initiate the differentiation programme. The phenotype and signalling pathways 
associated with proliferation in 5637 and UMUC9 cells may have implications 
for different subtypes of Muscle Invasive Bladder Cancer (MIBC). 
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Chapter 1 Introduction 
1.1 The urothelium 
Urothelium is the epithelial lining of the urinary tract including the renal pelvis, 
the ureters, the bladder and the proximal part of the urethra. It consists of three 
different layers of cells: the basal, intermediate and superficial cells, according 
to their morphology and localisation relative to the basement membrane 
(reviewed by Lewis, 2000). The superficial cells in human bladder are larger 
with occasional binuclear cells compared to the intermediate or basal layer cells. 
The intermediate layer consists of more than one layer of cells smaller than the 
superficial cells. Cells in the basal layer are cuboidal and attached to basement 
membrane (Jost et al., 1989). 
Mammalian studies suggested urothelial cells in the healthy adult mouse 
bladder have an extremely slow turnover, with about one cell cycle per year 
(Jost, 1986, 1989; Jost and Potten, 1986). During development, the cell cycle time 
decreases to approximately 30h (Jost, 1989; Jost and Potten, 1986). This 
relatively quiescent state in adult mice can be interrupted by infection or injury 
to the urothelium (de Boer et al., 1994; Mysorekar et al., 2002), which stimulated 
regenerative repair as early as 4 h, as determined from the proliferation rate 
using BrdU assay. Reinstatement of the quiescent state of mouse urothelium 
was observed within 24h followed by differentiation of superficial layer cells 
(de Boer et al., 1994). A recent study in murine urothelium demonstrated that 
some basal cells showed significantly increased proliferation one day post E.coli 
inoculation, which reduced significantly two days after infection and returned 
to non-significant amount compared to control (Colopy et al., 2014).  
Human urothelium demonstrated the same features, showing rare Ki67 positive 
cells in adult tissue (Varley et al., 2005). When wounded in vitro, cell cultures 
also demonstrated ability to recover rapidly (Fleming et al., 2012; Varley et al., 
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2005). The features of mitotically quiescence and rapidly repair of urothelium 
facilitated the tissue to perform its function, which is to stably act as a urinary 
barrier. 
1.2 Differentiation of urothelium and the related features 
Early study of rat urothelium described superficial cells as localised at the 
interface of urothelial tissue and the lumen in contact with urine (Hicks, 1965) 
and providing a functional barrier to prevent underlying tissue exposure to 
substances in the urine (Negrete et al., 1996). Superficial cells are highly 
specialised through differentiation to provide the barrier function. Gene 
products expressed in urothelium indicating specialisation have been 
investigated by several studies to understand their roles in urothelial function. 
The most frequently studied markers are summarised in the following sections. 
1.2.1 Uroplakins (UPK) 
The highly differentiated superficial cells display multiple plaques of 
asymmetric unit membrane (AUM) present on the apical cell surface. The 
plaques consist of thousands of subunits of conserved membrane proteins 
called uroplakins. Uroplakins (UPK1a, UPK1b, UPK2 and UPK3a/b) are 
urothelial differentiation-restricted markers that have been demonstrated to 
have important roles in the urinary barrier (reviewed by Jenkins and Woolf, 
2007). Four major UPKs were assembled as heterodimers (UPK1a/UPK2 and 
UPK1b/UPK3a) at the first stage and then altered their conformation to form 
16nm particles essential for the formation of multiple plaques (reviewed by Wu 
et al., 2009). Transcript expression of UPK1a, UPK2 and UPK3 are urothelium-
specific in humans, whereas UPK1b was also detectable in non-urothelial 
tissues (Olsburgh et al., 2003).  
Crucial roles of uroplakin proteins in urinary tract development and urothelial 
differentiation have been investigated in transgenic mice. UPK2 and UPK3a 
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knockout mice demonstrated a hyperplastic urothelium with atypical 
superficial cells (Aboushwareb et al., 2009). The apical cells were much smaller 
in UPK2 knockout mice and the uroplakin particles were lost in these cells 
(Kong et al., 2004). Expression of other UPK proteins was reduced in UPK2 KO 
mice (Kong et al., 2004). Studies of UPK3a deficient mice demonstrated much 
smaller apical cells with microvilli instead of normal rugged cells (Hu et al., 
2002). The knockout of UPK3a led to a compensatory overexpression of UPK1b 
transcript and abnormal distribution of UPK1b protein (Hu et al., 2000). 
Features like large plaques and rugged surface of urothelium were lost in 
UPK3a knock out mice (Hu et al., 2000). Diminished ability to retain methylene 
blue dye was detected, showing compromised function of urothelium in the 
UPK3a knock out mice (Hu et al., 2000). Water permeability was significantly 
higher in UPK3a KO mice than in wild type mice, whereas permeability to urea 
did not change significantly, suggesting that UPK proteins contribute to 
maintaining the functional barrier (Hu et al., 2002).  
1.2.2 Tight junctions (TJ) 
Tight junctions are intercellular junctions localised to the lateral membranes 
and composed of multiprotein complexes including zonula occludens (ZO) 
proteins, occluding and claudins. The claudin family consists of 24 distinct 
members (reviewed by Ichikawa-Tomikawa et al., 2011). The differential 
expression of claudins by different tissues indicates different roles of individual 
claudin proteins. For example, in human urothelium, claudin 3 is expressed at 
the “kissing point” of the terminal superficial junction, whereas claudins 4, 5 or 
7 are localised to intercellular borders (Varley et al., 2006). Transgenic mice and 
shRNA knock down have been used to investigate the physiological roles of 
specific claudin proteins. 
Research on physiological roles of claudin proteins has demonstrated 
involvement of claudins in salt homeostasis. Knockout of claudin (CLDN) 7 in 
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mice resulted in chronic dehydration characterised by wrinkled skin and death 
within 12 days (Tatum et al., 2010). Other study on functions of claudin proteins 
also suggested their role. Using small interfering RNA targeting claudin 1-4 and 
7 in Madin-Darby canine kidney (MDCK) cells showed that knock down of 
claudin 4 or 7 led to an elevated permeability of Na+ (Hou et al., 2006).  
The essential role of CLDN4 has also been demonstrated by a recent in vivo 
study, showing urothelial hyperplasia and hydronephrosis in CLDN4 knock 
out mice, which reduced their survival rate to 59% compared to 94% of CLDN4 
(+/-) mice. The tight junction structure was not affected, but compensatory 
enhanced expression of CLDN3 and CLDN8 at renal medullary regions and 
CLDN7 accumulation at ureters was also observed (Fujita et al., 2012). This 
finding suggested complementary expression of other claudin proteins, and 
may indicate the interrelationship of different claudins.  
1.2.3 Cytokeratins (CK) 
CKs are the intermediate filaments of epithelial cells and constitute a major 
cytoskeletal component. There are at least 20 isoforms of CKs. The expression 
and distribution of CK isoforms is epithelial type-specific and related to 
proliferation and differentiation of the tissue (reviewed by Southgate et al., 
1999). In urothelium in vivo, CK13 was expressed cytoskeletally in the 
intermediate and basal layer of urothelium (Varley et al., 2004b). CK20 was only 
present in the superficial layer and considered a terminal differentiation marker 
(Harnden et al., 1995; Varley et al., 2004b).  
1.3 Models to investigate the urothelium 
1.3.1 Normal human urothelial (NHU) cells 
To investigate mechanisms of maintaining barrier function and response to 
injury or infection in vivo, NHU cells may be cultured using in vitro models. 
These cells may be isolated from surgical specimens during surgery and 
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collected with patient consent. Intact sheets of healthy human urothelial tissue 
were detached from stroma after incubation in EDTA buffer, which enables the 
urothelial cells to be separated and proliferate as adherent monolayer cultures 
to form cell lines with a finite lifespan in culture. The cultures demonstrate a 
basal/intermediate-like proliferative phenotype showing expression of Ki67 as a 
proliferation marker when maintained in Keratinocyte serum-free medium 
(KSFM) with growth supplements (Southgate et al., 1994; Southgate et al., 2002). 
NHU cells have been shown to be able to proliferate in vitro and have potential 
to be used in replacement of defective urothelium as regenerative tissue. A 
characterisation of normal human urothelial cells suggested that continued 
subculture may result in culture senescence, which may affect the quality of 
transplantation, and should be taken into consideration before transplantation 
(Chamorro et al., 2015). 
1.3.2 Differentiation of NHU cells in vitro 
In order to understand the regulation of development and differentiation of 
urothelium in vivo, two methods were developed to induce a differentiated 
phenotype from proliferating NHU cells cultured in vitro. One method is to add 
troglitazone (TZ) and PD153035 (PD) to proliferating cells, and induce the 
expression of terminal differentiation genes (Varley et al., 2006; Varley et al., 
2004a; Varley et al., 2004b). However, by addition of TZ/PD, the urothelial cells 
differentiated but did not form a functional barrier, thus a further biomimetic in 
vitro model was developed involving subculture of NHU cells in medium 
supplemented with serum (5% ABS) and physiological (2 mM) calcium 
(ABS/Ca2+) (Cross et al., 2005). ABS/Ca2+ induced NHU cells were able to form 
three morphologically distinguished layers with high transepithelial electrical 
resistance (TER) (>3000 Ω•cm2), which represented a functional barrier and 
simulated the in vivo tissue (Cross et al., 2005). These two methods together 
(TZ/PD and ABS/Ca2+) facilitate the study of urothelial development and 
differentiation in vitro. 
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In cell culture, NHU cells adapt a non-differentiated basal-like phenotype 
characterised by a switch to an EGFR autocrine-driven rapidly proliferating 
CK14+ CK13- phenotype. When induced to differentiate using TZ/PD, NHU 
cells were switched to a transitional (CK13+, CK14-) differentiated phenotype 
(Varley et al., 2004b).  
The in vitro induced differentiated NHU cells can be used to study the effect of 
altered expression of differentiation-associated proteins on other 
differentiation-related features. For example, change of claudin protein 
expression was shown to have affected the expression of other tight junction 
proteins such as the ZO proteins. Knock down of CLDN3 in NHU cells reduced 
the protein expression of ZO1α+, which was more prevalent in differentiated 
NHU cells than untreated or stratified cells. These CLDN3 knock down cells 
also demonstrated a significantly impaired ability to form a functional barrier 
assessed by transepithelial electrical resistance (Smith et al., 2015).  
1.3.3 Other models to study urothelium 
In order to investigate essential roles of specific genes in vivo, transgenic knock 
out mice have been utilised. Knock out of terminal differentiation-associated 
genes like UPK2 or UPK3a demonstrated loss of function of bladder urothelium 
such as non-voiding contractions and increased residual volume of urine 
(Aboushwareb et al., 2009), whereas knock out of CLDN7 affected the function 
of urothelium and other tissues and led to death (Tatum et al., 2010). Knock 
outs of differentiation-associated transcription factors like ELF3 and GRHL3 
have been generated to understand their essential roles. ELF3 knock out mice 
demonstrated dysmorphogenesis of intestinal epithelium and 30% lethality (Ng 
et al., 2002). Knock out of GRHL3 significantly affected the morphology of 
murine bladder and resulted in the decreased expression of urothelial 
differentiation-related downstream genes (Yu et al., 2009). 
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Furthermore, a UPK2 promoter transgenic mouse demonstrating expression of 
UPK2 proteins in the suprabasal layer of urothelium was established (Lin et al., 
1995). The expression of UPK2 protein in mouse is confined to urothelial tissue, 
which enabled the transgenic urothelium-specific expression of other genes 
such as oncogenes or inactivated tumour suppressor genes, resulting in 
advantage for studies of bladder tumorigenesis (reviewed by Wu et al., 2009). 
1.4 Transcription factors that regulate differentiation 
To develop from embryo to mature functional tissue, cells are regulated to 
differentiate. This differentiation process is mediated by transcription factors, 
demonstrating different roles in controlling distinct stages of development and 
differentiation. 
1.4.1 Regulated differentiation by PPARγ  
The thiazolidinediones (TZDs) are regarded as potent insulin sensitizers used 
for treatment of type II diabetes. To understand the mechanism of reversed 
insulin resistance by TZDs, nuclear receptor PPARγ was investigated 
extensively as a nuclear transcription factor stimulated by TZDs. Most studies 
about PPARγ mainly focused on its role in adipogenesis in the literature. It 
mainly acts as a central transcription factor in adipocyte differentiation, as 
knock out of PPARγ in embryonic stem cells by homologous recombination 
inhibited adipogenesis and abolished the expression of adipocyte-related 
differentiation markers after induction of differentiation (Rosen et al., 1999). 
Other studies regarding the characterisation of PPARγ transcript variants and 
isoforms will be discussed in Chapter 5. 
However, the role of PPARγ in normal urothelial differentiation was not 
greatly investigated until recently. It was shown that in urothelial 
differentiation, activating PPARγ by TZ (troglitazone, one of the TZD drugs) in 
proliferating NHU cells significantly induced the expression of differentiation-
associated genes, including the UPKs, CLDN3 and CK20. Co-inhibition of the 
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autocrine EGFR signalling pathway using PD153035 was also required to de-
phosphorylate PPARγ for its transcriptional activity (Varley et al., 2006; Varley 
and Southgate, 2008; Varley et al., 2004a; Varley et al., 2004b). PPARγ 
antagonists GW9662 or T0070907 reduced the TZ/PD induced transcript or 
protein expression of differentiation-associated markers (Varley et al., 2006; 
Varley et al., 2004a), which verified the essential role of PPARγ in regulating 
urothelial differentiation.  
Among the differentiation-associated marker genes, PPREs (peroxisome 
proliferator response elements) were found within 2kb upstream of the 
transcriptional start site of CLDN3 and CLDN7 promoters (Varley et al., 2006). 
However, no PPRE sites were found in 1000bp upstream of CK13 or CK20 
promoters (Varley et al., 2004b). Similarly, no PPRE could be observed in many 
of the UPK genes, and the up-regulation of UPK genes was delayed till 96h 
(Varley et al., 2004a), suggesting that the induction process by PPARγ ligands 
was indirect and mediated via intermediary transcription factors. 
1.4.2 Other transcription factors related to urothelial 
differentiation 
The role of IRF1 (Interferon regulatory factor 1) and FOXA1 (forkhead box A1) 
as differentiation-associated intermediate transcription factors in human 
urothelium was identified by human GeneChip® array (Varley et al., 2009). 
Binding sites for both IRF1 and FOXA1 were found present in UPK1b, UPK2 
and UPK3a. Also, high affinity PPRE site was reported in promoters of IRF1 
and FOXA1 (Varley et al., 2009). In TZ/PD induced NHU cells, expression of 
IRF1 and FOXA1 was massively up-regulated and was inhibited by PPARγ 
inhibitors. Knock down of IRF1 and FOXA1 using siRNA reduced the protein 
expression of CLDN3 and CK13, which indicated the essential role of IRF1 and 
FOXA1 in regulating urothelial differentiation (Varley et al., 2009). 
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Expression of FOXA1 protein (alternative name: hepatocyte nuclear factor 3α, 
endodermal marker) was observed on mouse embryonic day 16, postnatal day 
1 and adult mice bladder, whereas increased protein expression of UPK (broad-
spectrum) was detectable concurrently (Oottamasathien et al., 2007). This result 
also suggested an essential role of FOXA1 in urothelium development and 
regulation of differentiation.  
Transgenic mice studies demonstrated the role of GRHL3 (grainyhead-like 3) in 
mouse embryonic development. GRHL3 was highly expressed in superficial 
cells in mouse urothelium on embryonic days E16.5 and E18.5 (Yu et al., 2009), 
which were the time of developing the unique urothelial apical plasma 
membrane (Erman et al., 2006) constituted mainly by uroplakins. The GRHL3 
knockout mouse demonstrated smaller and rounded immature superficial cells. 
Protein expression of uroplakins in these abnormal cells was extremely low. 
GRHL3 knockout mice developed defective bladders lacking expression of 
CK18, CK20 and UPK proteins on E18.5 compared to control. These findings 
suggested the involvement of GRHL3 in urothelial differentiation and 
development (Yu et al., 2009).  UPK2, a terminal differentiation marker, was 
regulated by GRHL3 directly by binding to its promoter, which also indicating 
a potential role of GRHL3 as an intermediate transcription factor involved in 
mouse urothelial development (Yu et al., 2009) .  
1.5 Urothelial cancer (UC) 
1.5.1 Incidence and causes of bladder cancer 
Bladder cancer is the 7th most common cancer in the UK, and the 4th most 
common cancer in British men (Cancer Research UK). About 60% of bladder 
cancer cases occurred in more developed countries worldwide, particularly in 
Europe and North America in 2012 (Ferlay et al., 2015).  
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Urothelium is the tissue in direct contact with excreted chemicals and waste 
products in the urine that may cause cancer, and therefore is at risk to develop 
cancer. It was reviewed that urothelial cancer risk increased in occupations 
involving exposures to polycyclic aromatic hydrocarbons (Bolt, 2014). Lifetime 
arsenic exposure, smoking and secondhand smoke also increased the odds ratio 
of developing bladder cancer (Ferreccio et al., 2013). Exposure to mineral oils, 
diesel engine exhaust, painting material and aromatic amines was reported to 
be the main causes for bladder cancer in the UK (Rushton et al., 2012). 
1.5.2 Brief classification of bladder cancer 
When classifying urothelial cancer according to the extent of differentiation, the 
morphology can be divided into low grade (well differentiated) and high grade 
(poorly differentiated) cancers. This is known as the grade of bladder cancer. 
According to the extent of cancer cell invasion into the detrusor muscle layer of 
the bladder wall, urothelial cancer is generally divided into non-muscle 
invasive cancers and muscle invasive bladder cancers (MIBC). In non-muscle 
invasive cancer, the cancer is confined in the urothelium or lamina propria and 
did not invade muscle layer. By contrast, MIBC indicate that the cancer cells 
have invaded into the muscle layer of the bladder wall. This is the staging scale 
of bladder cancer that indicates the extent of invasion and whether cancer cells 
have spread. MIBC was reported to have poor prognosis, which is about 50% 
survival rate 5 years after diagnosis (Cancer Research UK). 
In well-differentiated tumours, deletions on chromosome 9 were detected, 
whereas poorly differentiated muscle invasive cancers were shown to have loss 
of tumour suppressor genes (p53 and PTEN, for example) and mutation of 
oncogenes. Carcinoma in situ (CIS) characterised as non-muscle invasive, 
poorly differentiated cancers was more complicated. Loss of p53 was highly 
agreed in reports regarding characterization of CIS, but deletion of 
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chromosome 9 only occurred in some of the cases (reviewed by Goebell and 
Knowles, 2010).  
Recent reports based on large scale transcriptomic studies suggested that 
muscle invasive bladder cancers can be sub-classified the same as breast cancers, 
with basal and luminal subtypes (Damrauer et al., 2014). Expression of 
differentiation-associated genes was detectable in the luminal subtype of MIBC, 
but not in the basal subtype, which demonstrated expression of basal markers 
such as CK5/6 (Choi et al., 2014). These recent findings have improved the long 
standing views about pathways in bladder cancer and broke the boundary 
between the stage and grade system (reviewed by Knowles and Hurst, 2015).  
1.5.3 Urothelial cancer cell lines 
In vitro cultured urothelial cancer cell lines have been established and 
characterised. The stage and grade of UC cell lines and known mutations in cell 
lines provided background information for following studies. The bladder 
cancer cell lines used in this study are listed in Chapter 2. Bladder cancer cell 
lines showing different grade of differentiation can be used to investigate the 
relationship of differentiation and expression of other differentiation-associated 
genes to indicate the role of such genes in different cancer cell lines. One 
example was to knock down the expression of FOXA1 in well differentiated 
bladder cancer RT4 cell line and over-express it in poorly differentiated T24 cell 
line (DeGraff et al., 2012). The results suggested the alteration of FOXA1 protein 
expression increased the cell proliferation in RT4 cells and inhibited both the 
proliferation and the cell invasion in T24 cells (DeGraff et al., 2012). 
It is also suggested that autocrine growth signalling was present in some of the 
bladder cancer cell lines, as conditioned medium of human bladder cancer cell 
line 5637 has been used as medium for culture of growth factor-dependent 
hematopoietic cells. 5637 cells showed secretion of cytokines like granulocyte 
colony-stimulating factor, granulocyte-macrophage colony-stimulating factor 
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and interleukin 1β (Quentmeier et al., 1997). An autocrine mechanism has also 
been found in NHU cells and was regulated by EGFR pathway (Varley et al., 
2005). Signalling pathways indicating proliferation of bladder cancer cell lines 
like EGFR pathway will be explored in Chapter 4. 
1.6 Thesis aims 
The aims of this thesis were to investigate the role of transcription factors in 
regulating urothelial differentiation and pathways regulating proliferation in 
different UC cell lines.  
The objectives for the individual chapters were: 
 To understand the role of ELF3 as a candidate transcription factor 
identified by microarray in normal urothelial cell differentiation 
(Chapter 3). 
 To investigate the relationship between the phenotype of UC cells and 
the signalling pathways they depend on for growth (Chapter 4). 
 To explore whether the expression of different PPARγ transcripts was 
associated with urothelial differentiation or urothelial cancer and 
investigate the expression and localisation of PPARγ isoforms (Chapter 
5).  
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Chapter 2 Materials and Methods 
2.1 General 
Experiments were performed in the Jack Birch Unit in Department of Biology at 
the University of York. The Technology Facility in Department of Biology also 
provided support and usage of equipment. 
Pipette tips (Starlab), Eppendorf tubes (Starlab) and glassware (Scientific 
Laboratory Supplies; SLS) were either purchased sterile and free of nuclease, or 
were autoclaved for 20 min at 121 °C. Stock solutions were prepared as 
described in the buffer recipe and listed in Appendix section 7.4. Tissue culture 
solutions were prepared in ELGA water from an ELGA water purification 
system (Veolia Water Technologies) and autoclaved, the other solutions were 
made with deionised water (dH2O). All chemicals were obtained from Sigma 
Aldrich unless otherwise stated. Information of suppliers was listed in 
Appendix section 7.5. 
2.2 Tissue culture 
2.2.1 Establishment and maintenance of NHU cells as finite cell 
lines 
Tissue samples were collected from patients undergoing urology-related 
surgical procedures for non-cancer conditions with appropriate consent and 
approvals from NHS and local Research Ethics Committees. Each individual 
sample was allocated with the laboratory sample number (Y number, see Table 
2.2.1) showing research-related information. Procedures were followed as 
described in detail (Southgate et al., 1994; Southgate et al., 2002). After 
detachment from stroma, urothelial cells were maintained and passaged for a 
finite life span in Keratinocyte serum-free medium (KSFM; Life Technologies) 
with supplements, which are recombinant EGF (rEGF; Life Technologies) and 
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bovine pituitary extract (BPE, Life Technologies) at final concentrations of 5 
ng/mL and 50 ng/mL, respectively, and addition of  30 ng/mL cholera toxin 
(CT). This complete KSFM (KSFMc) was pre-warmed at 37 °C and then utilised 
to nourish the cells. Cells were cultured either in 25 cm2, 75 cm2 flasks or in 6 cm 
dishes (Primaria™; SLS), and maintained in HERAcell™ 240 incubator (Thermo 
Scientific) at 37 °C in a humidified atmosphere of 5%  CO2 in air. Cells used in 
this thesis were provided as growing or cryopreserved cell cultures by Ros 
Duke (technician, JBU).  
Sample ID number Type of operation Tissue Type Age/ sex 
Y588 nephrectomy ureter ? 
Y1116 ? ureter 64/F 
Y1156 nephrectomy ureter 72/F 
Y1194 nephrectomy ureter 52/M 
Y1233 nephrectomy ureter 81/F 
Y1236 nephrectomy ureter 57/M 
Y1289 nephrectomy ureter  54/F 
Y1436 renal transplant ureter 73/F 
Y1441 renal transplant ureter 57/M 
Y1456 renal transplant ureter 78/F 
Y1529 nephrectomy ureter 68/F 
Table 2.2.1 List of Y numbers and sample information for all NHU cell lines used in this 
thesis. Question marks indicate unclear information. 
NHU cells were cultivated as a monolayer until just confluent. After incubation 
with 0.1% EDTA for 5-10 min at 37 °C, cells were able to separate from each 
other. When they visibly dissociated from each other, depending on the size of 
flasks or dishes, EDTA was replaced with 0.25% (w/v) 0.5-1 mL of trypsin 
versene (TV) and incubated with cells for 1-2 min until detachment. Cells were 
then harvested into 5 mL of KSFMc with 1.5mg/mL of trypsin inhibitor (TI). 
After centrifugation, cells were resuspended in KSFMc before seeding on to 
fresh flasks or dishes. Cells at passages between 2 to 5 were utilised. 
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Cells were counted as single cell solution using haemocytometer (VWR) before 
seeding. Each chamber was filled with 10 µL of cell suspension. Cells were 
counted in a 5X5 grid and averaged with another chamber. The average 
number multiplied by 104 was the total number of cells in 1 mL of medium. 
2.2.2 In vitro induction of differentiation in NHU cells 
The differentiated phenotype was obtained with two methods (described as 
TZ/PD (Troglitazone and PD153035) and ABS/Ca2+ in section 1.1). When 
reaching 70-80% confluent, cultures were stimulated with 1 μM TZ and 1 μM 
PD153035 (Calbiochem) (Varley et al., 2004a). If the treatment is more than 24h, 
medium with addition of TZ is to be replaced with vehicle control (DMSO) 24h 
later, whereas medium with PD153035 is to be renewed every 2 or 3 days.  
The other method was generated by Cross et al (Cross et al., 2005), which was 
to treat cultures with serum and physiological concentration of calcium 
(ABS/Ca2+). Cultures from passage 1-3 were maintained in KSFMc with 5% 
adult bovine serum (ABS, pretested batch; Harlan Sera-Lab) for 5 days, and 
then harvested and seeded in flasks, dishes or Snapwell™ membranes, 
depending on the following experiments. On the next day, 180 µL of 1 M CaCl2 
was added into 100 mL of KSFMc to provide 2 mM final calcium concentration. 
2.2.3 Maintenance and subculture of established UC cell lines 
Urothelial bladder cancer cell lines were cultured in either Dulbecco’s Modified 
Eagle’s Medium (DMEM; Life Technologies) or Roswell Park Memorial 
Institute 1640 medium (RPMI 1640; Life Technologies) supplemented with FBS 
(Harlan Sera-Lab) and 1% L-glutamine. Table 2.2.2 displays information of UC 
cell lines and the standard growth medium used for UC cell lines utilised in the 
study. Cells were sub-cultured when about confluent. When passaging UC cells, 
no trypsin inhibitor was required as the serum was able to neutralise the effect 
of trypsin. Cells were seeded in Corning® flasks or dishes and maintained in 
humidified incubators in 10% CO2 in air (DMEM) or 5% CO2 in air (RPMI).  
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Mycoplasma spp testing was performed. Cells were seeded on 12 well slides at 
4-5x104 cells /mL for 50 µL each well, immersed with growth medium 2-4 h 
later and left overnight. Slides were washed with PBS and fixed by Methanol 
/Acetone (1:1) for 30 s before drying in the air. Slides were incubated with 0.1 
µg/mL Hoechst 33258 diluted in PBS-Tween 20 (0.25%, W/V) for 5 min and 
rinsed with distilled water. After air dry, slides were mounted with antifade, 
covered using coverslip and sealed using nail polish. Nuclei were visualised as 
described in section 2.6.6. No extra nuclear DNA staining should be observed 
otherwise cultures are potentially contaminated with Mycoplasma spp. 
Genotyping was performed when cell line first arrived. Table 2.2.2 displays 
general information of cell lines utilised in the study.   
Cell line Bladder cancer grade Ref. Standard medium 
5637 Grade II carcinoma (Fogh et al., 1977) RPMI (5% FBS) 
UMUC9 Grade III carcinoma (Grossman et al., 1988) DMEM (10% FBS) 
SD48 Carcinoma N/A DMEM (10% FBS) 
RT4 Grade I carcinoma (Rigby and Franks, 1970) 
DMEM:RPMI 
(50:50) (5% FBS) 
RT112 Grade II carcinoma (Marshall et al., 1977) 
DMEM:RPMI 
(50:50)  (5% FBS) 
T24 Grade III carcinoma (Marshall et al., 1977) 
DMEM:RPMI 
(50:50) (5% FBS) 
Table 2.2.2 Urothelial cancer cell lines and their standard growth medium. 
2.2.4 Adapting cancer cells to KSFM for growth 
Cancer cells were cultivated in medium with serum, which contains many 
kinds of growth factors. The serum in the medium of the cells grown in was 
gradually reduced by increasing the percentage of KSFM and decreasing the 
percentage of standard medium (Table 2.2.2 for information regarding different 
cell lines). After the medium was changed to 100% KSFM, cells were sub-
cultured to check whether they could survive. If the cells were not able to 
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proliferate in KSFM without serum, the cell line was considered as not 
adaptable. Information regarding whether cell lines were adaptable is listed in 
Chapter 4. 
2.3 Growth assay (Alamar Blue® assay) 
Alamar Blue® (AbD Serotec) is an oxidation-reduction indicator that fluoresces 
and changes colour when growth medium was metabolised by growing cells. 
Continued growth produced a reduction environment that results in the 
alteration of indicator from oxidized (non-fluorescent, blue) form to reduced 
(fluorescent, red) form. The growth rate of cells then can be calculated from 
data generated using absorbance-based (or fluorescence-based) instrument. For 
absorbance-based instrument, absorbance is monitored at 570 nm and 630 nm. 
No cell control was included by adding Alamar Blue® to empty wells for 
calculation of reduction rate. 
Cells were seeded at 2x104/mL (seeding in 200 μL) on 96 well plates and 
maintained for 7-9 days. Alamar Blue® was diluted 1/10 on day of assay with 
growth medium. Medium of cultures was removed and replaced with diluted 
reagent. Cells were incubated in 200 μL Alamar Blue® solution for 4 h. 
Absorbance at 570 nm and 630 nm was measured, after which the value was 
calculated and converted to the reduction rate of Alamar Blue®. 
2.4 Transepithelial electrical resistance (TER)  
Differentiated cultures were established using the ABS/Ca2+ method and seeded 
onto the upper chamber (growth area 1.12 cm2) of Snapwell™ membranes 
(Corning) with 6 replicates of 5x105 cells /well. Voltage and current recording 
microelectrodes were placed in both the apical and basal chambers and 
connected to the voltage-current clamp. The voltage and current were recorded 
and shown as the resistance across the cell sheets by an Electronic Voltage Ohm 
Meter (EVOM). Medium was renewed with fresh KSFMc containing 5% ABS 
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and 2 mM calcium after the first reading and on alternative days. Once the 
measurements stabilised, a single scratch about 250 µm wide was generated in 
the culture using a 20 μL pipette tip. TER readings were recorded regularly 
until the value returned to and stabilised around its initial number. 
2.5 Analysis of gene expression 
2.5.1 RNA isolation and DNA digestion 
Cultures were washed with phosphate buffered saline (PBS) before addition of 
Trizol®. After 5 min of incubation on a rocking platform, cultures with Trizol® 
solution were scraped and transferred to a sterile centrifuge tube pre-treated 
with 0.1% diethylpyrocarbonate (DEPC) water (diluted in ELGA water) 
overnight. RNA lysates could be stored at -80 °C and remain stable. On day of 
extraction, RNA lysates were thawed completely and left at ambient 
temperature for 5 min. 0.2 mL chloroform was added to the solution per mL of 
Trizol®. Following 15 sec of vortex and a further 2-3 min incubation, RNA was 
extracted and remained solubilised in the upper aqueous phase. After 15 min of 
12000 g centrifugation at 4 °C, the aqueous phase was aspirated to a fresh tube. 
0.5 mL of isopropanol (Fisher Scientific) per mL of Trizol® was utilised to 
precipitate the RNA before centrifugation for 20 min at 12000 g at 4 °C and 
washed with 70% ethanol. After a 5 min 7500 g centrifugation, 70% ethanol 
wash was repeated to improve the quality of RNA isolated. The final pellet 
generated by centrifugation for 5 min at 7500 g was solubilised in 30 µL of 
DEPC treated water.  RNA was stored at -80 °C. 
DNA-easy AMBION kit (Ambion) was utilised to remove any residual DNA. 1 
μL of DNase I (2 U/μL) was added to 30 μL of obtained RNA with DNAse 1 
buffer at a 1/10 dilution. After 30 min incubation at 37 °C, the enzyme was 
inactivated and precipitated. Solution containing RNA was transferred to a 
fresh tube. 40 U of RNAseOUT (Life Technologies) was added to the solution to 
prevent any degradation of RNA. 
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The quality of RNA was inspected by NanoDrop™ spectrophotometry. The 
ratio of absorbance at 260 nm and 280 nm would indicate whether the sample 
had any protein or phenol contamination, whereas 260/230 ratio indicates the 
possibility of salt contamination. High quality RNA shows a ratio of 260/280 
between 1.9 to 2.1 and a 260/230 ratio between 1.5 to 2.0. 
2.5.2 Synthesis of complementary DNA (cDNA) 
Random hexamers (50 ng) were added to equal amount of RNA samples and 
diluted with DEPC water to obtain same volume. The mixture was incubated at 
65 °C for 10 min to anneal the primers before 0.1 M DTT and 10 mM dNTP were 
added. Equal amounts of RNA from each sample were converted to cDNA by 
addition of 50 U SuperScript II (Life Technologies) per 20 µL and incubated at 
25 °C for 10 min and 42 °C for 50 min. Samples without addition of SuperScript 
II were included as RT negative control to confirm no DNA contamination was 
present. Inactivation of reverse transcription was achieved by heating the 
mixture for 15 min at 70 °C.  
2.5.3 Reverse Transcription Polymerase Chain Reaction (RTPCR) 
RTPCR was performed using GoTaq™ polymerase (Promega) in T100 thermal 
cycler (BioRad). A typical 20 µL reaction contains 4 µL of GoTaq buffer, 0.4 µL 
of dNTP (10mM), 2 µL of MgCl2, 2 µL of each forward and reverse primer 
(10µM) and 0.1 µL of GoTaq polymerase. For positive control, human genome 
DNA was added to the reaction, whereas only nuclease-free water was added 
to the no-template negative control. 
PCR cycle was initialised at 95 °C for 2 min for denaturation, followed by 
generally 25 to 30 cycles of amplification depending on the abundance of the 
templates. The amplification cycle was 30 sec denaturation at 95 °C, 30 sec 
annealing at 45-65 °C depending on the optimal temperature of primers and 
extension at 72 °C. The time for extension depends on the length of product, for 
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about 1 min every 1 kb DNA amplified. A final extension period was added 
after the amplification cycles for 7 min followed by incubation at 4 °C. 
2.5.4 Gel electrophoresis 
1%-2% (w/v) electrophoresis grade agarose was solubilised in 1x Tris Borate 
EDTA (TBE) microwave boiled buffer and cooled to around 50 °C before 
addition of 1/10000 SYBR® safe stain (Life Technologies). Gels were poured and 
allowed to set. PCR products and Hyperladder IV ladder (Bioline) were 
electrophoresed on the gel covered by 1x TBE for required amount of time to 
separate the bands. DNA products were visualised under UV light. Gel images 
were captured using a Gene Genius Gel Imaging System (Syngene) with 
GeneSnapTM software.  
2.5.5 RT quantitative PCR (RTQPCR) 
Complementary DNA samples were diluted 1 in 5 with nuclease-free water to a 
final volume of 100 µL. 5 µL of cDNA was mixed with 300 nM sense and 
antisense primers and Fast SYBR® Green (Life Technologies) QPCR master mix. 
PCR reactions were completed on 96 well plates on StepOnePlus™ QPCR 
System (Applied Biosystems) using the comparative quantification method 
(Schmittgen and Livak, 2008). GAPDH was utilised as an internal control. 
Negative controls using RT negative samples as template were included.  
2.5.6 Primer design and list of primers 
Transcript information of specific genes was obtained from the Ensembl 
Genome Browser (http://www.ensembl.org/index.html). Primers for RT-PCR 
were designed using Primer Blast (http://www.ncbi.nlm.nih.gov/tools/primer-
blast/). Primers for RTQPCR were either available in the lab or were designed 
using Primer Express® Software (Applied Biosystems) and purchased (Eurofins). 
The best ten sets of primers were checked for specificity using Primer Blast. 
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Primers were designed to target all known transcript variants unless otherwise 
stated. 
To demonstrate the efficiency of the primer sets, newly designed primers for 
RTQPCR were tested using gradient diluted (1:10, 1:100 and 1:1000) positive 
control cDNA samples. The standard curves of primers showing a slope of -
3.333 and R2 of 0.999 within ±10% deviation were consider as acceptable for 
further study. Figures demonstrating standard curves of newly designed 
acceptable primers are displayed in Appendix 7.2. Primer sets used in the thesis 
are listed in Table 2.5.1. 
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Gene  Sequence 
ELF3 q Fwd TCAACGAGGGCCTCATGAA 
ELF3 q Rev TCGGAGCGCAGGAACTTG 
GRHL3 q Fwd TGGAATATGAGACGGACCTCACT 
GRHL3 q Rev CAGACACGTTCTCTGTCAGGAATT 
IRF1 q Fwd CTGTCGCCATGTGCTGTCA 
IRF1 q Rev TGTCCGGCACAACTTCCA 
FOXA1 q Fwd CAAGAGTTGCTTGACCGAAAGTT 
FOXA1 q Rev TGTTCCCAGGGCCATCTGT 
CLDN7 q Fwd GCAGTGGCAGATGAGCTCCTAT 
CLDN7 q Rev CATCCACAGCCCCTTGTACA 
GAPDH q Fwd CAAGGTCATCCATGACAACTTTG 
GAPDH q Rev GGGCCATCCACAGTCTTCTG 
UPK3A q Fwd CGGAGGCATGATCGTCATC 
UPK3A q Rev CAGCAAAACCCACAAGTAGAAAGA 
GATA3 q Fwd CTTCCCCAAGAACAGCTCGTT 
GATA3 q Rev GGCTCAGGGAGGACATGTGT 
KLF5 q Fwd TTCTTCCACAACAGGCCACTT 
KLF5 q Rev TCTGCTTGTCTATCTGGACTTCCA 
PPARG2 q Fwd TCCTTCACTGATACACTGTCTGC 
PPARG2 q Rev CAAAGGAGTGGGAGTGGTCT 
UPK2 q Fwd CAGTGCCTCACCTTCCAACA 
UPK2 q Rev TGGTAAAATGGGAGGAAAGTCAA 
KRT20 q Fwd CAAAAAGGAGCATCAGGAGGAA 
KRT20 q Rev CAACCTCCACATTGACAGTGTTG 
GAPDH Fwd ACCCAGAAGACTGTGGATGG 
GAPDH Rev TTCTAGACGGCAGGTCAGGT 
ELF3 Fwd GTTCATCCGGGACATCCTC 
ELF3 Rev GCTCAGCTTCTCGTAGGTC 
Table 2.5.1 List of primers. Primers utilised for RTQPCR are marked with a q. Forward and 
reverse primers were noted as Fwd and Rev, respectively. Sequence of the primers was 
displayed from 5’ to 3’. 
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2.6 Analysis of protein expression 
2.6.1 Protein lysis and quantification 
Cultures were washed with cold PBS and scrape-harvested with Sodium 
dodecyl sulphate (SDS) lysis buffer containing 2 mg/mL DTT and 0.2% Protease 
Inhibitor Cocktail Set 3 (Calbiochem). Lysates were collected into chilled 
microfuge tubes on ice and sonicated with Branson Sonifier probe set to 25 W, 
40% amplitude for 2x 10 sec bursts with 10 sec rest between bursts. Cell lysates 
were left on ice for 30 min and centrifuged for 30 min at 18000 g at 4 °C. 
Solutions were transferred to a fresh chilled tube and stored at -80 °C. Samples 
used for Polyacrylamide gel electrophoresis (PAGE) were whole cell lysates 
unless otherwise noted. 
Protein lysates were diluted 1/12.5 in water. Samples were added to 96 well 
plates as duplicates and mixed with 200 μL of Coomassie protein assay reagent 
(Pierce). Absorbance of samples was measured using a MRX II 96-well plate 
spectrophotometer (Dynex). Bovine serum albumin (BSA, Pierce) standard 
curve was generated every time with standard proteins diluted to different 
concentrations (0-1000 μg/mL). The concentration of protein samples was 
calculated according to the standard curve generated by standard proteins. 
Equal amounts of proteins from each sample were mixed with 4X Lithium 
Dodecyl Sulphate (LDS, Life Technologies) sample buffer and 10X reducing 
agent (Life Technologies).  
2.6.2 Cytoskeletal extraction (CSK extraction) 
This method was used to separate soluble proteins from DNA-bound proteins 
by using different concentrations of salt with 0.1% Triton X-100 or DNA 
digestion enzyme. The experiment included in this thesis used a 0.5 M NaCl 
solution. The buffer recipe was originally obtained from (Ainscough et al., 2007) 
and is listed in Appendix 7.4. 
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Three dishes of cells were required for each time point /treatment. One dish was 
used for whole cell extraction, and two dishes for salt extraction followed by 
DNA digestion (DNase I or buffer as digestion control). 
Buffer used was chilled on ice before harvesting cells. For 6 cm dishes, 3 mL of 
ice-cold 0.1 M NaCl solution without TX-100 was used to wash the cells. 1 mL 
0.1 M NaCl buffer without TX-100 was supplemented with 1 mM PMSF, 0.1 
mM ATP, 1 mM DTT and 0.2% Protease Inhibitor Cocktail Set 3 (Calbiochem) to 
each dish, after which the cells were scrape-harvested. Cell suspension was 
centrifuged at 10,000 g for 1 min. Supernatant was discarded.  
For salt and DNA enzyme extraction samples, the pellet was flipped gently and 
resuspended using 100 μL of 0.5 M NaCl with 0.1% TX-100 and other 
supplements added from previous step. The suspension was incubated for 5 
min on ice, mixed by pipetting gently and centrifuged at 4 °C for 1 min at 
10,000 g. The supernatant was retained as the soluble protein sample. The pellet 
was washed in 1X DNase I buffer without breaking apart. After centrifuging 
briefly as previous steps, the pellet was resuspended in either 50 μL 1X DNase I 
buffer without enzyme or 50 μL 1X DNase I buffer with 1:30 DNase I (Qiagen). 
The cell suspension was incubated at 37 °C for 30 min. 
For whole cell extract, pellet was resuspended in 50 μL 0.1M NaCl solution 
without TX-100. Microfuge tubes were left on ice until processing of next step. 
After DNA enzyme digestion, 50 μL of 1 M NaCl with 0.2% TX-100 was added 
to the suspension and mixed by pipetting gently 3 times to adjust the 
concentration of NaCl and TX-100 to 0.5 M and 0.1%, respectively. The 
suspension was incubated on ice for 5 min and centrifuged at 10,000 rpm for 2 
min. Supernatant from digested and non-digested samples was retained and 
kept on ice. Pellets were washed with 0.1M NaCl (no TX-100) without being 
disturbed and collected by centrifuging at 10,000 rpm for 2 min. Supernatant 
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was removed and discarded. Pellets were resuspended in 100 μL of 0.1 M NaCl 
without TX-100.  
To supernatants and pellets, 4X LDS and 10X reducing agent were added to 
achieve 1X final concentration. All pellets were sonicated 3X 10 s on ice and 
centrifuged for 10 min at 14,000 g as the procedure for preparation of protein 
lysates. For western blot, 5-10 μL of extracts was loaded per well. As LDS was 
used for protein lysis, Coomassie protein assay was not available for protein 
quantification.  
2.6.3 Immunoblotting 
Protein samples were heated at 70 °C for 10 min and loaded on 4-12% Bis-Tris 
NuPage polyacrylamide gels (Life Technologies) with 5 μL of All-Blue pre-
stained ladder (BioRad). Electrophoresis was performed after addition of 200 
μL antioxidant (Life Technologies) to the inner chamber in 1X MOPS buffer 
(Life Technologies) for about 1h at 200 V.  
Gels were removed and cut to appropriate size before equilibrating in transfer 
buffer. PVDF-FL (Polyvinyldifluoride-fluorescence) 0.45 µm membranes 
(Millipore) were cut and dipped to wet in methanol. After rinsing with distilled 
water, membrane was then equilibrated in transfer buffer with filter paper 
(Whatman® grade 1) and fibre blotting pads (Life Sciences, E-PAGE™ Blotting 
Pads). Proteins were electro-transferred to PVDF membrane at 30 V for 3 h.  
The membrane was washed with Tris buffered saline (TBS), checked with 
Ponceau red for transfer efficiency and then blocked with Odyssey blocking 
buffer (Li-CoR) 1:1 diluted by TBS for 1h and probed with primary antibody 
(Table 2.6.1) diluted in Odyssey blocking buffer/ TBST (1:1) overnight at 4 °C. 
Secondary antibody (Goat anti-mouse IgG Alexa 680 or Goat anti-Rabbit IRDye 
800) was diluted 1/10000 in Odyssey blocking buffer/ TBST (1:1) and incubated 
with the membrane for 1h in the dark. Membrane was washed four times with 
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0.1% Tween 20 in TBS (TBST) before and after incubation with secondary 
antibody.  
Detection of labelled proteins was performed by scanning the membrane on a 
Li-CoR® Odyssey infrared imaging system. Scans were analysed using Odyssey 
v1.1 software (Li-CoR). Band intensity was analysed using Odyssey software by 
drawing boxes around the bands and subtracting the background using the 
median intensity of pixels. Densitometry of β-actin bands was calculated for 
normalisation of loading difference. 
Membranes were stripped using western blot recycling kit (Source Bioscience) 
for 30 min to remove bound antibodies before analysis of other antibodies. To 
ensure no binding of remnant antibodies, membrane was incubated in 
secondary antibody and scanned before applying of other primary antibodies. 
2.6.4 Immunohistochemistry (IHC) 
After TER measurements (section 2.4), differentiated cell sheets on Snapwell™ 
membranes were harvested by 2% (w/v) dispase (Roche) treatment at 37 °C for 
30 min to release intact cell sheets. Intact cell sheets were put into histology 
cassettes, fixed in 10% formalin overnight and transferred to 70% ethanol 
solution until further processing.  
Samples were dehydrated by incubation in 70% ethanol, absolute ethanol, 
isopropanol and xylene (Fisher Scientific) sequentially. Samples were 
transferred to molten paraffin wax (Thermo Scientific) at 60 °C for incubations. 
Following 4X 15 minutes incubation in molten wax, cell sheets were removed 
from the cassette into metal moulds and embedded in molten wax.  Cell sheets 
in the metal moulds were left on a cold table (RA Lamb) to allow the wax to 
cool. Wax blocks were cut to 5 µm sections using a Leica RM 2135 microtome. 
Cut sections were floated into a water bath at 37 °C and collected onto 
Superfrost PlusTM microscope glass slides (VWR). Once air-dried, sections were 
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stored temporarily at ambient temperature or melted on a hot block (RA Lamb) 
at 50 °C for one hour.  
Sections were de-waxed and rehydrated by submerging the slides in xylene, 
absolute alcohol, 70% alcohol and then water. Antigen retrieval was performed 
to restore the immunoreactivity of antigens masked by tissue processing (Shi et 
al., 1997). Methods of antigen retrieval used depended on the primary antibody 
(Table 2.6.1). The best retrieval method was identified by comparing sections 
restored with different methods. For trypsinisation, sections were incubated in 
0.1% (w/v) trypsin in 0.1% (w/v) calcium chloride solution at 37 °C for 10 min. 
For microwave heating, sections were placed in a PyrexTM dish filled with 350 
mL10 mM citric acid buffer and microwaved for 13 minutes at 900 W. After 
heating, sections in the dish were cooled on ice and washed with tap water. 
Slides were placed in multi-well Shandon Sequenza units using cover plates 
(Thermo Scientific). Appropriate sealing between slides and cover plates was 
checked by filling wells with TBS. Avidin and biotin (blocking kit, Vector 
Laboratories) were added separately to block any endogenous non-specific 
binding site by incubation the slides for 10 min, with TBS wash in between. 10% 
normal serum (Dako) of the host of secondary antibody was added to slides to 
block non-specific antibody binding. Sections were incubated with diluted 
primary antibody (Table 2.6.1) at 4 °C overnight. For each different secondary 
antibody, one well was incubated with TBS as negative control. 
Biotinylated secondary antibody (rabbit anti-mouse IgG at 1/200, goat anti-
rabbit IgG at 1/600 or rabbit anti-goat IgG at 1/600) was applied for 30 min 
before further 30 min incubation with (Strept) avidin-biotin complex (Dako). 
Signal amplification reagent was applied if using a CSA (catalysed signal 
amplification) kit (Dako) to amplify the reactions undetectable using Strept 
avidin-biotin method. After incubation with Diaminobenzidine (DAB) solution 
(SigmaFastTM DAB tablets dissolved in 5 mL distilled H2O), sections were 
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counterstained with haematoxylin and dehydrated through 70% alcohol, 
absolute alcohol and 2X xylene. Dehydrated sections were mounted in DPX and 
covered by glass coverslips (SLS). Sections were visualised on an Olympus 
BX60 microscope under bright-field illumination with x60 oil immersion 
objectives. Images were captured and analysed using Image-ProTMPlus software 
(Media Cybernetics). 
2.6.5 TissueGnostics analysis 
For sections showing difference between control and test samples, slides were 
scanned using AxioScan.Z1 slide scanner (Zeiss). The images were captured by 
the scanner and further analysed with HistoQuest software (TissueGnostics). 
Haematoxylin and DAB staining were used as markers of nuclear labelling. 
After defining the size of nuclei, the staining background and setting of the 
threshold, the nuclei were picked up by the software. Manual corrections were 
applied if the nuclei were not selected correctly. 
Cut-off value was set based on the DAB staining of positive/negative cell 
population. Individual cells were linked with corresponding data points and 
can be visualized by backward gating. Diagram showing the intensity of DAB 
and the area of nucleus was analysed to determine the cut off. The number of 
positive DAB staining cells distributed in the upper quadrant was divided by 
total cell number, which was indicated by area of haematoxylin. The ratio of 
positive cell number to total cell number was calculated and considered as 
percentage of positive cell population to further indicate whether the 
expression of nuclear protein was different between control and treatment. 
2.6.6 Immunofluorescence (IF) labelling 
Cells were seeded on 12 well slides in chambers of Heraeus boxes (Greiner) and 
treated for appropriate time as required according to individual experiment. To 
maintain antigenicity, two fixation methods were used. For methanol/acetone 
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fixation, slides were washed with methanol/acetone (50:50) for 30 sec and air-
dried. For formalin fixation, slides were incubated with 10% formalin for 10 
min and permeabilised in 0.1% Triton X100 for 30 min, then washed in PBS. 
Primary antibodies (Table 2.6.1) were diluted in TBS with 0.1% (w/v) bovine 
serum albumin (BSA) and 0.1% NaN3. Wells on slides were separated using 
liquid repellent grease pen to confine antibodies in individual wells. Negative 
wells were filled with TBS only to check for background binding of secondary 
antibody. 
Primary antibodies (Table 2.6.1) were incubated overnight at 4 °C, and then 
slides were washed with PBS on an orbital shaker. For methanol/acetone fixed 
slides, another 30 sec methanol/acetone wash was applied before air dry. 
Secondary antibodies (Alexa Fluor 594 goat anti-mouse IgG (A-11005, 
Molecular Probes) at 1:700 dilution and Alexa Fluor 488 goat anti-rabbit IgG 
(A11008, Molecular Probes) at 1:400 dilution) were added on slides after 
removal of excess PBS or air dry (methanol/acetone fixed slides) and incubated 
at ambient temperature in the dark for 1 h. Slides were washed in PBS as before, 
and incubated for 5 min with 0.1 μg /mL Hoechst 33258 in PBS for nuclear 
staining. Slides were washed in PBS and in distilled water. After air-drying, 
slides were covered in antifade solution (Appendix 7.4 for recipe), mounted 
with glass coverslips and sealed with nail polish at the edge. Slides were 
visualised on an Olympus BX60 microscope under epifluorescent illumination 
with x60 oil immersion objectives unless otherwise noted. Images were 
captured using respective channels depending on the secondary antibodies, 
and analysed with Image-ProTMPlus software (Media Cybernetics). Same 
exposure time was used for individual antibodies to make sure the amount of 
fluorescence was related to the amount of protein expressed. 
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2.6.7 List of antibodies 
Antigen Cat. No Supplier Host Application 
Claudin 7 34-9100 Zymed R 
WB 1/1000 
IHC 1/100 MW 
CK13 (1C7) MAB1864 Abnova M 
WB 1/1000 
IF 1/500 
IHC 1/500 
MW+Tr 
CK14 (LL001) N/A Gift M IF 1/5 
CK14 (LL002) MCA890 Serotec M WB 1/1000 
CK20.3 03-61032 Cymbus M IF 1:100 
CK7 
NCL-CK7-
OVTL 
Novocastra M IF 1:40 
PPARγ (E8) sc-7273 Santa Cruz M 
WB 1/500 
IHC 1:4000 
MW+Tr CSA 
PPARγ2 ab45036 Abcam  WB 1/500 
PPARγ2 (A-1) sc-166731 Santa Cruz  IF 1/100 
ELF3 ab97310 Abcam R 
IHC CSA 1/750 
MW 
ELF3 ab133621 Abcam R* 
WB 1/10000 
IF 1/1000 
HNF-3α (C20) sc-6553 Santa Cruz G IHC 1/150 MW 
Claudin 4 32-9400 Zymed M WB 1/1000 
p-SMAD3 
(S423&S425) 
ab52903 Abcam R WB 1/2000 
Active β-
catenin(8E7) 
05-665 Millipore M IF 1/100 
Phospho-
Akt(Ser 473) 
9277 Cell Signaling R IF 1:200 
p-ERK 9101 Cell Signaling R WB 1/1000 
Total ERK 610123 
Becton-
Dickinson 
M WB 1/2000 
PPARγ  GSK M IF 1/400 
E-cadherin 
(HECD-1) 
ab1416 Abcam M IF 1/1000 
Vimentin (V9) V6630 Sigma Aldrich M IF 1/800 
ZO-1 339100 Invitrogen M WB 1/500 
ZO-3 3704 Cell signaling R* WB 1/1000 
β-actin A5441 Sigma Aldrich M WB 1/250000 
Table 2.6.1 Antibodies utilised in the study. M, mouse; R, rabbit; G, goat. Rabbit monoclonal 
antibodies were noted with *. Antigen retrieval methods for antibodies used by IHC were noted 
as MW for microwave heating and Tr for trypsinisation. CSA indicates the CSA kit used for 
signal amplification. For detailed information, see section 2.6.4. Detailed information regarding 
two ELF3 antibodies is included in Appendix 7.1.4. 
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2.7 Establishment of ELF3 modified NHU cell lines 
2.7.1 ELF3 over expressing NHU cell lines 
ELF3 was amplified from cDNA of NHU cells and enzyme digested using 
EcoRI and HpaI. The fragment was ligated with digested pGEM-T vector. After 
transformation into E.coli, positive colonies were selected. Plasmid DNA was 
extracted and double digested using the same enzymes (EcoRI and HpaI). Gel 
electrophoresis was performed to detect whether the inserted fragment was the 
correct size before confirming with DNA sequence. 
The ELF3 inserted plasmids were sequenced to confirm the cloning sequence 
and then double digested with EcoRI and HpaI from pGEM-T vector and 
ligated into pLXSP vector. The backbone of pLXSP contains a puromycin 
resistance cassette, which enabled the post-transduction selection. This vector 
has parts of the retroviral gene integrated, except for the structural genes 
expressed in the packing PT67 cell line. 
PT67 packaging cell line (Clontech) was used for the production of infectious 
virus, as the essential retroviral genes gag, pol and env were integrated. PT67 
cultures at 60% confluency were transfected with 3 µg of plasmid DNA using 
the EffecteneTM Transfection Reagent Kit (Qiagen). At 48h post transfection, 
cells were sub-cultured into medium with 4 µg/mL puromycin to select 
transfected cells.  A mock transfected flask was included to indicate whether 
the antibiotic selection succeeded.  
PT67 cells were cultured to 100% confluence in DMEM with 10% FBS. On the 
day before transduction, PT67 cells were washed in Dulbecco`s Phosphate 
Buffered Saline (DPBS, Life Technologies) followed by medium replacing with 
DMEM: RPMI (1:1) with 5% FBS to reduce the concentration of serum and 
calcium. The conditioned medium containing virus was aspirated, filtered 
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through 0.45 µm Tuffryn filter to remove any cellular debris. With addition of 8 
µg /mL polybrene to enhance the transduction efficiency, filtered medium was 
added to actively proliferating NHU cultures. The medium of transduced NHU 
cultures was changed to KSFMc 6 h post transduction. NHU cells were selected 
with 1 µg/mL puromycin after being passaged 48 h post transduction. 
Genome of control and ELF3 transduced cells was extracted and analysed by 
gel electrophoresis to check whether the ELF3 gene was successfully integrated 
to the genome of NHU cells. 
2.7.2 ELF3 knock down NHU cell lines 
ELF3 ShRNA was cloned into pSiren-RetroQ plasmid, transfected into PT67 cell 
line and integrated into NHU cell line by Jenny Hinley before the work started. 
Sequence for ELF3 ShRNA is listed below: 
 ELF3-ShRNA-01 GCTACCAAGTGGAGAAGAACA 
 ELF3- ShRNA-02 GCTCTTCTGATGAGCTCAGTT 
 ELF3- ShRNA-03 GCTCAGTTGGATCATTGAGCT 
2.8 Statistics 
Statistical analysis was performed using InStat3 software (GraphPad). Mean 
and standard deviation (SD) were used to describe statistics. Error bars on 
figures represent SD obtained from technical or experimental replicates stated 
individually.  
Data was input to the software before selection of calculating the ANOVA 
using appropriate method. For data showing relationship between groups, a 
Bonferroni multiple comparisons post-test was performed; for data indicating 
the difference between two types, an unpaired t-test was performed. It was 
considered as statistically significant if the p value was less than 0.05.  
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Chapter 3 Role of ELF3 in Urothelial 
Differentiation 
3.1 Introduction 
3.1.1 ELF3 and its expression in humans 
ELF3 (E74-like factor 3) is localised to human chromosome 1q32.2, which is an 
epithelial cancer-related region associated with breast, lung and prostate 
cancers (Tymms et al., 1997). The human ELF3 gene contains 9 exons and spans 
5.8kb of genomic DNA (Oettgen et al., 1999). ELF3 belongs to the ETS (E26 
transformation specific) family, which is a group of proteins sharing a similar 
ETS domain (35% amino acid identity for the most two divergent  proteins) and 
binds to the conserved core motif (C/A)GGA(A/T) as transcription factors to 
transactivate target genes (reviewed by Wasylyk et al., 1993).  
ELF3 is expressed by epithelial tissues, and particularly the lung in human fetal 
tissues and small intestine in adult tissue, illustrating a specialised expression 
associated with tissues showing a high content of epithelial cells (Oettgen et al., 
1997). It is not expressed in hematopoietic organs like spleen and thymus or 
peripheral blood lymphocytes, which distinguishes ELF3 from other ETS family 
proteins (Oettgen et al., 1997; Tymms et al., 1997).  
The tissue specificity of ELF3 also limits its transcriptional activity. Andreoli et 
al. showed that transcriptional activity of terminal epidermal differentiation 
markers like TGM3 (transglutaminase 3) and profilaggrin genes were up-
regulated by ELF3 only in epithelial primary cells or cell lines. The 
transactivation by ELF3 was more prominent in normal human epidermal 
keratinocyte (NHEK) cultures with high calcium (Andreoli et al., 1997). These 
findings suggest that ELF3 is massively involved in regulating differentiation in 
epithelial cells. 
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3.1.2 Structure of ELF3 
3.1.2.1 Cis-regulatory elements on ELF3 genes 
The 5’-flanking region of ELF3 genes has been implicated as an upstream 
regulatory region with binding motifs of other transcription factors. A CCAAT 
box, an ESE (ERT promoter specific element) and a NF-κB site were found both 
in human and murine ELF3 sequence (Hou et al., 2004; Oettgen et al., 1999; Park 
et al., 2001). The ESE site at -186 to -183 in human ELF3 acted as an enhancer 
element and was essential for promoter activity of ELF3 in a human gastric 
cancer cell line expressing ELF3 (Park et al., 2001). A 94bp DNA sequence 2kb 
upstream of the transcription start site was sufficient to elevate the promoter 
activity of murine ELF3 in F9 differentiated EC (embryonal carcinoma) cells, 
although the sequence showed no consensus with any known eukaryotic 
transcription factors  (Hou et al., 2004). So far no reports confirmed any site for 
known transcription factors within this 94bp sequence. The findings suggest 
that ELF3 has essential elements in its promoter or enhancer region, which 
facilitates the regulation by other transcription factors.  
3.1.2.2 Trans-activation by ELF3 and functions of different ELF3 domains 
To analyse the function of particular regions in full length murine ELF3 protein 
(371 amino acids, 89% identity and 93% similarity to human ELF3 cDNA 
(Tymms et al., 1997)), reporter assay was utilised on TGFβRII (type II 
transforming growth factor receptor) with point mutated ELF3 proteins in 
differentiated mouse F9 EC cells (Kopp et al., 2007), as it was shown that 
transactivation of TGFβRII, which contains two ETS sites, was regulated by 
ELF3 in differentiated mouse F9 EC cells (Kopp et al., 2004). Several domains 
common to other ETS family members or other factors are shown with different 
colours in Fig 3.1.1. 
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Fig 3.1.1 Domains of murine ELF3 cDNA. Diagram adapted from (Kopp et al., 2007). N and C 
indicate two terminals. Numbers indicate the amino acids counted from N terminal. PNT, 
pointed domain. TAD, transactivation domain. SAR, serine- and aspartic acid-rich domain. AT, 
A/T hook domain. ETS, E26 transformation specific domain. 
Site-directed mutations on three different helixes in the ETS domain (orange 
part in Fig 3.1.1, 272th-354th amino acid, 100% identical to human ELF3 cDNA 
(Tymms et al., 1997)) led to a complete loss of TGFβRII promoter activity, 
whereas mutations in between the helix did not affect the ability of 
transactivation of TGFβRII by ELF3 (Kopp et al., 2007). The regions flanking the 
ETS domain in ELF3 cDNA at both the N-terminal and the C-terminal played 
an essential role for ELF3 binding to the ETS motifs, as the deletion of part or all 
of either side disrupted the transactivation (Kopp et al., 2007).  
In addition to an ETS domain, ELF3 has a unique A/T hook domain (pink part 
in Fig 3.1.1). Role of A/T hook domain (236th-256th amino acid) in transcriptional 
activation is promoter specific, as deletion of A/T hook domain in ELF3 did not 
affect the transactivation of TGFβRII, but reduced the promoter activity of 
collagenase-1(contains only one ETS site) and mutated TGFβRII promoter 
containing only one ETS site (Kopp et al., 2007). This A/T hook domain is 
common to a series of nuclear factors, particularly HMG (high mobility group) 
proteins (Oettgen et al., 1997), which are the second most abundant chromatin 
proteins after histones. One important feature of the HMG proteins is that they 
play important roles in regulating transcription and differentiation. A subgroup 
of HMG protein called HMGA proteins are expressed mostly during embryonic 
development (Bianchi and Agresti, 2005). The structural homology of ELF3 and 
HMG proteins may suggest a potential role of ELF3 in embryonic development.  
A serine- and aspartic acid-rich (SAR) domain (black part in Fig 3.1.1, 189th -
229th amino acid) was significantly essential for ELF3 to regulate the activity of 
TGFβRII promoter. (Kopp et al., 2007).  
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Removal of the TAD (transactivation domain, green part in Fig 3.1.1, 129th-159th 
amino acid) increased the ability of ELF3 binding to TGFβRII promoter. 
Specifically, point mutations of leucine 142 or tryptophan 137 to proline within 
the TAD domain led to the increased binding ability (Kopp et al., 2007).  
Mutation of PNT domain (pointed domain, blue part in Fig 3.1.1, 63th -127th 
amino acid), which was verified as a protein- protein interaction dependent 
domain in other ETS family proteins (Foulds et al., 2004; Seidel and Graves, 
2002), did not affect the transcriptional activity of ELF3 on TGFβRII  promoter, 
indicating a direct regulation of TGFβRII by ELF3 (Kopp et al., 2007). Table 3.1.1 
summarised the essentiality of domains on mELF3 proteins. 
Domains PNT TAD SAR AT ETS 
Influence  
Not 
affected 
Binding 
↑ 
Transcriptional 
↓ 
Transcriptional 
↓* 
Transcriptional 
↓ 
Table 3.1.1 Influence of mELF3 domains. Either the binding activity or transcriptional activity 
was assessed when certain domain was mutated or deleted. Increased activity was shown by ↑; 
decreased activity was shown by↓. * suggested a promoter specific influence. 
3.1.3 Requirement of ETS motif when regulating target genes by 
ELF3  
To be trans-activated by ELF3, ETS motifs in promoters or enhancers of genes 
were essential. Band shift assay demonstrated that ELF3 could bind to ETS 
motif of TGM3 (transglutaminase 3) but not mutated motifs, which indicated 
that the ETS binding site was critical for binding of ELF3 (Andreoli et al., 1997). 
Some other reports also demonstrated the regulation on epithelial-related genes 
by ELF3. In human keratinocytes cultured in vitro, transcript expression of ELF3 
accumulated dramatically at 12h after induced differentiation by treating 
keratinocytes with calcium and serum. Simultaneously, increased ELF3 up-
regulated transcript expression of SPRR2A, which is a terminal differentiation 
marker in keratinocytes with ETS motif on its promoter. At 24h, ELF3 increased 
the transcript expression of CK8, which is primarily expressed in epithelial cells 
 Chapter 3 
53 
and contains ETS sites on its enhancer. The transcriptional regulation on 
SPRR2A and CK8 by ELF3 was conducted by directly binding to the ETS 
binding sites, as mutants of ETS domain in SPRR2A or CK8 reduced 
dramatically the transcriptional activity induced by ELF3 (Oettgen et al., 1997).  
Similarly, ELF3 was able to bind to the ETS motif at -150bp of CLDN7 promoter 
and directly regulate the transcriptional activity of CLDN7 in human synovial 
sarcoma tumor tissue and cell lines with epithelial structure. Mutations on the 
ETS motif in CLDN7 abolished the transactivation. Transcript expression of 
CLDN7 was simultaneously decreased along with knock down of ELF3 in a 
120h time course. De novo transcript expression of CLDN7 was induced by 
exogenous ELF3 at 48h, but there was no CLDN7 protein accumulation, which 
suggested that the ETS motif was essential for regulating of target genes like 
CLDN7 by ELF3, but the regulation was not sufficient. Other factors may also 
be involved in determining the expression of CLDN7 (Kohno et al., 2006).  
Taken together, these findings suggest that ELF3 was associated with 
regulating epithelial-related genes, and was able to bind to ETS motif in 
promoters or enhancers of target genes when mediating transactivation 
directly, in which case, any mutation would abolish the ability of regulating by 
ELF3. 
3.1.4 Regulating differentiation from embryonic development to 
tissue regeneration 
As a transcription factor, roles of ELF3 regulating its target genes has been 
reported in various tissues or cells, a majority of which were induced to 
differentiate, suggesting a central role of ELF3 in regulating differentiation. 
This importance in regulating differentiation by ELF3 was found in embryonic 
development. It is reported that in early development of mouse gastrointestinal 
tube, ELF3 was not essential. On embryonic day E17.5, however, the ELF3-
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deficient embryos showed a delay in the formation of villi, the villi are fewer 
and abnormally shaped as well. Dysfunction of ELF3 led to abnormal 
phenotype of enterocytes compared to the wild type ones in mice embryo cells. 
The sialomucin (nonsulfated acidic mucin glycoproteins) secreted by goblet 
cells also reduced significantly in both duodenum and ileum, suggesting the 
requirement of ELF3 in morphogenesis and maturation of cells in mouse small 
intestine.  
In vivo experiment demonstrated that expression of TGFβRII was reduced in 
ELF3 deficient mice, which verified the in vitro study showing TGFβRII as a 
potential target of ELF3 and the expression of TGFβRII was directly regulated 
by ELF3 (Ng et al., 2002). Exogenous expression of the TGFβRII transgene in 
small intestinal epithelium of ELF3-null mice restored the morphogenesis of 
small intestine and enabled the differentiation and polarization of enterocytes. 
With restored TGFβRII in ELF3 deficient mice, goblet cells were able to 
synthesise acidic mucins as normal enterocytes, which supported the important 
role of ELF3 as a regulator of TGFβRII expression in intestinal development 
(Flentjar et al., 2007). 
Another report regarding a role of ELF3 in embryonic development 
demonstrated the expression of ELF3 in cornea epithelium on embryonic day 
E16.5 by in situ hybridization in mouse. Localisation and expression of ELF3 
demonstrated a similar pattern compared to CK12, which is a cornea 
differentiation marker, suggesting that ELF3 was involved in corneal epithelial 
cell differentiation. Forced expression of ELF3 antisense RNA led to a 
significant (P<0.05) reduction of differentiated human corneal epithelial (HCE) 
cells (Yoshida et al., 2000), indicating a crucial role in regulating differentiation 
in cornea epithelium.  
ELF3 was also shown as an important factor involved in regulating 
regeneration of damaged tissue. The renewal of Clara cells (also known as 
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bronchiolar exocrine cells) was delayed in ELF3 knockout mice compared with 
normal mice. Following Clara cell damage, cell proliferation and mitosis was 
postponed in the bronchiolar airway epithelium of ELF3 deficient mice. 
TGFβRII protein was up-regulated significantly in the repair process in ELF3 
positive mice, but maintained a low level in ELF3 deficient mice, implicating 
participation of ELF3 during airway injury repair (Oliver et al., 2011).  
In E. coli infected mouse bladder urothelium, expression of ELF3 increased 
rapidly at 1.5h only after inoculation of FimH+ strain but not FimH- strain. An 
ELF3 target gene, iNOS, was significantly accumulated at transcript level and 
acted as the host defense response to FimH+ UPEC infection (Mysorekar et al., 
2002). 
3.1.5 Requiring other factors to regulate target genes by ELF3 
When regulating expression of target genes, other factors were found to be 
recruited to enhance the effect of ELF3. In human skin, ELF3 was shown to 
cooperate with Oct 11, up-regulating the transcription of SPRR2A in a 
synergistic dose-dependent manner (Cabral et al., 2003).  
In intestinal epithelium, Crif (CR6-interacting Factor) 1 was reported to regulate 
the development and differentiation of the cells. Crif1 interacted with ETS 
domain (Not PNT domain which is associated with protein-protein binding) 
and increased the DNA binding activity of ELF3, which further regulated the 
promoter activity of TGFβRII. Knock out of Crif1 led to similar morphology 
and function of intestinal cells compared to ELF3 knock out mice, implicating 
possibly a central role of ELF3 but requiring co-activator in mediating intestinal 
differentiation (Kwon et al., 2009). 
In human esophageal squamous epithelium, ELF3 was able to enhance the 
transcriptional activity of SPRR2A. However, promoter activity of CK4, 
representing early differentiation of the esophageal squamous epithelium, was 
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repressed by ELF3. Deletion of various regions in the CK4 promoter did not 
reverse the suppression of transcription activity, indicating that ELF3-regulated 
repression may not be caused directly by binding to the promoter region. A 
PNT domain (pointed domain) deletion of ELF3 in the N-terminal amino acids 
was able to reverse the suppression of the CK4 promoter activity, whereas 
deletion of ETS domain only partially rescued the suppression (Brembeck et al., 
2000). This finding indicated a dual role of ELF3 in regulating the early 
differentiation and the involvement of other proteins in mediating downstream 
target in esophageal squamous epithelium, as PNT domain has been implicated 
in protein-protein interaction in other ETS family proteins (Foulds et al., 2004; 
Seidel and Graves, 2002). 
3.1.6 Signalling pathways mediated ELF3 regulation 
Apart from recruitment of co-factors, the regulation of target genes by ELF3 
was reported to be mediated by signalling pathways. Otero et al. recently found 
that in human primary osteoarthritis (OA) articular chondrocytes, ELF3 
regulated MMP13 (Matrix metalloproteinase 13) expression, which was 
indirectly affected by MAPK pathway activity (Otero et al., 2012). MMP13 is a 
key factor associated with cartilage remodelling and degradation. In human 
primary OA chondrocytes, IL-1β treatment increased the expression of ELF3 
and endogenous ELF3 binding to MMP13 promoter, which was further 
transactivated by enhanced expression of ELF3. The transactivation of the 
MMP13 promoter was also enhanced by overexpression of MEK1/ERK1 in 
chondrocytes. Such enhancement of MMP13 promoter regulation by ELF3 after 
IL-1β treatment was reduced significantly by inhibition of MEK/ERK signalling 
pathway. Also, MKP1 (MAPK phosphatase 1), acted as a repressor of MAPK 
mediated pro-inflammatory in airway smooth muscle cells (Manetsch et al., 
2012), reduced ELF3-induced MMP13 activation (Otero et al., 2012). These 
findings indicate the regulation by ELF3 in inflammation was via a MAPK-
mediated pathway. 
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3.1.7 Involvement of ELF3 in cancer development 
Several reports have shown the involvement of ELF3 during cancer 
development, but the role of ELF3 is not consistent. In human prostate cancer, 
ELF3 repressed androgen receptor (AR) mediated transcriptional activity by 
interacting with AR directly, and further impaired the ability for AR to be 
recruited to target genes with specific ARE binding sites. Knock down of ELF3 
reversed the suppression and increased migration of LNCaP (androgen-
sensitive human prostate adenocarcinoma) cells. Tumour growth was inhibited 
by ELF3 expression in mouse xenograft model, suggesting an anti-cancer role of 
ELF3 in prostate cancer (Shatnawi et al., 2014). 
In human breast cancer cell line Hs578T over-expression of ELF3 dramatically 
increased endogenous expression of TGFβRII and reduced the growth of 
Hs578T cells by 50% in presence of exogenous TGFβ1. Time of forming tumours 
was delayed in nude mouse inoculated with ELF3 over-expressing Hs578T cells 
compared to control Hs578T cells. The size of xenograft tumour decreased to 
30% (Chang et al., 2000). But whether this cancer cell growth and tumour 
formation inhibition was related to the regulation of TGFβRII by ELF3 or the 
expression of ELF3 directly was not further investigated. 
Another report suggested that endogenous ELF3 was restricted to the 
cytoplasm in human breast cancer T-47D cell line and normal breast tissue, but 
its protein was nuclear in transiently-transfected MCF-12A cells. This nuclear 
localization induced apoptosis in MCF-12A and MCF-10A cells. Deletion of the 
ELF3 TAD domain impaired its apoptotic function (Prescott et al., 2004).  
However, other reports indicate a carcinogenesis role of ELF3. In breast cancer, 
frequent copy number amplification at 1q21 and 1q32 indicated three ETS genes, 
one of which is ELF3. 1q21 and 1q32 were the two chromosome bands showing 
the most frequent genomic copy number gains among 141 breast carcinomas by 
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chromosomal  CGH (comparative genomic hybridisation) (Mesquita et al., 
2013).  
Also, in cervical carcinomas, 13% of somatic mutation was observed in 24 
samples of adenocarcinoma. Frame shift insertional events were found in 
AT/hook domain and ETS domain, suggesting ELF3 might be involved in 
development of epithelial cancers (Ojesina et al., 2014).  In bladder cancer, ELF3 
was reported to have 8% mutation, which was statistically significant and 
mostly occurred in papillary tumours (Cancer Genome Atlas Research, 2014). 
These contrary reports indicate different roles of ELF3 implicated for cancer. 
Further investigation is still required to verify the link between expression 
alteration of ELF3 and development of cancer. 
3.1.8 Summary 
Studies of ELF3 in various tissues, primary cells and cell lines demonstrated a 
major role of ELF3 in regulating epithelial differentiation. ELF3 was also 
involved in other cellular activities by interacting with other transcription 
factors or directly binding to the promoter of its potential targets, with ETS 
binding site especially. Detailed mechanism is not completely investigated, thus 
requires further research, which would provide implication towards tissue 
development, cell differentiation, host defence and cancer therapy.  
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3.2 Experimental approach 
3.2.1 Aims and hypothesis 
The aims for this chapter were to characterise the expression pattern of ELF3 in 
normal human urothelial tissues and cells and investigate whether it is a 
differentiation-related transcription factor in urothelium, which would affect 
the function of urothelial cells when the expression of ELF3 was modified in 
NHU cells. 
The hypothesis is that as a transcription factor regulating differentiation, ELF3 
would alter the phenotype of proliferating NHU cells to a differentiated 
phenotype when it was over expressed in vitro in NHU cells. 
3.2.2 Differentiation-associated markers 
To indicate the phenotype of urothelial tissues or NHU cells cultured in vitro, 
differentiation-associated genes/proteins were investigated either by RT-QPCR 
for transcript expression or by other approaches (Western blotting (WB), 
immunohistochemistry (IHC), and immunofluorescence (IF)) for protein 
expression. Table 3.2.1 displays applications for each individual marker 
assessed. 
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Name Transcript 
Protein 
(WB) 
Protein 
(IHC) 
Protein 
(IF) 
Function 
CK13  √ √ √ Urothelial differentiation 
CK14  √   Squamous 
CK20 √   √ 
Terminal urothelial 
differentiation 
CLDN4  √   
Late urothelial 
differentiation 
CLDN7 √ √ √  Target of ELF3 
UPK2 √    
Terminal urothelial 
differentiation 
UPK3A √    
Terminal urothelial 
differentiation 
ZO1  √   Urothelial differentiation 
ZO3  √   
Terminal urothelial 
differentiation 
Table 3.2.1 Applications performed for examining of differentiation-associated markers. 
Functions showed the general role of these genes/proteins in urothelium. Checks (√) indicate 
the assessed application for individual markers. 
3.2.3 Expression profile of ELF3 in human urothelium 
To demonstrate the expression profile of ELF3 in situ, immunohistochemistry 
was performed using formalin-fixed paraffin wax embedded sections of 
urothelial tissue.  
To study which factors affected the expression of ELF3, NHU cell cultures were 
treated for a time course (6h, 24h and 96h) with DMSO (vehicle control), TZ, 
PD153035 or TZPD. Transcript expression of differentiation-associated genes 
and transcription factors (ELF3 and FOXA1) was examined by RT-QPCR. 
PPARG2 was assessed as one of the PPARγ transcript variants (chapter 5 for 
detailed information).  
Expression of ELF3 protein was assessed by immunofluorescence on vehicle 
control (DMSO) or TZPD treated NHU cells. Protein expression of CK13 and 
CK20 was used as positive control to demonstrate that TZPD-treated NHU cells 
had undergone transitional differentiation. 
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3.2.4 Genetic modification of ELF3 expression in NHU cells 
In order to understand whether ELF3 is important in regulating differentiation, 
the expression of ELF3 in NHU cells was modified by manipulating the genome 
of NHU cells using retroviral integration.  
Retroviral transduction was performed either with shRNA pSiren-retroQ 
system to knock down the expression of ELF3 or with ELF3 cDNA ligated into 
pLXSP vector to increase its expression. To knock down ELF3 expression, 
scrambled shRNA that did not target specific genes was integrated in parallel to 
ELF3 shRNA as an experimental control. For ELF3 over expression, full length 
of ELF3 coding sequence inserted into pLXSP vector and transfected into PT67 
packaging cells was performed in parallel to empty pLXSP vector as control. 
After selection with puromycin, conditioned medium containing retroviral 
particles from cultured PT67 cells was aspirated and added to proliferating 
NHU cells. NHU cells were selected with puromycin until the mock transduced 
cells died. 
Assessment of changes in ELF3 expression was performed by RT-PCR before 
further experiments performed. Growth assays were performed to study the 
effect of ELF3 modification on cell proliferation in retroviral integrated NHU 
cells using the Alamar Blue assay.  
3.2.5 Effect of ELF3 knock down on NHU cells 
Transcript expression of ELF3 was examined to indicate whether the modified 
expression was successful. RT-PCR was performed to show the alteration of 
ELF3 transcript expression. RT-QPCR was utilised to quantify the altered 
expression of ELF3 transcript. For assessment of ELF3 knock down, scrambled 
shRNA control and ELF3 shRNA knock down NHU cells were treated with 
TZPD to differentiate for a time course (12h, 24h, 48h and 72h). 72 hours 
treatment was selected for RT-QPCR, as the transcript expression in the control 
was the most abundant in the time course. Transcript expression of other 
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transcription factors (ELF3, GRHL3, IRF1, FOXA1 and KLF5) and 
differentiation-associated genes was examined.  
To indicate the impact of ELF3 expression on urothelial differentiation, the 
ability to form a functional barrier was assessed using cell sheets constructed 
from ELF3 knock down and scrambled control cell sheets. NHU cells were 
induced to differentiate and form cell sheets using the ABS/Ca2+ method and 
assessed to demonstrate the formation of a functional barrier. TER 
measurements indicating the barrier of stratified cell sheets were taken every 
day for control and ELF3 knock down NHU cells. Scratch wound healing assay 
was performed after the values of TER stabilised to show the recovery time of 
damaged cell sheets. During the healing process, images of cultures were 
captured at different time points to illustrate the relative closure of the scratch 
wound. 
Stratified cell sheets (scrambled shRNA control and ELF3 knock down) were 
harvested intact using dispase and then fixed and embedded in paraffin wax to 
investigate the effect on expression of differentiation-associated proteins by 
IHC when ELF3 was down regulated. Expression of transcription factors 
PPARγ and FOXA1 along with ELF3 was examined to show the effect of ELF3 
knock down. CK13 and CLDN7 were included to demonstrate the polarisation 
of cell sheets and show the effect of ELF3 knock down on differentiation-
associated proteins. 
Differentiation-associated proteins were assessed by western blotting to 
demonstrate the effect of ELF3 knock down. Scrambled shRNA control and 
ELF3 shRNA knock down cells were pre-treated with 5% ABS and seeded on 
60mm dishes; medium was replaced with 5% ABS and 2mM calcium the next 
day. Cultures were harvested after 2 days, 4 days and 6 days of incubation. 
Expression of ELF3 was examined by immunoblotting to indicate the knock 
down effect on protein expression. PPARγ protein was also assessed to verify 
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the effect of ELF3 knock down observed by IHC. Downstream proteins CLDN4 
and CLDN7 were examined to indicate the effect of ELF3 knock down. 
Phosphorylated SMAD3 was assessed to suggest whether the delay of wound 
closure was associated with TGFβ pathway (Fleming et al., 2012). 
3.2.6 Effect of ELF3 over-expression on NHU cells 
To determine whether ELF3 was over-expressed, transcript expression of ELF3 
was assessed in both empty vector control and ELF3 over-expressed NHU cells. 
In order to explore the effect of TZPD on ELF3 over-expressed cells, control and 
ELF3 over-expressed cells were induced to differentiate by TZPD for 6h to 
indicate whether the effect of TZPD was magnified by ELF3 over-expression. 
Transcript expression of PPARG2, IRF1, GRHL3 and FOXA1 genes was 
examined.  
To further testify the role of ELF3 in urothelial differentiation and the 
hypothesis, western blotting was performed to indicate whether over-
expression of ELF3 would alter the phenotype of proliferating NHU cells. 
Lysates from proliferating NHU cells integrated with ELF3 were utilised to first 
verify the integration of ELF3 into NHU cells and to illustrate the phenotype of 
proliferating NHU cells integrated with either empty vector or ELF3 full length 
cDNA. 
The importance of ELF3 was also assessed by examining differentiation-
associated proteins in ABS and/or calcium induced NHU cells. Empty vector 
control and ELF3 over expressed NHU cells were seeded in 35mm dishes, and 
treated with ABS alone, calcium alone or combined ABS/calcium for a time 
course. Protein expression of both transcription factors and differentiation-
associated markers was analysed. Expression of ZO proteins (ZO1 and ZO3) 
was assessed to indicate the differentiated barrier phenotype. ZO1α+ and ZO1α- 
are two isoforms of ZO1 proteins. Increased expression of ZO1α+ should 
suggest a more differentiated barrier phenotype (Smith et al., 2015).  
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3.3 Results 
3.3.1 Expression and localisation of ELF3 in situ 
In urothelial tissue, ELF3 was expressed in the nuclei of all layers of urothelial 
cells in the ureter. Occasionally absent expression of ELF3 was observed in 
dispersed urothelial cells (Fig 3.3.1, noted by arrows). CLDN7 showed 
intercellular junction expression in basal, intermediate and superficial layers 
(Fig 3.3.1). Expression of CK13 was confined to the cytoplasm in basal and 
intermediate layers and was absent from superficial cell layer (Fig 3.3.1). 
 
Fig 3.3.1 Expression of differentiation-associated proteins in urothelial tissue (Ureter, Y1233). 
Immunohistochemistry labelling was performed following IHC protocol with primary 
antibodies specific to ELF3, CLDN7 and CK13, respectively. Arrows indicate absent expression 
of ELF3 in some nuclei. Scale bar equals 50µm. 
3.3.2 Expression and localisation of ELF3 in NHU cells in vitro 
3.3.2.1Transcript expression 
NHU cells were treated with DMSO, TZ, PD153035 and TZPD for a time course. 
Transcript expression of ELF3 was significantly synergistically up-regulated by 
TZPD combined treatment and increased over time, suggesting that ELF3 was 
induced following in vitro differentiation of NHU cells by activation of PPARγ. 
The accumulation was dramatic at 96h by TZPD treatment. PD153035 alone 
increased the expression of ELF3, which was not significant though. In vehicle 
control (DMSO) treated cells, low but still noticeable expression of ELF3 was 
observed after 96h growth in culture. Transcript expression of FOXA1 was up-
regulated significantly by activation of PPARγ after 6h of treatment. It 
increased dramatically at 24h but decreased slightly afterwards. The increase 
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was significant in all time points by TZ only and TZPD, which may suggest its 
direct regulation by PPARγ. The transcript expression of PPARG2 was up-
regulated at 6h by TZPD and decreased at late time point (Fig 3.3.2). 
Elevation of UPK2 and CK20 transcript expression indicated that differentiation 
of NHU cells was achieved by TZPD at 96h. CLDN7 showed similar transcript 
expression pattern as ELF3 (Fig 3.3.2). 
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Fig 3.3.2 Transcript expression of transcription factors and differentiation-associated genes in 
NHU cells (Y1194) pharmacologically induced to differentiate. Cells were treated with vehicle 
control (DMSO, 0.1%), TZ (1µM), PD153035 (1µM) or TZPD (1µM) for 6h, 24h and 96h. RT-
QPCR was performed as described in the method. Transcript expression of ELF3, FOXA1, 
PPARG2, UPK2, CK20 and CLDN7 was normalized to expression of GAPDH in each sample. 
Fold changes were obtained by comparing to 6h DMSO treated control. Error bars indicate the 
standard deviation of three technical replicates. Statistical analysis was calculated by one-way 
ANOVA with Bonferroni multiple comparisons post-test (*** P<0.001). 
3.3.2.2Protein expression by immunofluorescence 
Immunofluorescence showed that ELF3 was diffuse and the expression was low 
but unequivocal in proliferating cells, whereas in differentiated NHU cells ELF3 
was mainly localised in the nuclei (Fig 3.3.3). However, several cells showed 
low expression even in differentiated NHU cells, which was consistent with 
localisation of ELF3 in urothelial tissues (Fig 3.3.3, indicated by arrowhead). 
 
Fig 3.3.3 Expression and localisation of ELF3 in proliferating and differentiated NHU cells 
(Y1436). Cells were treated with either DMSO (0.1%) or TZPD (1µM) for 4 days. Slides were 
fixed using 50:50 Methanol/Acetone fixation and incubated with ELF3 primary antibody 
following immunofluorescence protocol. Hoechst 33258 was used to stain the nuclei. Pictures 
were taken with constant exposure time for comparison. Colour information was extracted 
from each channel and merged to a new image (Merge). Scale bar represents 50µm. Note, low 
expression of ELF3 pointed by arrowheads in some differentiated cells. 
A differentiated phenotype was demonstrated by expression of CK13 and CK20 
in TZPD differentiated NHU cells. CK13 was localised to the cytoplasm of 
differentiated cells, indicating a transitional differentiated phenotype of NHU 
cells (Fig 3.3.4). CK20 was only present in some cells indicating a terminal 
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differentiated phenotype. The expression of CK20 was less than that of CK13, as 
it is a late differentiation marker. 
 
Fig 3.3.4 CK13 and CK20 proteins in NHU cells (Y1116). Primary antibodies for CK13 and 
CK20 were applied on cells treated with TZPD for 72h and fixed using Me/Ac method. Hoechst 
33258 was used to stain the nuclei. Colour information was extracted from each channel and 
merged to a new image (Merge). Scale bar represents 50µm. 
3.3.3 Effect of ELF3 knock down on NHU cells in vitro 
3.3.3.1 Verification of ELF3 knock down 
ELF3 knock down NHU cells were generated using shRNA retroviral 
integration. Transcript expression of ELF3 was up-regulated following TZPD 
induced differentiation and accumulated mostly at 72h. Knock down of ELF3 
by retroviral integration in NHU cells reduced the transcript expression of 
ELF3. The most efficient knock down effect was obtained after 72h TZPD 
treatment, to about 60% of its original transcript amount. It appeared that there 
was no knock down effect at 12h, which might be due to the low amount of 
transcript expression of ELF3 (Fig 3.3.5). 
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Fig 3.3.5 Transcript expression of ELF3 in scrambled shRNA control (Ctrl) and ELF3 knock 
down (K/d) NHU cells (Y1117). Cultures were harvested after incubation with TZPD (1µM) for 
12h, 24h, 48h and 72h. The transcript expression was shown as percentage compared to the 
expression of ELF3 after 72h TZPD treatment after normalisation to the amount of GAPDH in 
each sample. Densitometry of each band was measured using Image J software. No reverse 
transcription enzyme was added in RT (-) samples. GAPDH showed the equal amount of cDNA 
and was included as internal control. Water or genomic DNA was utilised as template in (-) and 
(+) samples, respectively. 
Control and knock down cells were induced to differentiate by TZPD for 72h, at 
which point the knock down of ELF3 was most effective. RT-QPCR result 
showed that after induction of a differentiated phenotype, knock down of ELF3 
was significant at transcript level to around 40% of control sample. Transcript 
expression of GRHL3, IRF1 and FOXA1 was reduced significantly by ELF3 
knock down to about 50%. Knock down of KLF5 transcript expression was 
about 40% and less significant. As a potential target of ELF3, transcript 
expression of CLDN7 was significantly knocked down to 30% of control sample 
(Fig 3.3.6A). 
The amount of UPK3A transcript was similar in control and ELF3 knock down 
cells and relatively low compared to GAPDH. The effect of ELF3 knock down 
was not significant on UPK3A. Transcript expression of KLF5 was the most 
abundant among candidate genes in TZPD differentiated NHU cells (Fig 
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3.3.6B), suggesting its essential role in regulating differentiation, but may not be 
an ELF3 downstream transcription factor. 
 
Fig 3.3.6 Transcript expression of candidate genes (Y1117). (A) Scrambled shRNA control 
(Control) and ELF3 knock down (ELF3 k/d) cells were incubated with TZPD (1µM) for 72h. RT-
QPCR was performed following the protocol. Transcripts of GAPDH in both control and knock 
down samples were used as internal control for comparison of expression of other genes. 
Transcript expression of ELF3, GRHL3, IRF1, FOXA1, KLF5, UPK3A and CLDN7 was 
calculated and displayed as fold change of knock down to control. Statistical analysis was 
calculated by one-way ANOVA with Bonferroni multiple comparisons post-test (**P<0.01, *** 
P<0.001). (B) Relative transcript expression of each sample was compared to the relative amount 
of GAPDH in each sample to indicate the relative amount of individual transcripts. Error bars 
indicate the standard deviation of three technical replicates. 
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3.3.3.2 Proliferation 
To assess whether knock down of ELF3 affected the proliferation of NHU cells, 
a growth assay was performed.  
Knock down of ELF3 reduced the growth rate compared to control cells. The 
growth reduction was significant from day 3 until the plateau on day 10. Knock 
down of ELF3 not only slowed down cell proliferation but also prevented cells 
reaching maximal density compared to control cells, as the reduction of Alamar 
Blue in ELF3 knock down cells was less than that in control cells through the 
time course (Fig 3.3.7).  
 
Fig 3.3.7 Effect of ELF3 knock down on proliferation of non-differentiated NHU cells (Y1117). 
Scrambled shRNA control (Control) and ELF3 knock down (ELF3 K/d) cells were seeded on day 
0 and incubated for different days indicated in the graph. Reduction of Alamar Blue 
demonstrated proliferating rate of NHU cells shown as the reduction percentage. Error bars 
indicate the standard deviation of six experimental replicates. Statistical analysis was calculated 
by ANOVA with unpaired t-test at each time point (**P<0.01, *** P<0.001). 
3.3.3.3 Barrier function 
Inhibition of ELF3 expression reduced the ability for differentiated NHU cells to 
form an effective barrier (less than 2000 Ω∙cm2 compared to 3500 Ω∙cm2 in 
control differentiated cells), which was statistically extremely significant on day 
4, day 7 and the following days (Fig 3.3.8A).  
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After wounding, TER values of both control and ELF3 knock down cell lines 
dropped down to around 200 Ω∙cm2 and increased afterwards gradually. 
Wound healing process was slowed down in ELF3 knock down cells 
significantly. Knock down of ELF3 did not affect the ultimate recovery from 
wounding, as TER value of ELF3 knock down cells returned to its original 
amount (Fig 3.3.8B), suggesting that ELF3 was crucial in developing an effective 
barrier, but may not be the pivotal factor determining the formation of the 
barrier. 
 
Fig 3.3.8 Effect of ELF3 knock down on formation of functional barrier in NHU cells (Y1117). 
Scrambled shRNA control (Control) and ELF3 knock down (ELF3 k/d) cells were induced to 
differentiate following the ABS/Ca2+ method. (A) TER measurements were taken every day for 8 
days. (B) Cultures were wounded on day 8. TER values were measured before and after 
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wounding for 61h. Error bar indicates standard deviation of six experimental replicates. 
Statistical analysis was calculated by ANOVA with unpaired t-test at each time point (*P<0.05, 
**P<0.01, *** P<0.001). 
Images in Fig 3.3.9 showed that ELF3 knock down delayed the wound healing 
process. The wound was closed at between 17 to 20 hours in control cells, 
whereas knock down of ELF3 slowed down the healing to more than 20 hours. 
The wound in both control and ELF3 k/d cell sheets were able to heal within 36 
hours (Fig 3.3.9). These images suggested that the less effective barrier after 
wounding was due to slow migration, which may suggest a direct or indirect 
role of ELF3 in regulating cell migration. 
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Fig 3.3.9 Effect of ELF3 knock down on wound healing in NHU cells (Y1117). Scrambled 
shRNA control (Control) and ELF3 knock down (ELF3 k/d) cells were treated as described in 
Fig. 3.3.8. Images were taken after cultures wounded on day 8 at different time points. Scale bar 
represents 200µm. 
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3.3.3.4 Differentiation-associated proteins by immunohistochemistry 
Barrier study indicated that ELF3 was essential in urothelial differentiation. To 
further confirm the ELF3 knock down effect and determine the effect on 
expression of downstream proteins, ELF3 and other proteins were examined by 
immunohistochemistry with control and ELF3 knock down cell sheets. As seen 
previously (Fig 3.3.1), ELF3 showed occasional absence in positive ureter 
control (Fig 3.3.10 positive control). However, no prominent change of ELF3 
expression was observed, as both control and ELF3 knock down cell sheets 
showed absent nuclear expression in some of the cells (examples were pointed 
out with arrows, Fig 3.3.10). The relatively stable ELF3 protein expression in 
control and ELF3 knock down cell sheets might be caused by the non-specific 
binding of the antibody, which requires further experiments to confirm.  
 
Fig 3.3.10 Effect of ELF3 knock down in cell sheets (Y1117). Scrambled shRNA control and 
ELF3 knock down cell sheets were treated as described in method for immunohistochemistry 
using CSA kit and incubated with ELF3 primary antibody. Positive control, ureter section 
(Y1233). Negative control was shown to inform the background. Scale bar represents 50µm. 
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Differentiation-associated proteins were assessed to indicate the polarisation of 
cell sheets and to show the effect of ELF3 on their expression 
In both shRNA control and ELF3 knock down cell sheets, CK13 demonstrated 
cytoplasmic localisation, which was the same as in ureter section (positive 
control). Any difference between control and ELF3 knock down was not 
obvious (Fig 3.3.11). 
 
Fig 3.3.11 Effect of ELF3 knock down on localisation and expression of CK13. Scrambled 
shRNA control, ELF3 knock down cell sheets (Y1117) and ureter section (positive control, Y1233) 
samples were incubated with CK13 primary antibody. Secondary only negative control was 
also included. Scale bar represents 50µm. 
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Localisation of CLDN7 was confined to intercellular junctions in ureter section 
(positive control), shRNA control and ELF3 knock down cell sheets, suggested 
that there was no apparent knock down of CLDN7 protein expression (Fig 
3.3.12). 
 
Fig 3.3.12 Effect of ELF3 knock down on localisation and expression of CLDN7. Scrambled 
shRNA control, ELF3 knock down cell sheets (Y1117) and ureter section (positive control, Y1233) 
samples were incubated with CLDN7 primary antibody. Secondary only negative control was 
examined. Scale bar represents 50µm. 
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As a transcription factor, FOXA1 was localised to the nuclei in normal tissue 
mostly in basal and intermediate layers (positive control). Both shRNA control 
and ELF3 knock down cell sheets showed nuclear expression with occasional 
absence (Fig 3.3.13, noted by arrows). 
 
Fig 3.3.13 Effect of ELF3 knock down on localisation and expression of FOXA1. Scrambled 
shRNA control, ELF3 knock down cell sheets (Y1117) and ureter section (positive control, Y1441) 
samples were incubated with FOXA1 primary antibody. Secondary only negative control was 
included to show the background. Scale bar represents 50µm. 
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PPARγ demonstrated consistent nuclear expression in shRNA control cell 
sheets and ureter section (positive control). In ELF3 knock down cell sheets, 
nuclear expression of PPARγ was absent in some cells (Fig 3.3.14, pointed out 
by arrows), suggesting a possible feedback of ELF3 knock down to PPARγ.  
 
Fig 3.3.14 Effect of ELF3 knock down on localisation and expression of PPARγ. Scrambled 
shRNA control and ELF3 knock down cell sheets were treated as described in method for 
immunohistochemistry using CSA kit and incubated with PPARγ primary antibody. Positive 
control, ureter section (Y1233). Negative control is shown to inform the background. Scale bar 
represents 50µm. 
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To quantify the effect on PPARγ expression by ELF3 knock down, cell sheets 
were scanned using the AxioScan.Z1 slide scanner and analysed using 
HistoQuest software. The analysis process of one ELF3 knock down cell sheet 
slide stained with PPARγ was captured as screenshots and shown as workflow 
in Appendix 7.3. Analysed in the same way, control samples showed 94% and 
97% positive PPARγ nuclear staining, whereas ELF3 knock down samples 
demonstrated 57% and 52% positive cells (Fig 7.3.9, Appendix 7.3), suggesting 
40%-50% cells in ELF3 knock down cell sheets were absent of PPARγ nuclear 
expression. 
3.3.3.5 Differentiation-associated proteins by immunoblotting 
Protein expression of ELF3 was assessed by immunoblotting to verify the knock 
down of ELF3 in ABS/Ca2+ differentiated NHU cells. Expression of full length 
ELF3 protein (41kDa) was reduced in retroviral-transduced ELF3 knock down 
NHU cells (Fig 3.3.15, labelled as ELF3-1). Lower band (25kDa) was observed, 
which was speculated to be a 3’ incomplete coding sequence (Ensembl, 
ENST00000446188, see 6.1 for discussion) (Fig 3.3.15, labelled as ELF3-2). 
Expression of both ELF3 isoforms was knocked down and the effect was more 
obvious in samples harvested on day 6. 
 
Fig 3.3.15 Effect of ELF3 knock down at protein level in NHU cells (Y1117). Scrambled shRNA 
control (Ctrl) and ELF3 knock down (ELF3 k/d) cells were harvested and seeded on 6 cm dishes 
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after 5 days of 5%ABS treatment. Medium was changed with final concentration of 2mM Ca2+ 
and 5% ABS on the next day and alternative days. Protein lysates were harvested on day 2, day 
4 and day 6, respectively. Proliferating (Pro) and TZ/PD differentiated (Dif) NHU cells (Y1456) 
were included as control. Arrows indicate the two ELF3 bands (ELF3-1 and ELF3-2). β-actin was 
included as loading control.  
Knock down of PPARγ by ELF3 knock down was assessed by immunoblotting. 
Two main PPARγ isoforms were knocked down slightly (Fig 3.3.16). Knock 
down effect on the lower band (B) was more obvious, as it had more protein 
expression than PPARγ upper band (A). On day 6, knock down effect of PPARγ 
band B was obvious (Fig 3.3.16). 
 
Fig 3.3.16 Effect of ELF3 knock down on PPARγ protein expression (Y1117). Scrambled 
shRNA control (Ctrl) and ELF3 knock down (ELF3 k/d) cells were treated as described in Fig 
3.3.15. Proliferating (Pro) and TZ/PD differentiated (Dif) NHU cells (Y1456) were included as 
control. Arrows indicate the two PPARγ bands (PPARγ A and PPARγ B). β-actin was included 
as loading control.  
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Downstream differentiation-associated tight junction proteins CLDN4 and 
CLDN7 were selected to verify the effect on differentiation-associated proteins 
by Western blotting. The blots did not show obvious protein expression 
changes (Fig 3.3.17). 
 
Fig 3.3.17 Effect of ELF3 knock down on expression of tight junction proteins (Y1117). 
Scrambled shRNA control (Ctrl) and ELF3 knock down (ELF3 k/d) cells were treated as 
described in Fig 3.3.15. Proliferating (Pro) and TZ/PD differentiated (Dif) NHU cells (Y1156) 
were included as control. CLDN7 and CLDN4 were selected as candidates of barrier-associated 
proteins. β-actin was included as loading control. 
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Whether the TGFβ pathway was associated with the delay of wound healing in 
ELF3 knock down samples was assessed by p-SMAD3. The activated p-SMAD3 
in ELF3 knock down cells was reduced by ELF3 knock down to 57%, although 
the activation was not dramatic compared to the activation of p-SMAD3 in 
control (last three lanes, Y1545), which demonstrated the involvement of TGFβ 
pathway in differentiated NHU cells and TGFβ1 treated differentiated cells. 
This result suggested that knock down of ELF3 might have affected the TGFβ 
pathway (Fig. 3.3.18). 
 
Fig 3.3.18 Effect of ELF3 knock down on TGFβ pathway (Y1117). Scrambled shRNA control 
(Ctrl) and ELF3 knock down (ELF3 k/d) cells were seeded in 6cm dishes, after which the cells 
were treated with 5% ABS for 5 days and 5% ABS and 2mM Ca2+ for 6 days. NHU cells (Y1545, 
lysates taken by Jennifer Hinley) were included as controls, which were induced to differentiate 
using the ABS/Ca2+ method. Sample labelled as ABS/Ca ctrl was used as non-treated control. 
Differentiated cells from the same line (Y1545) were also treated with SB431542 or TGFβ1, as 
negative or positive controls, respectively. Picture was taken with combination of two colour 
channels to indicate the relative expression of p-SMAD3 (green channel) compared to β-actin 
(red channel). Percentage of activated p-SMAD3 expression after normalisation with β-actin is 
shown for control and ELF3 knock down samples. 
  
100%     57% 
 Chapter 3 
85 
3.3.4 Effect of ELF3 over-expression on NHU cells in vitro 
3.3.4.1 Establishment of ELF3 over-expressed NHU cell line 
To further understand role of ELF3 in urothelial differentiation, ELF3 was over-
expressed in NHU cells by cloning into an expression vector and integrated into 
genome of urothelial cells using retroviral transduction. The insertion was cut 
off using EcoRI and HpaI, demonstrating a band at the size of ELF3 full length 
cDNA by electrophoresis (Fig 3.3.19 Lane 2-5). 
 
Fig 3.3.19 Double digestion of pGEM-T vectors. Lane 1 demonstrated a non-digested plasmid 
as control. Bands on lane 2-6 showed the double digestion of five colonies. Bands at 1116bp 
were cut off by double digestion, indicating the correct insertion of ELF3 (lane 2-5). 
To investigate whether the over-expression of ELF3 in NHU cells was 
successful, genomic DNA of transduced NHU cells was isolated and amplified 
using primers binding to the vectors. ELF3 integrated sample demonstrated a 
band at the same size compared to the ELF3 band amplified from ELF3-pGEM-
T plasmid (Fig 3.3.20, lane 2, noted by arrow). 
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Fig 3.3.20 Amplification of ELF3 from genomic DNA of transduced NHU cells (Y1365). 
Templates in lane 1 and 2 were genomic DNA from transduced NHU cells, empty vector and 
ELF3-inserted vector, respectively. ELF3-inserted plasmid was used as positive control and is 
shown in lane 3. Lane 4 was negative control using water as template. 
3.3.4.2 Proliferation 
In order to understand whether over-expression of ELF3 affected the 
proliferation of NHU cells, growth assay was performed in ELF3 over-
expressing and control cells. Growth rate of empty vector control and ELF3 
over-expressed NHU cells showed similar trend initially. Control cells were still 
able to proliferate until 12 days after seeding, whereas ELF3 over-expressed 
cells demonstrated growth arrest 8 days afterwards, which was statistically 
significant, suggesting that over-expression of ELF3 had some effect on 
population doubling rate of cells, which may imply an alteration of 
proliferative phenotype. Empty vector and ELF3 integrated cells showed 
reduction of Alamar blue for less than 50% or 30%, respectively (Fig 3.3.21). A 
lower density of ELF3 over-expressed cells when arrested for growth was 
observed. 
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Fig 3.3.21 Over-expression of ELF3 on proliferation. Empty vector or ELF3 wild type (ELF3 
WT) integrated cells (Y1314) were seeded on day 0 and incubated for different days indicated in 
the graph. Reduction of Alamar Blue demonstrated proliferating rate of NHU cells shown as 
the reduction percentage. Error bars indicate the standard deviation of six experimental 
replicates. Statistical analysis was calculated by ANOVA with unpaired t-test at each time point 
(**P<0.01, *** P<0.001). 
3.3.4.3 Phenotype of NHU cells 
To investigate whether growth arrest was the result of a differentiated 
phenotype that might be due to the over-expression of ELF3, western blotting 
was performed using vector and ELF3 over-expressed NHU cells. 
Full length of ELF3 cDNA was integrated into NHU cells, which is about 41kDa 
indicated by arrow. Lower band (25kDa) was observed in all NHU cell lysates. 
In ELF3 integrated cells, protein level of ELF3 was increased compared to 
vector only integrated cells, but the expression was less than differentiated 
NHU cells (Fig 3.3.22). 
Expression of CK13 and CK14 suggested the over-expression of ELF3 did not 
alter the phenotype of proliferating NHU cells (Fig 3.3.22), which was CK13 (-) 
and CK14 (+). By contrast, differentiated control cells demonstrated a 
phenotype showing CK13 (+) and CK14 (-). 
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Fig 3.3.22 Over-expression of ELF3 and the effect on phenotype of NHU cell (Y1365). Empty 
vector (Empty) and ELF3 full length cDNA (ELF3) integrated NHU cells were harvested at 90% 
confluence. Untransduced differentiated NHU lysate (Dif, Y1156) was included as positive 
control for differentiation. Primary antibodies for ELF3, CK13 and CK14 were applied to the 
blot separately. β-actin was included as loading control. 
3.3.4.4 Differentiation-associated transcripts 
Since over-expression of ELF3 did not affect the CK13 (-) and CK14 (+) 
phenotype, control and ELF3 integrated cells were utilised to examine whether 
ELF3 over-expressed cells demonstrated more abundance of differentiation-
associated genes and proteins when induced to differentiate.  
To investigate the transcript expression of ELF3 and whether TZPD stimulated 
cells affected ELF3 transcript expression. ELF3 over-expressed cells were 
induced to differentiate by TZPD treatment for 6h, at which time point the 
expression of ELF3 was little in non-transduced control cells (Fig 3.3.2).  
Transcript expression of ELF3 was dramatically up-regulated in ELF3 
integrated NHU cells. TZPD increased the transcript expression slightly in 
vector only integrated cells shown as a faint band. No obvious expression 
change can be observed between vehicle control (DMSO) and TZPD treated 
samples in ELF3 integrated cells, suggesting treatment of TZPD for 6h might be 
not sufficient to induce any visible change (Fig 3.3.23). 
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Fig 3.3.23 Effect of TZPD induced differentiation on ELF3 integrated cells (Y1314). Empty 
vector (Empty) and full length ELF3 (ELF3 WT) induced cells were treated with either vehicle 
control (DMSO, 0.1%) or TZPD (both at 1µM) for 6h. No reverse transcription enzyme was 
added in RT (-) samples. GAPDH showed the equal amount of cDNA and was included as 
internal control. Water and genomic DNA was utilised as template in (-) and (+) samples, 
respectively. 
ELF3 over-expressed cells were utilised to further investigate the effect of ELF3 
on PPARγ transcripts. Primer set (2F & 4R, see chapter 5 for detailed 
information) targeting both PPARγ isoforms was utilised. Transcript expression 
of PPARγ by RT-PCR did not show expression alteration by 6h of TZPD 
treatment or ELF3 over-expression (Fig 3.3.24). 
 
Fig 3.3.24 Transcript expression of PPARγ in ELF3 over expressed cells (Y1314). Empty vector 
(Empty) and full length of ELF3 (ELF3 WT) samples were treated with either vehicle control 
(DMSO, 0.1%) or TZPD (both at 1µM) for 6h. GAPDH showed the equal amount of cDNA and 
was included as internal control. Water and genomic DNA was utilised as template in (-) and (+) 
samples, respectively. 
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By RT-QPCR, the over expression of ELF3 was confirmed. Dramatic increase of 
ELF3 transcript expression was significant, to about 100 times of its original 
amount in both empty and ELF3 integrated cells. Expression of ELF3 in vector 
integrated cells was induced by 6h TZPD treatment, but the induction was not 
significant. The expression of ELF3 in ELF3 over-expressed cells was down-
regulated by 6h TZPD treatment significantly (Fig 3.3.25). To confirm this 
finding, the experiment needs to be repeated with biological replicates. 
 
Fig 3.3.25 Effect of TZPD induced differentiation on ELF3 transcripts in ELF3 transduced 
cells (Y1314). Empty vector (Empty) and full length of ELF3 samples were treated with either 
vehicle control (DMSO, 0.1%) or TZPD (both at 1µM) for 6h. Transcript expression of ELF3 was 
normalised to GAPDH and compared to empty vector transduced DMOSO treated cells. Error 
bars indicate the standard deviation of three technical replicates. Statistical analysis was 
calculated by one-way ANOVA with Bonferroni multiple comparisons post-test (*** P<0.001). 
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By RT-QPCR (primer set 1F 2R, see chapter 5 for detailed information), 
PPARγ2, which is one of the PPARγ isoforms showed no statistically significant 
change. Transcript expression of IRF1 and FOXA1 was up-regulated by 6h of 
TZPD treatment in both control and ELF3 over-expressed cells, but was not 
statistically significant. Increase of GRHL3 transcript expression by 6h of TZPD 
treatment was significant, suggesting that GRHL3 might be an intermediate 
transcription factor expressed at early stage during differentiation. However, 
the effect on expression alteration of transcription factors by ELF3 over-
expression was not significant (empty samples vs. ELF3 samples, Fig 3.3.26). 
 
Fig 3.3.26 Transcript expression of transcription factors in ELF3 over-expressed cells (Y1314). 
Empty vector (Empty) and full length of ELF3 samples were treated with either vehicle control 
(DMSO, 0.1%) or TZPD (both at 1µM) for 6h. Transcript expression of all tested genes was 
normalised with expression of GAPDH. Transcript expression in treated and/or transduced 
cells was compared to that of vehicle treated empty vector transduced cells, and demonstrated 
as fold change. Error bars indicate the standard deviation of three technical replicates. Statistical 
analysis was calculated by one-way ANOVA with Bonferroni multiple comparisons post-test 
(*** P<0.001). All other comparisons not noted were considered as not significant. 
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3.3.4.5 Differentiation-associated proteins 
Over-expression of ELF3 was confirmed at the transcript level, but did not 
induce the proliferating NHU cells to differentiate. Whether it would enhance 
expression of differentiation-associated proteins in differentiated NHU cells 
was further investigated. Serum and calcium were applied to cultures 
separately or simultaneously to identify whether ELF3 over-expressed cells 
would be affected by different treatments. Expression of ELF3 and PPARγ was 
assessed (Fig 3.3.27) together with differentiation-associated proteins (Fig 
3.3.28). 
Full length ELF3 was detected at about 41kDa (labelled as ELF3-1, Fig 3.3.27). 
The effect of over expression on ELF3 proteins was detectable but not as 
dramatic as transcripts. Treatment with both ABS and calcium did not affect 
ELF3-1 obviously. However, ELF3-2 protein, which was a truncated ELF3 
isoform, appeared to be up-regulated by ABS or calcium only treatment (Fig 
3.3.27, noted by a rectangular). 
Two PPARγ antibodies were applied to demonstrate the effect of ELF3 over 
expression on PPARγ. PPARγ2 antibody demonstrated two main bands 
showing no obvious pattern. The lower band was the same one as raised by 
PPARγ E8 antibody. Another band was also observed at 80kDa, and suggested 
to be a sumoylated form of PPARγ (Fig 3.3.27). PPARγ E8 antibody was 
designed to bind to all PPARγ isoforms. The main band shown on the blot at 
about 50kDa appeared that the amount of protein was reduced by ELF3 over-
expression (Fig 3.3.27). 
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Fig 3.3.27 Effect of ELF3 over-expression on ELF3 and PPARγ (Y1314). Empty vector control 
(C) and full length ELF3 integrated cells (ELF3) were harvested and seeded on 35 mm dishes. 
Upon reaching 90% confluence, cells were either harvested as proliferating samples (Pro) or 
treated with 5% ABS alone, 2mM calcium alone or ABS/Ca2+ for 1 day, 3 days or 6 days. 
Medium was changed on alternative days. Protein lysates were harvested after the treatment. 
PPARγ2 antibody binds to N terminal of PPARγ2, whereas PPARγ E8 antibody binds to the 
PPARγ protein C terminal, which is shared among majority of PPARγ isoforms. Total ERK was 
applied on the blot as loading control. Note, the expression of ELF3-2 protein was increased 
slightly by over-expression of ELF3. 
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Whether over-expression of ELF3 affected the differentiated phenotype was 
assessed by examining transitional and terminal differentiation-associated 
proteins (Fig 3.3.28). Protein expression of CK13 was increased slightly by over-
expression of ELF3 in calcium or ABS/calcium treated cells (Fig 3.3.28, noted 
with a rectangular). CK14 proteins decreased in ELF3 over expressed cells, with 
dramatic effect in ABS or calcium only treatment cultures especially (Fig 3.3.28, 
noted with a rectangular). However, expression of tight junction proteins 
showed no obvious pattern. ZO1 and ZO3 were expressed mostly in 
ABS/calcium treated cells without apparent difference by ELF3 over-expression 
(Fig 3.3.28).  
 
Fig 3.3.28 Effect of ELF3 over-expression on differentiation-associated proteins (Y1314). 
Empty vector control (C) and full length ELF3 integrated cells (ELF3) were treated as described 
in Fig 3.3.27. Total ERK was applied on the blot as loading control. Note, expression of CK13 
and CK14 was altered by ELF3 over-expression (indicated by a rectangular). 
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3.3.5 Summary of results 
ELF3 was localised to the nuclei in urothelial tissue samples. In vitro expression 
of ELF3 was up-regulated by TZPD induced differentiation, which also resulted 
in translocation of ELF3 to nuclei.  
Knock down of ELF3 reduced transcript expression of other transcription 
factors such as IRF1, FOXA1 and GRHL3. An ELF3 downstream gene CLDN7 
was down-regulated by ELF3 knock down. 
However, knock down of ELF3 did not obviously affect protein expression of 
tight junction proteins or transitional differentiation marker CK13. 
A feedback of ELF3 knock down to PPARγ protein expression may be present, 
as absent nuclear expression of PPARγ was observed in two different cell sheet 
samples (generated from the same ELF3 knock down cell line). 
The formation of a functional barrier in ABS/calcium differentiated NHU cells 
was delayed by ELF3 knock down significantly, suggesting an essential role of 
ELF3 in maintaining differentiated phenotype of NHU cells. 
The original hypothesis that over-expression of ELF3 would induce the 
differentiated phenotype in NHU cells was disproved by the observation of 
stable expression of CK14, as well as no visible expression of CK13 in ELF3 
over-expressed proliferating cells. 
Transcript expression of ELF3 was massively up-regulated by ELF3 over-
expression, which was independent of induction of differentiation. 
Protein expression of ELF3 was not dramatically affected after induction of 
differentiation. The expression of CK13 and CK14 was slightly altered by ELF3 
over-expression after calcium treatment. But no convincing change regarding 
terminal differentiation-associated markers by ELF3 over-expression was 
observed (ZO1 or ZO3). 
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3.4 Future work 
The knock down of PPARγ was observed when the expression of ELF3 was 
knocked down. To investigate whether there is a feedback to PPARγ by ELF3 
knock down and confirm the previous results, immunohistochemistry 
experiments regarding the expression of PPARγ in other ELF3 knock down 
NHU cell lines are worth doing. 
The functional role of ELF3 was demonstrated by TER study, but little effect in 
terms of differentiation-associated proteins expression was observed. Further 
studies about proteins associated with formation of functional barrier may 
suggest link between ELF3 and other target proteins or mechanisms of 
regulating differentiation in NHU cells. 
As the protein expression of ELF3 was not significantly up-regulated by over-
expression, whether it was degraded after translation or not being translated 
may indicate the mechanism of regulating the expression of ELF3 in NHU cells, 
or the initiation of differentiation programme. 
For ELF3 over-expressed NHU cells, the functional study by measuring TER in 
differentiated cells may provide further information about the role of ELF3. 
Assessment of PPARγ expression in ELF3 over-expressed NHU cell sheets may 
be important to investigate the relationship between ELF3 and PPARγ. Protein 
expression of other transcription factors related to urothelial differentiation in 
ELF3 over-expressed cells may provide further information. 
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Chapter 4 Signalling Pathways involved in UC 
4.1 Introduction 
4.1.1 Classification and general characterisation of pathways in 
UC 
There are two main pathways associated with development of bladder cancer, 
the Ta pathway associated mainly with FGFR3 mutation and the CIS pathway 
associated with TP53 mutation. Ta tumours contribute to 50% of bladder 
cancer, but although they often recur, they rarely progress to T2-T4 via T1. By 
contrast, CIS tumours have 50% incidence to progress via T1 to T2-T4 tumour, 
which indicates the tumour has invaded to the smooth muscle layer of the 
bladder (Billerey et al., 2001; Biton et al., 2014). Recent studies have 
distinguished three different types of muscle invasive bladder cancers (MIBC): 
luminal cancers (with PPARγ activation and FGFR3 activating mutation), basal 
cancers with P63 activation, and P53-like cancers (Choi et al., 2014).  
The main difference between basal and luminal MIBC was that the luminal 
cancers had differentiation-associated genes expressed at both transcript and 
protein level (CK20, PPARγ, FOXA1, for example). Transcription factors like 
PPARγ and FOXA1 were up-regulated in luminal MIBCs and down-regulated 
in basal MIBCs (Choi et al., 2014). In all three subtypes of MIBC, activated 
transcription factors were found to induce both the up-regulation and down-
regulation of different genes. For example, in the PPARγ pathway, transcripts 
of PPARγ, CK18 and CK20 were up-regulated, whereas vimentin (an 
intermediate filament protein expressed in mesenchymal cells) was down-
regulated in luminal MIBC (Choi et al., 2014).  
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4.1.2 Genome-wide alteration of genes in urothelial cancer 
Analysis utilising various types of UC samples suggested that somatic mutation 
and copy number alteration were involved in urothelial cancer with high 
incidence. P53/Rb pathways had 93% alteration. 49% of samples had TP53 gene 
inactivating mutations (Cancer Genome Atlas Research, 2014). P63 showed a 
significant reduction at protein level in high grade invasive cancers. Transcript 
expression of P63 also demonstrated a dramatic decrease in high grade bladder 
cancer cell lines (e.g. T24) compared to low grade bladder cancer lines (RT4, for 
example) (Urist et al., 2002). RTK (Receptor tyrosine kinases)/PI3K pathway had 
72% mutation, among which included FGFR3, EGFR family members and 
PIK3CA(Cancer Genome Atlas Research, 2014). 
Histone modification was another highly altered system (89%) (Cancer Genome 
Atlas Research, 2014). Frequent chromatin remodelling event has been reported 
in urothelial cancer (59% of 97 samples), and was regarded as hallmark of 
bladder cancer (Gui et al., 2011). The role of EGFR family members and the 
PI3K pathway and the influence of pathway alteration will be introduced in 
more detail in the following sections.  
4.1.3 Role of the EGFR pathway in normal urothelial cells and the 
alteration in cancer 
The EGFR pathway is important in regulating cell proliferation and thus plays 
crucial roles in cultures of normal urothelial cells in vitro (Varley et al., 2005). By 
binding of its specific ligands, EGFRs are activated and form homodimer (or 
heterodimer with other ERBB family members) to stimulate cascades of 
downstream pathways. In proliferative NHU cells, EGFR pathway autocrine 
activated by amphiregulin was the dominant pathway. Inhibition of EGFR 
tyrosine kinase (TK) by PD153035 significantly inhibited the wound repair and 
migration of NHU cells in vitro (Varley et al., 2005). Inhibition of EGFR pathway 
by EGFR TK inhibitor, or a downstream MAPK/ERK inhibitor decreased the 
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proliferation. Inhibition of MAPK/ERK by U0126 led to activation of AKT 
pathway (MacLaine et al., 2008). Regeneration of in vitro cultured urothelial 
cells were shown to be inhibited by EGFR inhibitor AG1478 and anti-EGFR 
antibody (LA22) at 50% and 30% respectively, and stimulated by amphiregulin, 
EGF and TGFα added exogenously (Daher et al., 2003).  
In bladder cancer, expression of EGFR increased significantly compared to 
normal tissue. A dramatic increase of EGFR transcript was observed in higher 
stages of bladder cancer biopsies among 45 tumour samples compared to 5 
normal samples (Chang et al., 2013). Also, in cancer treatment, anti-EGFR 
therapy in basal-like MIBC was demonstrated as therapeutic target in both 
human bladder cancer cell lines and chemically induced bladder cancer mouse 
model (Rebouissou et al., 2014). However, over-expression of EGFR in 
transgenic mice showing up-regulation of EGFR and hyperplasia of urothelium 
did not induce tumour formation on its own (Cheng et al., 2002).  
ERBB2, also known as HER2 or EGFR2, was another EGFR family member 
expressed more in confluent and differentiated NHU cells compared to freshly 
isolated cells or proliferating cells (Varley et al., 2005). ERBB2 was reported to 
play essential role in urothelial wound repair process. Only the antisense 
oligonucleotides of c-erbb2 (blocked the production of endogenous ERBB2 
protein) delayed the regeneration of damaged primary urothelial cultures by up 
to 50%, whereas the sense or the mutated antisense oligonucleotides showed no 
effect. The inhibition of wound repair was not affected through the proliferative 
ability, as all three oligonucleotides (sense, antisense and mutated antisense to 
c-erbB2) showed similar influence on proliferation of urothelial cultures by 
BrdU assay, suggesting a role of ERBB2 in migration of normal urothelium 
(Bindels et al., 2002). 
ERBB2 showed the highest mutation frequency in bladder cancer among all 
tested tumour types (Cancer Genome Atlas Research, 2014). Translocation of 
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ERBB2 was found in four tumours with different fusion partners. One case 
showed that exon 4 to 29 of ERBB2 was fused to promoter plus exon1 of DIP2B 
(disco-interacting protein 2 homolog B), which contains a binding site for the 
transcriptional regulator DNA methyltransferase 1 associated protein 1. The 
fused product was amplified, which resulted in over-expression of ERBB2 
(Cancer Genome Atlas Research, 2014). Breast cancer cells depleted of ERBB2 
on the cell surface lost the ability of EGF family induced migration, whereas 
over-expression of ERBB1 (EGFR) partly compensated the EGF induced 
migratory ability in ERBB2 devoid cancer cells (Spencer et al., 2000), suggesting 
a crucial role of ERBB2 in mediating EGF induced migration of carcinoma cells. 
4.1.4 PI3K /AKT pathways and the alteration in UC 
The PI3K (Phosphoinositide 3-kinase)/AKT (also known as protein kinase B, 
PKB) pathway is downstream of the EGFR pathway and involved in cell 
proliferation, differentiation, survival and motility. In cultures with low 
calcium (0.09 mM), NHU cells mainly utilised the MAPK (mitogen-activated 
protein kinases)/ERK (extracellular signal-regulated kinases) pathway 
downstream of EGFR pathway for growth, whereas in high calcium condition 
(physiological concentration, 2 mM), NHU cells depended on the PI3K pathway 
to proliferate, as AKT pathway was activated whereas inhibition of PI3K using 
LY294002 reduced the proliferation of calcium induced growth acceleration 
significantly (Georgopoulos et al., 2010). During wound healing process in 
NHU cells, the AKT pathway also contributed to the regulation of cell 
migration, which was prevented by inhibition of the AKT pathway using 
LY294002 (Varley et al., 2005).  
The increased calcium concentration in NHU cultures led to plasma membrane 
expression of E-cadherin, which is a calcium dependent homotype cell-cell 
adhesion glycoprotein (Georgopoulos et al., 2010).  To form intercellular bonds, 
E-cadherin dimerised between cells and integrated in cytoplasm with either β-
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catenin or γ-catenin, which integrated to α-catenin linking to actin cytoskeleton. 
This interaction of E-cadherin with β-catenin was essential in normal tissue and 
cancer cell lines with a well differentiated phenotype. In fibroblast-like cell 
lines, loss of E-cadherin and expression of truncated β-catenin were often seen 
and resulted in increased cell mobility (reviewed by Wijnhoven et al., 2000). In 
controlling cell migration, the β-catenin pathway is also associated with 
cadherin pathway and GSK3β (Glycogen synthase kinase-3β) /Wnt pathways 
(reviewed by Nelson and Nusse, 2004), and will be introduced in the next 
section. 
Activation of PI3K/AKT pathway may also be associated with urothelial cancer. 
In T24 bladder cancer cells, the PI3K inhibitor LY294002 reduced the 
proliferation of T24 cells via PI3K/AKT pathway significantly, as expression of 
phosphorylated AKT decreased (Fan et al., 2014), which suggested an 
important role of AKT pathway in cancer proliferation. PIK3CA demonstrated 
15% somatic mutation and 5% copy number alteration, both of the two 
alteration resulted in activation of PI3K pathway. Within the altered cases 
(17%), all the mutations were recurrent point mutations (Cancer Genome Atlas 
Research, 2014). The crosstalk of PI3K/AKT pathway with other pathways and 
the activating mutations found in urothelial cancer may play important roles 
and thus worth to be further investigated. 
4.1.5 GSK3β/Wnt/β-catenin pathway and insight for tumorigenesis 
by crosstalk with other pathways 
GSK-3β is a serine/threonine protein kinase. In absence of a Wnt signal, GSK-3β 
combines with other proteins to form a destruction complex, which targets and 
ubiquitinates β-catenin for degradation. With Wnt signal present, β-catenin is 
released and translocated to the nucleus to activate expression of genes 
downstream, which is known as canonical Wnt signalling pathway. SB415286 is 
a GSK3β inhibitor, which also disrupts the destruction complex and stimulates 
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canonical Wnt signalling pathway, resulting in release of β-catenin from the 
destruction complex (MacAulay et al., 2003). Inactivation of GSK3β also 
activated a β-catenin-LEF/TCF sensitive reporter vector in HEK293 cells, 
suggesting direct regulation of β-catenin by GSK3β pathway (Coghlan et al., 
2000). But a new model suggested that activation of the Wnt pathway only 
blocked the ubiquitination of β-catenin without releasing it from the destruction 
complex (reviewed by Clevers and Nusse, 2012). 
Another Wnt related pathway, Wnt/Ca2+ pathway, was considered as one of the 
two noncanonical Wnt pathways that does not stimulate β-catenin. Recent 
result showed that, however, the canonical and noncanonical pathways were 
not independent of each other (Thrasivoulou et al., 2013). They demonstrated 
that in prostate cancer PC3 cell line and bladder cancer cell line 253J, Wnt5A 
increased the intracellular calcium concentration and further caused the 
translocation of β-catenin to nucleus. Such β-catenin translocation was inhibited 
significantly by incubation cells with thapsigargin, an inhibitor to Wnt induced 
intracellular calcium release (Thrasivoulou et al., 2013). But in normal urothelial 
cultures, when the extracellular calcium concentration was escalated, β-catenin 
translocated to the intercellular membranes and bound to E-cadherin, of which 
the interaction was enhanced by the calcium concentration increase 
(Georgopoulos et al., 2010). E-cadherin mutated NHU cells in physiological 
calcium concentration demonstrated an abolished E-cadherin expression and 
nuclear localisation of β-catenin (Georgopoulos et al., 2010). In PC3 cell line, 
when expression of E-cadherin was increased by stimulation of luteolin, a 
common dietary flavonoid, invasion was inhibited by the induction of E-
cadherin, but can be reversed by siRNA against E-cadherin (Zhou et al., 2009), 
suggesting an anti-invasion role of E-cadherin. Taken together, the expression 
of E-cadherin in normal cells might be related to the calcium-induced 
translocation of β-catenin and involved in Wnt signalling pathway related gene 
regulation. 
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Research on GSK3β/β-catenin pathway also suggests its interaction with other 
carcinogenesis related pathways in normal cells and cancer cell lines/ tissues. 
An interaction between MAPK and GSK3β/β-catenin pathways was 
demonstrated in proliferative NHU cells (Georgopoulos et al., 2014). Active β-
catenin was up-regulated 48h post seeding along with increase of 
phosphorylated ERK. This enhanced β-catenin expression was inhibited by 
either EGFR inhibitor (PD153035) or ERK pathway inhibitor (U0126). Knock 
down of β-catenin reduced the proliferation of NHU cells together with 
attenuated phosphorylated ERK signal expression (Georgopoulos et al., 2014).  
In prostate cancer cell line, inactivation of GSK3β increased the protein 
expression of β-catenin and further induced EGFR proteins. This correlated link 
was further confirmed by shRNA silence of β-catenin transcript and protein 
showing down regulation of EGFR, and inhibition of EGFR demonstrating 
reduction of active β-catenin expression (Guturi et al., 2012). Human urothelial 
carcinoma samples also have demonstrated expression of both β-catenin and p-
ERK, which did not express in normal tissue (Ahmad et al., 2011). To further 
confirm the correlation, transgenic mice were generated with mutated Ras 
and/or activated β-catenin. Within 12 months, neither mutated Ras or activated 
β-catenin alone induced tumour formation, but urothelial carcinoma was 
rapidly formed in mice with both mutated Ras and activated β-catenin, which 
suggested an important relationship between co-expression of Ras/β-catenin 
and formation of urothelial carcinoma (Ahmad et al., 2011). The mechanism of 
this interaction was not yet clear but may indicate a dual target for tumour 
therapy.  
Crosstalk between Wnt/GSK3β and PI3K/AKT was shown in cancer cell lines. 
GSK3β is a downstream effector of the PI3K/AKT pathway. It can be 
phosphorylated by EGF-induced activation of AKT pathway in human prostate 
cancer cell lines DU145 and PC3. This process can be reversed by inhibition of 
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AKT (Gan et al., 2010). In metastatic T24-L (lung metastasis) cell line, inhibition 
of PI3K/AKT by LY294002 reduced the phosphorylated AKT and downstream 
phosphorylated GSK3β in a dose-dependent manner, resulted in activation of 
GSK3β and followed by suppression of β-catenin transcription activity, which 
led to reduced invasive ability (Wu et al., 2012).  
In colon cancer cells, over expression of β-catenin induced the expression of 
PPARγ protein, which can also be achieved by inhibition of GSK3β pathway 
using LiCl. The promoter activity of PPARγ was enhanced dramatically, which 
may suggest a cross talk between Wnt/β-catenin and nuclear receptor PPARγ in 
cancer formation, as expression of PPARγ in colon cancer was aberrantly 
abundant (Jansson et al., 2005).  
These findings regarding the role of canonical and noncanonical Wnt/GSK3β 
pathways and the interaction with other signalling pathways provide evidence 
of involvement of Wnt/GSK3β pathway in carcinogenesis. 
4.1.6 PPARγ pathway and its importance in controlling cell 
proliferation and differentiation 
PPARγ pathway is considerably involved in urothelial differentiation, for 
example, activating PPARγ pharmacologically in EGFR inhibited NHU cells 
can induce a differentiated phenotype (Varley et al., 2004a). Phosphorylation of 
PPARγ by MAPK suppressed the transcriptional activity of PPARγ (Camp and 
Tafuri, 1997). Another report suggested the PPARγ agonist troglitazone was 
able to induce phosphorylation of ERK pathway in EGFR exogenous expressed 
porcine aorta endothelial (PAE) cells, and such process was PPARγ 
independent as PPARγ antagonist GW9662 did not abolish the phosphorylated 
MAPK, though it reduced the PPRE promoter activity stimulated by 
troglitazone (Li et al., 2009). 
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In cancer cells, a few studies have shown different roles of PPARγ. In bladder 
cancer cell line 5637, knock down of PPARγ significantly reduced the migration 
of cells. When treated with rosiglitazone (PPARγ agonist), cell migration and 
invasion was increased in 5637 cells (Yang et al., 2013). By contrast, other 
studies showed growth inhibition on cancer cells by activation of PPARγ 
pathway. Combined treatment of EGFR inhibitor gefitinib and PPARγ agonist 
DIM-C sensitised EGFR inhibitor gefitinib resistant bladder cancer cell lines 
(UMUC3, UMUC13 and KU7) (Mansure et al., 2013). In vivo experiment also 
showed that combined treatment of EGFR inhibition and PPARγ activation 
reduced the tumour weight significantly compared to control (Mansure et al., 
2013). In colon cancer, one therapy method suggested that troglitazone, as one 
of the PPARγ modulators, was used to demonstrate compromised cell growth 
compared to vehicle control treated cells in several colon cell lines. This 
decreased proliferation was caused by induction of differentiation assessed 
using CEA (carcinoembryonic antigen, a marker of differentiation in colon 
cancer cell lines). It was also shown that this effect was not observed by using 
ligands having no PPARγ binding abilities, suggesting a specific PPARγ 
induced growth inhibition. Significantly reduced tumour volume in nude mice 
was detected in troglitazone fed mice compared to vehicle controls after 
implanting human colon carcinoma CX-1 tumour cells and allowing the tumour 
to grow to 70 mm3 (Sarraf et al., 1998). These findings indicate that activation of 
PPARγ signalling pathway may play different roles in cancer development or 
metastasis in different circumstances. 
However, the effect of PPARγ ligands on apoptosis of cancer cells should be 
considered with caution, as it may be caused by off target concentration of 
PPARγ ligands, which was demonstrated by PPARγ independent mechanism 
such as activation of store-operated calcium channel (SOC) (Chopra et al., 2009). 
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Other differentiation-associated transcription factors like FOXA1 were shown 
to play roles in preventing cancer cell proliferation. It was suggested that poorly 
differentiated cancers were associated with loss of transcription factors, as loss 
of FOXA1 expression at transcript and protein level was associated with high 
grade of bladder cancer. FOXA1 negative tumours were more proliferative 
(DeGraff et al., 2012). Over expression of FOXA1 in bladder cancer cell line T24 
cells increased the expression of E-cadherin and reduced the proliferating rate. 
By contrast, knock down of FOXA1 promoted the growth of bladder cancer cell 
line RT4 cells (DeGraff et al., 2012).  
Biton et al. showed that most superficial tumour samples (papillary luminal 
tumours, for example) displayed a differentiated phenotype, as the majority of 
superficial tumour samples were distributed at the differentiated side in the 
heatmap, which showed the distribution of various genes in different types of 
tumours. Differentiation-associated markers (CK20, UPK1A, GRHL3, PPARγ, 
etc.) that generally expressed in normal tissue were also distributed at the 
differentiated side (Biton et al., 2014).  
Other reports also suggested high protein expression of PPARγ and DNA copy 
number gain were related to high grade bladder cancer (Conconi et al., 2012; 
Yang et al., 2013). The region in genome 3 encompassing PPARγ gene showed 
29% (in 51 of the 178 tumours) of copy number gains, whereas only 4% (in 7 of 
the 178 tumours) of copy number loss was detected. This event of copy number 
gain was not correlated with differentiation, as CK20 showed no consistent 
expression pattern (Biton et al., 2014). The somatic copy number alteration was 
confirmed by another study showing that 17% of UC samples had PPARγ 
amplified mutation, the amplification of which increased to at least 3 copies, to 
more than 5 copies in some cases (Cancer Genome Atlas Research, 2014). The 
exact link between PPARγ expression and urothelial cancer is yet to be 
understood and requires further investigation. 
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4.1.7 Summary 
Regarding differentiation, different types of bladder cancer have demonstrated 
different phenotype, with which they may have distinct signalling pathways 
associated. Understanding role of signalling pathways in regulating normal 
urothelium and alteration of such pathways in carcinogenesis may facilitate the 
study of normal urothelial function and tumourigenesis.  
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4.2 Experimental approach 
4.2.1 Aims and hypothesis 
The aims of this chapter were to investigate the pathways utilised by 
established in vitro UC cell lines and to understand the relationship between the 
phenotype of UC cells and the signalling pathways they depend on for growth.  
The hypothesis for this chapter was that the UC cells demonstrating a 
differentiated phenotype depend on tissue regenerating pathways for growth, 
for which it is predicted that they retain expression of transcription factors 
involved in regulating urothelial differentiation.  
4.2.2 Characterisation of urothelial cancer cell lines 
UC cell lines were cultured in medium with serum. To eliminate the effect of 
serum, 5637, T24 and UMUC9 cells were selected as candidates to adapt to 
KSFM.  
To understand whether the phenotype of these cells changed when cultured in 
different media and characterise the phenotype of all the cultured cell lines, 
UPK2, CLDN7 and CK20 were selected as differentiation-associated genes. 
Transcripts of these genes were analysed by RT-QPCR. Transcripts of PPARγ2, 
ELF3 and FOXA1 were also examined to suggest any possible links between 
expression of transcription factors and phenotype of UC cell lines. PPARγ2 is 
one of the PPARγ isoforms regulating differentiation in adipogenesis (See 
detailed information in chapter 5). 
To confirm the phenotype of cell lines and examine whether there was 
difference of PPARγ protein expression among cell lines, western blots were 
performed. Protein lysates were harvested from cell lines cultured in different 
media. PPARγ protein was analysed using PPARγ (E8) antibody. CK13, CK14, 
CLDN4 and CLDN7 were analysed to indicate the phenotype. 
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Immunofluorescence was performed to characterise the UC cell lines. CK13, 
CK14 and CK20 were examined to confirm whether the cells were transitional 
differentiated, squamous proliferating or differentiated, respectively. PPARγ 
and ELF3 were examined to indicate the expression of transcription factors in 
different UC cell lines. Markers of pathways that resulted in cell proliferation in 
NHU cells, like phosphorylated ERK, phosphorylated AKT and active β-catenin 
(Georgopoulos et al., 2014; Georgopoulos et al., 2010) were further examined. 
4.2.3 Growth assay to determine essential signalling pathways 
Alamar Blue assay was performed to determine whether addition of exogenous 
factors would be able to affect the proliferation of UC cells. Table 4.2.1 displays 
the factors used for the assay. 
Name Final Conc. Function/Effect 
DMSO 0.1% (V/V) Vehicle control 
FBS 2% (V/V) Positive control 
TZ 1 µM Activator of PPARγ (Varley et al., 2004a) 
TGFβ 2 ng/mL Promote migration in differentiated NHU cells 
(Fleming et al., 2012) 
EGF 5 ng/mL Growth factor that promotes proliferation of NHU 
cells (Varley et al., 2005) 
SB415286 10 µM GSK3β inhibitor, which further activates β-catenin 
pathway  
PD153035 1 µM Inhibitor of EGFR pathway  
U0126 5 µM Inhibitor of MEK/ERK  
LY294002 5 µM Inhibitor of PI3K/AKT pathway  
BPE 50 µg/mL Enable the proliferation of NHU cells (Southgate et 
al., 1994) 
CT 30 ng/mL Increase initial plating efficiency of NHU cells 
(Southgate et al., 1994) 
T0070907 1 µM Inhibitor of PPARγ pathway (Varley et al., 2006) 
SB431542 3 µM Inhibitor of TGFβ pathway 
Table 4.2.1 Tested factors on proliferation of UC cells. 
To identify key factors or combination of factors promoting proliferation, cells 
were seeded on plates before application of treatments. Growth factors known 
as activators for NHU cells were added to cultures demonstrating low 
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proliferation. By contrast, factors known as inhibitors for proliferation of NHU 
cells were added to cultures showing proliferative phenotype. 
4.2.4 Immunofluorescence to identify specific pathways 
promoting proliferation 
Immunofluorescence was performed with added inhibitors or activators 
affecting the cell proliferation. Associated pathways were analysed. CK13, 
CK14 and CK20 were examined to define the phenotype of cells when growth 
was modified. Transcription factors like PPARγ or ELF3 were assessed to check 
whether the added factors had altered the localisation and expression of 
transcription factors.  
The fluorescence intensity of nuclei was calculated using Image-Pro Plus 
software to suggest the amount of proteins expressed in the nucleus. Intensity 
of nuclei in images were measured and averaged. Bar charts for individual 
proteins were generated with fluorescence intensity of images captured for each 
treatment. 
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4.3 Results 
4.3.1 Adaption of UC cell lines 
In order to identify the key factors maintaining the cell growth and to compare 
to NHU cells that grown in serum-free medium (KSFM), cancer cells were 
adapted to grow in KSFM (Table 4.3.1). 5637 cells were able to grow in KSFM or 
KSFMc, whereas T24 cells were only able to proliferate in KSFM without 
supplements. After a week of incubation in KSFM, UMUC9 cells were still not 
able to grow in KSFM. To improve the growth of UMUC9 in KSFM, other 
factors were added to cultures and the detailed results are listed in 4.3.4. 
Cell line Standard medium KSFMc KSFM KSFM+Ca2+ 
5637 RPMI (5% FBS) Y Y No data 
T24 
DMEM:RPMI 50%:50% 
(5% FBS) 
N Y No data 
UMUC9 DMEM (10% FBS) * N N 
Table 4.3.1 Cell lines adapted to serum-free medium. Y indicates cell growth; N indicates no 
growth in at least one week. *, see 4.3.4 for more information of UMUC9 in complete KSFM 
(KSFMc). 5637 cells and T24 cells were able to be adapted to KSFM, so no more supplements 
was added (No data).  
4.3.2 Characterisation of UC cell lines 
4.3.2.1 Transcripts of Transcription factors and differentiation-associated 
genes by RT-QPCR 
To characterise the phenotype of urothelial cancer cell lines cultured in vitro, 
RT-QPCR was performed using primers of differentiation-associated genes. 
Transcript expression of UPK2 was variable between UC cell lines, suggesting 
that phenotype of cancer cell lines in terms of the degree of differentiation were 
different from each other. In NHU cells shown as control, the transcripts of 
UPK2 were only present in differentiated cells. UMUC9 was the most 
differentiated cell line demonstrating a similar amount of UPK2 expression as 
differentiated NHU cells. RT4, SD48 and RT112 cells had less UPK2 transcripts 
expressed. 5637 and T24 cells had little UPK2 expression, which resembled the 
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UPK2 transcripts in proliferative NHU cells and demonstrated non-
differentiated phenotypes (Fig. 4.3.1). 
Expression of CLDN7 was minimal in RT4 cells and T24 cells. Among the 
cancer cell lines, UMUC9 showed the most abundant CLDN7 transcript (Fig. 
4.3.1). 
CK20 demonstrated strikingly high transcript expression in UMUC9 and SD48 
cells (Fig. 4.3.1). A log scale bar chart is included in Appendix (Fig 7.1.1) to 
show the more detailed information of CK20 transcripts in differentiated NHU 
cells and other UC cell lines. 
The difference of differentiation-associated genes expressed by 5637 and T24 
cells in different media was not dramatic. These two cell lines demonstrated a 
non-differentiated phenotype, which was independent of the presence of 
serum. 
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Fig 4.3.1 Transcript expression of differentiation-associated genes. RNA samples were 
obtained from cancer cells cultured in medium with serum or adapted to KSFM (5637 cells and 
T24 cells). 5637RPMI indicates RNA sample of 5637 cells cultured in RPMI with serum; T24DR 
indicates RNA sample of T24 cells cultured in DMEM& RPMI with serum. Proliferating (NHU 
pro) and 7 days TZ/PD differentiated (NHU dif) NHU cells (Y1289) were included as control. 
RT-QPCR was performed. Gene expression of UPK2, CLDN7 and KRT20 was normalized to 
GAPDH. Fold change of each sample was obtained by comparing to the proliferating NHU cell 
sample. Error bars indicate standard deviation of three technical replicates. Note the high 
expression of UPK2, CLDN7 and KRT20 in the UMUC9 cell line. 
With a differentiated phenotype, UMUC9 cells also showed the most abundant 
expression of ELF3 and PPARG2 of all tested cell lines. Transcript of PPARG2 
was massively expressed in UMUC9, whereas ELF3 was expressed most 
abundantly in differentiated NHU cells. Another cell line (SD48) also showing a 
differentiated phenotype had the most abundant transcript of FOXA1 
expressed (Fig 4.3.2). 
 Though there was almost no diversity regarding expression of downstream 
differentiation-associated genes between 5637 or T24 cells grown in different 
media, the expression of transcription factors was more abundant in medium 
supplemented with serum. This finding may suggest that the expression of 
transcription factors can be up-regulated by factors in the serum, but for cells 
showing non-differentiated phenotype, the difference of transcription factors 
expression did not affect either the phenotype or the proliferation of cells 
necessarily, as both 5637 cells and T24 cells were able to proliferate regardless 
the absence of serum in the medium (Fig 4.3.2).  
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Fig 4.3.2 Transcript expression of transcription factors. RNA samples were obtained as 
described in Fig 4.3.1. Proliferating (NHU pro) and 7 days TZ/PD differentiated (NHU dif) 
NHU cells (Y1289) were included as control. 5637RPMI indicates RNA sample of 5637 cells 
cultured in RPMI with serum; T24DR indicates RNA sample of T24 cells cultured in DMEM& 
RPMI with serum. RT-QPCR was performed as described in the methods. Gene expression of 
PPARG2, ELF3 and FOXA1 was normalized to GAPDH. Fold change of each sample was 
obtained by comparing to the proliferating NHU sample. Error bars indicate standard deviation 
of three technical replicates. Note the high expression of PPARG2 in the UMUC9 cell line. 
4.3.2.2 Protein expression of PPARγ and other differentiation markers 
To further confirm the characterisation of UC cell lines, protein expression of 
PPARγ and differentiation-associated markers was examined by western 
blotting. 
On the blot, multiple protein bands appeared after incubation of PPARγ E8 
antibody. A band at about 40 kDa (Band D) was expressed in almost all 
samples, with the most expression in NHU cells. The 50/52 kDa bands (Band C / 
B) were present in all tested cell lines. The least amount of 50/52 kDa bands was 
observed in the T24 cell line. A switch of 50/52 kDa bands in 5637 cells cultured 
in different media was observed, suggesting a possible induction of different 
PPARγ isoform by factors in the serum .The 58 kDa band (Band A) was present 
in NHU cells and 5637 cells, but it was not always detectable (see chapter 3 for 
other PPARγ blots). UMUC9 cells displaying most abundant PPARG2 
transcript expression did not demonstrate any visible difference compared to 
the other cell lines. Bands with higher and lower molecular weight were also 
present on the blots (Fig 4.3.3). Expressing pattern of UC cells compared with 
lysates from other tissues/species is shown in Appendix (Fig 7.1.2). 
 Chapter 4 
117 
 
Fig 4.3.3 PPARγ E8 blot of different urothelial cancer cell lines. Lysates were obtained from 
cancer cells cultured in medium with serum or adapted to KSFM (5637 cell line, labelled as 5637 
KSFM). Proliferating (Pro) and 6 days ABS/ Ca2+ differentiated (Dif) NHU cells (Y588, lysates 
were taken by Ros Duke) were included as control. PPARγ E8 antibody was applied and 
detected following the western blotting protocol. Four main PPARγ bands appeared on blots 
were pointed by arrows and labelled as A, B, C and D. 
To obtain more information about the phenotype of the cell lines, expression of 
CK proteins and tight junction proteins was examined. Proliferating NHU 
cultures showed CK14 expression, whereas only differentiated NHU cells 
expressed CK13 proteins. RT112 cells demonstrated the expression of both 
CK13 and CK14. 5637 cells cultured in KSFM showed CK14 expression, 
whereas cells in RPMI with serum were CK14 negative, suggesting the 
adapting of 5637 cells into serum-free medium might have affected their 
phenotype, which was also associated with a distinct PPARγ expression pattern 
(Fig 4.3.4).  
The protein expression of CLDN7 was similar to the CLDN7 transcripts 
(negative in RT4 and T24 cells, see Fig 4.3.1). CLDN4 protein was expressed in 
all cell lines except T24, suggesting that T24 was poorly differentiated with 
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nearly no expression of differentiation-associated markers. A small band 
slightly lower than the main band of CLDN4 was detectable in UMUC9, SD48 
and differentiated NHU cells, all showing a differentiated phenotype (Fig 4.3.4). 
 
Fig 4.3.4 Expression of differentiation-associated proteins. Lysates were obtained as described 
in Fig 4.3.3. Proliferating and 6 days ABS/ Ca2+ differentiated NHU cells (Y588, lysates were 
taken by Ros Duke) were included as control. CK13, CK14, CLDN4 and CLDN7 antibodies 
were applied and detected following the western blotting protocol. β-actin was utilised as 
loading control. 
From the RT-QPCR and western blotting results, UMUC9 cell line was selected 
as the most differentiated urothelial cancer cell line among the tested cell lines 
and utilised to understand the importance of maintaining a differentiated 
phenotype. 5637 cell line was chosen as another candidate for further 
investigation, as it was less differentiated and showed different phenotypes in 
different media (with or without serum) by western blotting. 
4.3.3 Characterisation of UMUC9 cells by immunofluorescence 
UMUC9 cells demonstrated a differentiated phenotype with dramatic amount 
of PPARG2 transcript expression. Whether there is a relationship between such 
phenotype and PPARG2 transcript expression requires further investigation of 
the signalling pathways involved. Characterisation of UMUC9 cells by 
immunofluorescence was performed. 
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UMUC9 cells demonstrated negative CK14 expression along with positive 
cytoplasmic phosphorylated ERK. The expression of CK14 was present in 
proliferating NHU cells, which also showed the phosphorylated ERK 
expression in the nuclei (Fig 4.3.5). 
 
Fig 4.3.5 Expression of CK14 and p-ERK in UMUC9 cells. UMUC9 cells were cultured in 
DMEM (10% FBS) and seeded on slides. Proliferating NHU cells (Y1156) showed expression of 
both CK14 and p-ERK. Slides were fixed using 50:50 of Methanol:Acetone fixation (Me:Ac) for 
30s and incubated with primary antibodies of CK14 and p-ERK. Scale bar represents 50µm. 
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Differentiation-associated cytokeratin proteins were examined as well. UMUC9 
cells cultured in DMEM with serum did not show any CK13 expression. By 
contrast, CK20 demonstrated ubiquitous expression in UMUC9 cells. In 
differentiated NHU cells as positive control, CK13 and CK20 were both present, 
but the expression of CK20 was sporadic and only detectable in some cells (Fig 
4.3.6).  
 
Fig 4.3.6 Expression of CK13 and CK20 in UMUC9 cells. UMUC9 cells were seeded in DMEM 
with 10% FBS and fixed using Me:Ac fixation method.  NHU cells (Y1156) were induced to 
differentiate with TZ/PD for 72h as a differentiated control (TZ/PD dif NHU). Primary 
antibodies of CK13 and CK20 were applied on the slides. Scale bar represents 50µm. 
UMUC9 cells showed a differentiated phenotype without CK13 expression. To 
explore the difference between differentiated NHU cells and UMUC9 cells, 
expression of transcription factors was further analysed. PPARγ and ELF3 
demonstrated nuclear expression in UMUC9 cells, which resembled the 
expression of PPARγ and ELF3 in NHU cells. PPARγ2 that showed 
considerable transcript expression in UMUC9 cells was analysed to verify the 
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expression and indicate the localisation. It suggested that the expression of 
PPARγ2 was considerable and localised to nuclei of cells specifically (Fig 4.3.7). 
 
Fig 4.3.7 Expression of PPARγ and ELF3 in UMUC9 cells. UMUC9 cells were seeded in 
DMEM with 10% FBS and fixed using Me:Ac fixation. Differentiated NHU cells (Y1156) were 
induced to differentiate for 72h and shown as differentiation control (TZ/PD dif NHU). Primary 
antibodies of PPARγ and ELF3 were applied to UMUC9 and NHU cells. PPARγ2 was applied 
to UMUC9 cells. Scale bar represents 50µm. 
To understand the pathways UMUC9 cells dependent on for growth, the 
pathways driving proliferation in NHU cells were examined. In DMEM with 
serum, UMUC9 cells showed membrane expression of E-cadherin, active β-
catenin and phosphorylated AKT. When treated with calcium at physiological 
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concentration (2mM), NHU cells showed membrane E-cadherin and nuclear 
active β-catenin expression (Fig 4.3.8).  
 
Fig 4.3.8 Expression of proteins associated with proliferation in UMUC9. UMUC9 cells were 
seeded in DMEM with 10% FBS. Slides were either fixed with Me/Ac for examining of E-
cadherin or fixed with 10% formalin and permeabilised with 0.5% Triton X-100 for 30 min for 
detecting of active β-catenin and p-AKT. NHU cells (Y1156) were treated with 2mM calcium for 
72h as positive control and fixed with Me/Ac. Primary antibodies against E-cadherin, active β-
catenin and phosphorylated AKT were applied. Scale bar represents 50µm. 
UMUC9 cells cultured in DMEM with serum demonstrated a differentiated 
phenotype with features similar to NHU cells cultured in physiological calcium 
concentration. In order to understand the pathways driving proliferation in 
UMUC9 cells, and minimise the effect of serum on growth. UMUC9 cells were 
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adapted to 80% KSFM and 20% DMEM with serum (2% FBS as final conc.), as 
cells were unable to adapt to proliferate in 100% KSFM.  
4.3.4 Effect on proliferation of UMUC9 cells in KSFM by various 
factors 
UMUC9 cells were cultivated in 80% KSFM and 20% DMEM with 2% FBS as 
final concentration. To further investigate the pathways involved in 
proliferation of UMUC9 cells, inhibitors were added to cultures (See Table 
4.2.1). Growth assay showing the reduction of Alamar Blue on day 6 suggested 
that MEK/ERK pathway and Wnt/β-catenin pathway were associated with 
proliferation of UMUC9 cells significantly. But the decrease of cell growth was 
not dramatic, suggesting the role of these pathways was not critical or the 
remnant of serum was still able to promote proliferation (Fig 4.3.9). 
 
Fig 4.3.9 Growth inhibition on UMUC9 cells. UMUC9 cells were seeded at 2X104 /mL cultured 
in 80% KSFM and 20% DMEM (2% FBS). Various inhibitors were added to cultures. Growth 
assay was performed as described in the methods on the 6th day. Error bars indicate standard 
deviation of five experimental replicates. Statistical analysis was calculated by one-way 
ANOVA with Bonferroni multiple comparisons post-test (*** P<0.001). 
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Because the remnant of serum might affect the proliferation of UMUC9 cells, a 
further experiment was performed with UMUC9 cells seeded in 100% KSFM. 
Treatments of different media were added to cultures to indicate whether any 
additional factor was able to promote the growth of UMUC9 cells. 
In 100% KSFM, UMUC9 cells were unable to proliferate for almost two weeks. 
Physical calcium concentration did not promote proliferation. Cells cultured in 
medium with serum showed continuous proliferation, regardless of the 
concentration of serum (KSFM+10% FBS or 80% KSFM containing 2% FBS). 
KSFMc or KSFM supplemented with EGF promoted the cell growth after days 
of treatment but with a lower growth rate than cultures in media with serum. 
The cells with different treatments were cultured in 5% CO2, which might have 
affected the cell proliferation in DMEM (10% FBS, should be incubated in 10% 
CO2) (Fig 4.3.10).  
 
Fig 4.3.10 Growth assay of UMUC9 cells. Cells were seeded at 2X104 /mL in 100% KSFM on 96 
well plate and treated the next day with various media. For cells grown in 80% KSFM, the rest 
of the medium was DMEM (10% FBS). Growth assay was performed as indicated with separate 
plates as described in the methods. Error bars indicate standard deviation of six experimental 
replicates. 
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To display the difference of population doubling rate of UMUC9 cell in various 
media, the reduction of Alamar Blue on the 8th day was extracted and shown in 
a bar chart. Statistical analysis suggested that all the other media except for 
KSFM with calcium added significantly improved the growth rate, though it 
was not as tremendous as positive controls. 
 
Fig 4.3.11 Effect of different media on growth of UMUC9 on day 8. Bar chart was generated 
using the 8th day data. Error bars indicate standard deviation of six experimental replicates. 
Statistical analysis was calculated by one-way ANOVA with Bonferroni multiple comparisons 
post-test (*** P<0.001). Reduction rates of cells grown in media with serum supplied were 
shown as positive controls. 
To further investigate the factor promoting growth, UMUC9 cells were treated 
with various growth factors listed in Table 4.2.1. Treatments are grouped and 
listed in Table 4.3.2. 
DMSO (-) U0126 LY294002 PD153035 
TZ TZ U0126 TZ LY294002 TZ PD153035 
TGFβ TGFβ U0126 TGFβ LY294002 TGFβ PD153035 
SB415286 SB415286 U0126 SB415286 LY294002 SB415286 PD153035 
EGF BPE CT EGF BPE CT (KSFMc) 
TGFβ EGF TGFβ TZ TGFβ SB415286 2% FBS (+) 
Table 4.3.2 Growth factors added in cultures. Treatments are listed in the table. DMSO was 
used as vehicle control. 2% FBS was added to cultures to demonstrate the standard proliferative 
phenotype. Groups are shown either with different font colour or gray highlight in columns. 
Concentration of individual factor was listed in Table 4.2.1 along with their function on NHU 
cells. 
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Cell images of treatments that promote cell proliferation were displayed. EGF 
promoted proliferation of UMUC9 cells without apparently changed the shape 
of cells. The combination of EGF and TGFβ increased the proliferation as well, 
but the morphology of cells was altered from cuboidal shape (see positive 
control cells cultured in 2% FBS) to elongated fibroblast-like shape, which 
resembled the EMT process. KSFMc increased growth to a similar extent as EGF 
induced proliferation (Fig 4.3.12). 
  
 
Fig 4.3.12 Combination of factors required to promote growth in UMUC9 cells. Cells were seeded at 2.5X104 /cm2 in KSFM on 24 well plates and treated the next 
day. Media were replaced every other day for one week. Cultures were fixed with 50:50 of Methanol:Acetone for 30s, leaving only attached cells which were then 
stained with 0.1% w/v Crystal Violet (made up with 20% ethanol) for 5min. Phase contrast micrographs were taken after wash with distilled water. 0.1% DMSO was 
utilised as negative control demonstrating minimal proliferation. 2% FBS was included as positive control. Images with Crystal Violet staining shown fixed cells were 
displayed. Cell images of non-effective treatments that led to cell floating were not included. Treatments were combination of headings listed for individual 
row/column. For example, the last image on the second row indicates the UMUC9 cells treated with EGF, BPE and CT. Scale bar equals 200µm. 
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Growth assay with EGF and TGFβ was performed to test the growth promoting 
effects on UMUC9 cells cultured in KSFM. TGFβ treatment alone did not affect 
cell growth dramatically. Treatment with combined EGF and TGFβ showed 
similar proliferating trend to EGF alone, suggested that EGF was the main 
factor regulating growth. But the reduction rate of Alamar blue was less across 
the treatment compared to 2% FBS treated one, indicating other untested factors 
in the serum were critical for cell growth as well (Fig 4.3.13). 
 
Fig 4.3.13 Growth assay to test the effect of EGF and TGFβ in UMUC9. Cells were seeded at 
5X104 /mL in  KSFM and treated on the next day. Error bars indicate standard deviation of six 
experimental replicates. 
To understand the significance of growth promotion by EGF and TGFβ, 
reduction rate of Alamar Blue on the 5th day was displayed as bar chart in Fig 
4.3.14, which confirmed EGF as main growth promoting factor for UMUC9 cells 
growing in KSFM. 
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Fig 4.3.14 Effect of EGF and TGFβ on UMUC9 cell growth. Bar chart was generated with the 
5th day data from Fig 4.3.13. Reduction rate of cells in 2% FBS was shown as positive control. 
Error bars indicate standard deviation of six experimental replicates. Statistical analysis was 
calculated by one-way ANOVA with Bonferroni multiple comparisons post-test (*** P<0.001). 
In conclusion, EGF promoted the proliferation of UMUC9 cells, but the 
proliferation was not comparable to cells cultured in serum. Combined with 
TGFβ, EGF altered the morphology of UMUC9 cells to fibroblast-like cells.  
4.3.5 EGF-induced phenotype alteration of UMUC9 cells 
Immunofluorescence was performed to understand whether the phenotype had 
altered after EGF and TGFβ combined treatment. As UMUC9 cells were not 
proliferating in KSFM, negative control was not included. 
Transcription factors like ELF3 and PPARγ were expressed mostly in the nuclei 
in UMUC9 cells as shown in Fig 4.3.7. When treated with EGF and/or TGFβ in 
KSFM, however, UMUC9 cells showed diffuse cytoplasmic and peri-nuclear 
ELF3 and PPARγ expression. Localisation of PPARγ switched to the nucleus 
with diffuse cytoplasmic expression by 7 days EGF treatment. TGFβ treatment 
alone appeared to enhance the total amount of PPARγ expression. The 
expression of ELF3 and PPARγ in KSFM with 2% FBS was less abundant 
compared to the expression of cells cultured in DMEM (10% FBS), which might 
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be due to the decrease of calcium and serum concentration in KSFM with 2% 
FBS (Fig 4.3.15).  
 
Fig. 4.3.15 Expression of ELF3 and PPARγ in UMUC9 cells. UMUC9 cells were seeded at 1X105 
/mL on 12 well slides in KSFM with various treatments. Slides were fixed using 
methanol/acetone after 7 days of treatment. Primary antibodies against PPARγ and ELF3 were 
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applied. Pictures were taken with constant exposure time for individual antibodies for 
comparison. Scale bar represents 50µm. 
To confirm the expression alteration of PPARγ by TGFβ alone treatment, 
images showing a wider region were captured, in which PPARγ demonstrated 
nuclear localisation by EGF treatment. The fluorescence intensity was enhanced 
by TGFβ treatment, suggesting a possible up-regulation of PPARγ by TGFβ 
(Fig 4.3.16). 
 
Fig 4.3.16 Expression of PPARγ in UMUC9 cells (low magnification). UMUC9 cells in KSFM 
were treated as indicated in the figure for 7 days and immunolabelled with PPARγ antibody 
after Me/Ac fixation. Immunofluorescence images were captured using X20 oil lens to 
demonstrate the expression of PPARγ by different treatments. Pictures were taken with 
constant exposure time for comparison. Scale bar represents 100µm. Note, the expression of 
PPARγ was increased by TGFβ only treatment. 
The expression of PPARγ in UMUC9 cells (Figs 4.3.7, 4.3.15 and 4.3.16) is 
summarised in Table 4.3.3. PPARγ expression of UMUC9 cells cultured in 
DMEM (10% FBS) is included as positive control. Only EGF-treated UMUC9 
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cells in KSFM demonstrated nuclear expression (Fig 4.3.15). TGFβ alone 
induced the up-regulation of PPARγ expression in both nucleus and cytoplasm 
(Fig 4.3.15). 
Expression and 
localisation of 
PPARγ 
10% FBS 
(DMEM) 
EGF 
(KSFM) 
TGFβ 
(KSFM) 
EGF + TGFβ 
(KSFM) 
2% FBS 
(KSFM) 
Nuclear √√ √√    
Cytoplasmic  √    
Diffuse   √√√ √ √ 
Table 4.3.3 Expression of PPARγ in UMUC9 cells. The amount of protein expression was 
shown as √. Increased fluorescence intensity was demonstrated by √√ or √√√. PPARγ expression 
in UMUC9 cells growing in DMEM (10% FBS) was included as positive control. Where 
expression was observed in both nucleus and cytoplasm in the majority of cells, it was classified 
as diffuse. 
To explore the downstream pathways that EGF and/or TGFβ treated UMUC9 
cells grown in KSFM used for growth, canonical pathways promoting 
proliferation in NHU cells were further examined. By EGF and/or TGFβ 
treatments, active β-catenin was expressed and mostly demonstrated a diffuse 
cytoplasmic localisation, whereas in positive control cells in 2% FBS, β-catenin 
was localised to the membrane. The expression of phosphorylated ERK was not 
prominent. Phosphorylated AKT showed some membrane labelling in TGFβ-
treated cells (Fig 4.3.17). 
  
 
Fig 4.3.17 Signalling pathways of UMUC9 cells. UMUC9 cells were seeded at 1X105 /mL on 12 well slides in KSFM with various treatments for 7 days. Slides were 
fixed using formalin fixation and permeabilised with 0.5% Triton X-100 before processing for immunofluorescence. Primary antibodies against active β-catenin, 
phosphorylated ERK and phosphorylated AKT were applied. Scale bar represents 50µm. 
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Further characterisation on EGF and/or TGFβ treated UMUC9 cells was 
performed by immunofluorescence. In EGF and/or TGFβ treated UMUC9 cells, 
the most significant change was the expression of CK14. CK13 did not show a 
detectable change. RT112 cells were included to show positive expression of 
CK13. Expression of CK20 was still present in EGF treated cells but not 
detectable in other treatments with TGFβ. These findings suggested that the 
phenotype of UMUC9 cells was affected by the EGF and/or TGFβ treatment 
and altered to a more basal-like phenotype (Fig 4.3.18). 
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Fig 4.3.18 Phenotype of UMUC9 cells. UMUC9 cells were seeded at 1X105 /mL on 12 well slides 
in KSFM with treatments for 7 days and fixed with methanol /acetone. UMUC9 cells treated 
with 2% FBS showing CK13 (-), CK14 (-) and CK20 (+) was used to demonstrate the phenotype 
of UMUC9 cells in the presence of serum. RT112 was included as positive control for CK13. 
Scale bar represents 50µm. 
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The EMT process might be a possible mechanism for the alteration of 
phenotype in treated UMUC9 cells. Key factors like E-cadherin and vimentin 
were examined. Proliferating NHU cells demonstrated vimentin protein 
expression and were included as positive control. The expression of vimentin 
was expressed de novo in EGF and/or TGFβ treated UMUC9 cells, as UMUC9 
cells cultured in 2% FBS showed no detectable vimentin expression. However, 
in EGF and/or TGFβ treated cells, E-cadherin was still present and did not 
demonstrate any obvious loss following treatments (Fig 4.3.19).  
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Fig 4.3.19 Phenotype of UMUC9 cells. UMUC9 cells were seeded at 1X105 /mL on 12 well slides 
in KSFM with treatments for 7 days and fixed with methanol /acetone before processing for 
immunofluorescence. Proliferating NHU cells (Y1156) showed the expression of vimentin as 
positive control. Scale bar represents 50 µm. 
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The phenotypes of UMUC9 cells in different conditions are summarised in 
Table 4.3.4. 
Markers 
DMEM 
(10% FBS) 
KSFM 
EGF 
KSFM 
TGFβ 
KSFM 
EGF+TGFβ 
KSFM 
2%FBS 
CK13 - - - - - 
CK14 - + + + - 
CK20 + + -* -* + 
E-cadherin + + + + + 
Vimentin 
Not 
tested 
+ + + - 
Table 4.3.4 Phenotype of UMUC9 cells in different conditions.  UMUC9 cells in different 
media were tested. KSFM with 2% FBS was used as positive control medium for UMUC9 cells 
showing phenotype of cells in the presence of serum. For expression of CK20 in cells 
maintained in media with TGFβ, no detectable protein was observed on tested slides, which is 
noted by *. 
It appeared from these results that exogenous EGF might have altered the 
phenotype of UMUC9 cells. To confirm this finding, inhibitors were then added 
to UMUC9 cells. When treated with EGF, UMUC9 cells demonstrated 
noticeable proliferation, which was abolished by the ERK inhibitor U0126, 
suggesting a direct growth promotion by EGF via the MEK/ERK pathway. 
Other inhibitors like LY294002 and PD153035 inhibited the proliferation of 
EGF-treated UMUC9 cells significantly but not as noticeably as U0126. TZ was 
included as PPARγ activator that induced differentiation in NHU cells. In EGF-
treated UMUC9 cells grown in KSFM, TZ inhibited the EGF-promoted growth 
significantly but not dramatically. By contrast, T0070907 did not affect the EGF-
promoted growth, suggested that either the proliferation had little relationship 
with PPARγ pathway or the ligand binding site of PPARγ in UMUC9 cells was 
mutated (Fig 4.3.20).  
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Fig 4.3.20 Growth inhibition by the inhibitors. UMUC9 cells were seeded at 5X104 /mL in 
KSFM and treated with or without EGF. For cells treated with EGF, various pathway inhibitors 
were added. DMSO was added in non-treated cells as vehicle control. Growth assay was 
performed using Alamar Blue reagent. Error bars indicate standard deviation of six 
experimental replicates. Statistical analysis was calculated by one-way ANOVA with Bonferroni 
multiple comparisons post-test (*** P<0.001). 
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UMUC9 cells demonstrated almost no proliferation when cultured in KSFM. 
This growth arrest observed was reversed by EGF treatment partly (Fig 4.3.20), 
compared to UMUC9 cells grown in medium with serum (Fig 4.3.13). However, 
this improved growth by EGF was associated with alteration of phenotype and 
morphology, as the original differentiated phenotype of UMUC9 cells was 
altered to a more basal-like one, showing CK14 expression by EGF treatment, 
which was similar to proliferating NHU cells (Table 4.3.5). Other factors may be 
as well crucial for UMUC9 cells to proliferate, but whether maintaining the 
differentiated phenotype is required needs further study. 
 NHU (proliferating) UMUC9 (serum) UMUC9 (EGF and/or TGFβ) 
CK14 √ x √ 
E-cadherin √ (with 2mM calcium) √ √ 
Vimentin √ x √ 
Table 4.3.5 Phenotype of UMUC9 cells. UMUC9 cells grown in KSFM were compared to NHU 
cells and UMUC9 cells grown in medium with serum. Whether the proteins were expressed or 
not are indicated with either √ or x. 
4.3.6 Investigating signalling pathways of 5637 cells adapted to 
KSFM 
UMUC9 cells showed a differentiated phenotype in medium with serum but a 
basal-like phenotype in serum free medium. By contrast, 5637 cells were less 
differentiated. Fig 4.3.21 demonstrates the expression of PPARγ, ELF3, E-
cadherin and active β-catenin of 5637 cells cultured in RPMI (5% FBS). Active β-
catenin was not evidently expressed. Expression of ELF3 was minimal in 5637 
cells. The expression of total PPARγ was nuclear and prevalent, but PPARγ2 
specific antibody suggested that PPARγ2 was not detectable (Fig 4.3.21).  
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Fig 4.3.21 Expression of E-cadherin, active β-catenin, PPARγ and ELF3 in 5637 cells. Cells 
were seeded in RPMI (5% FBS) on slides and fixed with Me/Ac at about 80% confluence. Scale 
bar represents 50 µm. 
Adapting 5637 cells to KSFM did not affect the proliferation of cells (unlike 
UMUC9 cells). Also, 5637 cells were able to grow without exogenous EGF. To 
explore whether the phenotype of 5637 cells had altered when the cells were 
adapted to KSFM, cytokeratin proteins were first examined. When adapted 
from medium with serum to serum-free KSFM, 5637 cells obtained a positive 
expression of CK14, suggesting a more basal-like phenotype (Fig 4.3.22).  
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Fig 4.3.22 Phenotype alteration of 5637 cells by adapting to serum-free medium. 5637 cells in 
different media were seeded separately at 1x105 cells /mL.  Slides were fixed using Me/Ac 
method. CK13, CK14 and CK20 were assessed to demonstrate the phenotype of 5637 cells in 
different media. CK7 was examined as positive control for the experiment. Note the de novo 
expression of CK14 in serum free KSFM. Scale bar represents 50 µm. 
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To identify the essential pathways for 5637 cells to proliferate in KSFM, growth 
assay was performed with addition of growth inhibitors. 5637 cells 
demonstrated a significant growth inhibition by EGFR inhibitor PD153035 and 
MEK/ERK inhibitor U0126. Also, the GSK3β inhibitor SB415286 inhibited the 
proliferation significantly, which was reversed by inhibition of the PI3K/AKT 
pathway. Combination of SB415286 and the PPARγ inhibitor T0070907 
demonstrated limited cell proliferation. Inhibition of TGFβ pathway did not 
affecte the growth of 5637 cells compared to DMSO control (Fig 4.3.23). 
 
Fig 4.3.23 Growth assay to demonstrate the effect of pathway activators and inhibitors.  5637 
cells were cultured in KSFM without supplements and then treated with various inhibitors. 
After 8 days of treatment, Alamar blue assay was performed. Error bars indicate standard 
deviation of five experimental replicates. Statistical analysis was calculated by one-way 
ANOVA with Bonferroni multiple comparisons post-test (*** P<0.001). 
To examine the pathways associated with SB415286 induced growth inhibition 
and the growth rescue by LY294002, expression of total β-catenin (Fig 4.3.24), 
active β-catenin (Fig 4.3.25) and E-cadherin (Fig 4.3.26) was analysed by 
immunofluorescence.  
Total β-catenin was examined, as SB415286 induced GSK3β inhibition is known 
for preventing β-catenin degradation and releasing it to either the nucleus or 
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the membrane. However, SB415286-treated 5637 cells showed less total β-
catenin expression, whereas treatment with LY294002 induced high expression 
of total β-catenin. This increased total β-catenin expression was enhanced by 
SB415286 and LY294002, and reversed by SB415286 and T0070907. This 
expression pattern induced by different treatments correlated with the growth 
rate of 5637 cells treated correspondingly (Fig 4.3.24).  
 
Fig 4.3.24 Expression of total β-catenin in 5637 cells. 5637 cells were seeded in KSFM and 
treated for 72h. Treatments are displayed as combination of horizontal and vertical headings. 
Slides were fixed using formalin method. Total β-catenin antibody was applied. Scale bar 
represents 50µm. 
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The active form of β-catenin by immunofluorescence showed nuclear 
localisation with diffuse cytoplasmic expression in DMSO control group. After 
treatment with SB415286, active β-catenin was localised more to the membrane 
and less in the cytoplasm. The amount of active β-catenin was enhanced by 
combined treatment with LY294002. By contrast, LY294002 alone induced the 
nuclear expression of active β-catenin. T0070907 did not affect the localisation 
or the expression of active β-catenin (Fig 4.3.25). 
 
Fig 4.3.25 Expression of active β-catenin in 5637 cells. Cultures were grown in KSFM and fixed 
using formalin method after 72h treatment. Active β-catenin antibody was applied. Scale bar 
represents 50µm. 
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To further investigate whether there was association between β-catenin and E-
cadherin after treatment of SB415286, expression and localisation of E-cadherin 
was further explored. E-cadherin demonstrated membrane expression in 5637 
cells treated with DMSO and grown in KSFM. The membrane localisation was 
more obvious in SB415286-treated cells. LY294002 induced a diffuse E-cadherin 
localisation, resulted in less membrane localised E-cadherin expression. Though 
the proliferation was significantly reduced by combined treatment of SB415286 
and T0070907, the expression and localisation of E-cadherin did not show any 
noticeable change (Fig 4.3.26).  
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Fig 4.3.26 Expression of E-cadherin in 5637 cells. 5637 cells were seeded in KSFM and treated 
for 72h before fixed using Me/Ac method. Treatments are displayed as combination of the 
horizontal and vertical headings.  Primary antibody against E-cadherin was applied. Scale bar 
equals 50µm. 
As T0070907 reduced the cell proliferation dramatically with SB415286, the 
expression of PPARγ was further analysed. PPARγ showed diffuse expression 
in SB415286-treated cells, and demonstrated increased expression when 
LY294002 was also added. T0070907 resulted in cytoplasmic expression, which 
was cytoplasmic exclusively when cells were treated with SB415286 together. 
LY294002 alone induced a heterogeneous population regarding PPARγ 
localisation, distributing either to the nucleus or cytoplasm (Fig 4.3.27). 
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Fig 4.3.27 Expression of PPARγ in 5637 cells. 5637 cells were cultured in KSFM and treated for 
72h before fixed with Me/Ac method. PPARγ antibody for both all PPARγ isoforms was 
applied. Scale bar represents 50µm. 
After treatment with SB415286, the nuclear expression of PPARγ and total β-
catenin decreased. Nuclear expression intensity was analysed to inform the 
relationship of the expression of the three proteins. The analysis of nuclear 
fluorescence intensity confirmed that the expression of PPARγ, active β-catenin 
and total β-catenin had reduced nuclear expression when treated with 
SB415286, which also associated with growth inhibition of 5637 cells in KSFM 
(Fig 4.3.28). The reduced nuclear expression was reversed by addition of 
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LY294002. Total β-catenin and active β-catenin demonstrated similar expression 
pattern in the majority of treatments, but when T0070907 was added to the 
cultures, they showed different nuclear expression, which might be caused by 
the involvement of PPARγ pathway. 
 
Fig 4.3.28 Nuclear fluorescence intensity of treated 5637 cells. The nuclear fluorescence 
intensity was measured using Image-Pro Plus software and showed as bar graphs. LY 
(LY294002, 5µM), SB (SB415286, 10 µM) and T007 (T0070907, 1 µM) was added to cultures. 
DMSO (0.1%, v/v) was included as vehicle control. 
To summarise the alteration of cell proliferation by growth assay and 
expression of associated pathways by immunofluorescence, Table 4.3.4 is listed 
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below. Growth inhibition induced by SB415286 was associated with down-
regulation of PPARγ and β-catenin (total and active), which could be reversed 
by combined treatment with LY294002. Such reversed growth inhibition was 
accompanied by enhanced expression of PPARγ and β-catenin (total and active), 
all of which distributed in whole cells though. By contrast, combined with 
T0070907, growth inhibition caused by SB415286 was intensified, which also led 
to down-regulation of total β-catenin and nuclear PPARγ (trans-located to 
cytoplasm). For treatments that did not alter proliferation of cells, no clear 
expression pattern of tested pathways was observed. 
 
  
 DMSO SB415286 LY294002 SB415286+LY294002 T0070907 SB415286+T0070907 
Growth 
rate 
Control ↓↓*** NS ↓* NS ↓↓↓*** 
PPARγ 
(total) 
Control 
Nuclear 
Diffuse ↓ 
Nuclear 
+cytoplasmic 
Diffuse↑ Cytoplasmic 
Exclusively 
cytoplasmic 
Total 
β-catenin 
Diffuse Diffuse ↓ Diffuse ↑ Diffuse ↑↑ Diffuse ↑ Diffuse ↓↓ 
Active 
β-catenin 
Diffuse 
Membrane 
Diffuse↓ 
Nuclear↑ Diffuse↑ Diffuse ↓ Diffuse 
E-cadherin Membrane Membrane 
Membrane 
Diffuse↑ 
Peri-nuclear↓ Membrane Peri-nuclear 
Table 4.3.4 Affected cell growth rate and expression or localisation of associated pathways of 5637 cells in KSFM. Treatments that resulted in cell growth 
inhibition are listed. ↓ shows the inhibited growth or overall down-regulated expression. ↑ shows up-regulated expression. * indicates P value (NS, not significant, * 
P<0.05, ***P<0.001). Localisation was determined according to majority of cells, unless heterogeneous distribution was evident. Where the amount of protein 
expressed demonstrated no obvious change, no label was shown. 
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4.3.7 Summary of results 
UMUC9 cells demonstrated a differentiated phenotype with UPK2 and CK20 
expression at transcription and protein level. Both CK13 and CK14 were absent 
in UMUC9 cells cultured in medium with serum. 
UMUC9 cells showed extremely high expression of PPARγ2 transcript and 
nuclear PPARγ2 localisation. 5637 cells demonstrated expression of different 
PPARγ protein isoforms in different media by Western blots. 
Less differentiated urothelial cancer cell line 5637 was able to be adapted to 
serum-free medium (KSFM), whereas UMUC9 cells demonstrated no growth in 
KSFM. 
UMUC9 cells showed slower proliferation in KSFM supplemented with EGF 
(compared to UMUC9 cells grown in medium with serum).  
EGF promoted cell growth and induced a phenotype alteration of UMUC9 cells 
to a vimentin-positive and CK14 positive phenotype. But the role of TGFβ was 
not obvious, inhibition of TGFβ pathway did not affect UMUC9 cells grown in 
medium with serum. 
Proliferation of 5637 cells in KSFM could be inhibited by EGFR or MEK/ERK 
pathways inhibitors. Inhibition of GSK3β reduced growth of 5637 cells, which 
could be reversed by inhibition of the PI3K/AKT pathway. 
 UMUC9 5637 
Phenotype Well-differentiated Less-differentiated 
Adapt to KSFM No Yes 
Difference in medium with or without 
serum 
De novo expression 
of CK14 without 
serum 
Expression of 
different PPARγ 
isoforms 
Pathways may affect the cell growth MEK/ERK  MEK/ERK, Wnt/β-
catenin 
Table 4.3.5 Summary of two UC cell lines.  
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Chapter 5 Transcript Variants and Protein Isoforms 
of PPARγ 
5.1 Introduction  
5.1.1 Identification of PPARγ and its function 
PPARγ is a nuclear receptor containing a DNA binding domain (DBD) and a 
ligand binding domain (LBD). These domains are similar to other nuclear 
receptor family members (Mangelsdorf et al., 1995). Together with other PPARs 
(α, β/δ), this family was first found in mouse liver, kidney and heart with 
abundant expression (Issemann and Green, 1990). PPARγ has been mostly 
studied of this family. Fajas et al. showed that in human tissues, PPARγ1 was 
the predominant PPARγ isoform in large intestine, adipose, kidney and liver. 
PPARγ2 transcripts were most abundantly expressed in adipose tissue and 
liver (Fajas et al., 1997). PPARγ was shown to play an important role in 
regulating metabolism of glucose and fatty acids by induction of adipogenesis 
(reviewed by Kersten et al., 2000). Also, PPARγ is the target for the synthetic 
insulin sensitizers, thiazolidinediones (TZD), and studies of PPARγ may bring 
insight to type II diabetes (reviewed by Janani and Ranjitha Kumari, 2015). 
5.1.2 Transcript variants of PPARγ 
PPARγ is recognised as a key regulator of metabolism. Two main PPARγ 
isoforms PPARγ1 and PPARγ2 have been identified and extensively studied. In 
mice, PPARγ1 and PPARγ2 were reported to have different promoters and 
encode different transcripts (Zhu et al., 1995). There are 8 exons in PPARγ1 and 
7 exons in PPARγ2. The last six exons are shared between the two PPARγ 
isoforms. The first two exons in PPARγ1 (A1 and A2) contribute to the 5’ UTR, 
whereas the first exon (B) in PPARγ2 encodes the 5’ UTR with 30 (28 in human) 
amino acids different between PPARγ1 and PPARγ2 (Fajas et al., 1997; Zhu et 
 Chapter 5 
154 
 
al., 1995). Research in human showed that the PPARγ protein isoforms are 99% 
similar and 95% identical to mouse isoforms (Fajas et al., 1997). The cDNA 
sequence of hPPARγ1 was 91% identical to mPPARγ1, whereas hPPARγ2 was 
81% identical to mPPARγ2 (Elbrecht et al., 1996; Greene et al., 1995). A simple 
schematic diagram displays the difference between human PPARγ1 and 
PPARγ2. 
 
Fig 5.1.1 Schematic diagram to demonstrate exons on human PPARγ transcripts, γ1 and γ2 , 
respectively. The orange exons show γ1 specific exons, whereas the green exon demonstrates 
γ2 specific exon. Blue exons show the exons shared between γ1 and γ2. Arrows heading right 
demonstrate the direction of promoters. The ATG site shows the starting site of coding 
sequence for each transcript. Adapted from (Fajas et al., 1997; Zhou et al., 2002; Zhu et al., 1995). 
A novel human PPARγ3 transcript was identified with exons 1-6 in coding 
sequence and exon A2 in 5’ UTR. This transcript encodes the identical protein 
as the transcript for PPARγ1, but the protein translated from PPARγ3 was more 
specific to adipose tissue and large intestine, suggesting that different 
promoters may regulate the expression of the same protein (Fajas et al., 1998). 
More PPARγ transcripts were identified in monkey macrophages and named as 
PPARγ4, 5, 6 and 7. They shared identical ORF (Open Reading Frame) region 
encoded by exons 1-6 for protein coding and were only different from the 5’ 
UTR with novel exons C or D at the N-terminal UTR, which were also found in 
the human genome. Transcript expression of these novel transcripts were not 
affected by fat feeding compared to macrophages of monkeys with normal diet, 
whereas the total PPARγ transcripts showed accumulation in the adipose tissue 
of fat-fed monkeys assessed by using primer set binding to all the isoforms 
(Zhou et al., 2002). In human macrophages, PPARγ4, 5 and 7 transcript variants 
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were also detected (Chen et al., 2006b). Upon binding of troglitazone, transcript 
expression of PPARγ5 was induced in human THP-1 macrophage cells, 
whereas expression of both PPARγ1 and PPARγ2 was inhibited, indicating that 
different PPARγ transcripts had distinct expression pattern after activation by 
ligand in human THP-1 cells. This regulation of PPARγ transcripts suggested 
that in human macrophages, different isoforms of PPARγ transcripts may have 
different roles in regulating functions of macrophages upon binding of ligands 
(Chen et al., 2006b). 
5.1.3 PPARγ2 is the most critical isoform in adipocyte 
differentiation 
Among all the transcript variants, PPARγ2 showed the most obvious difference 
in terms of expression in differentiated adipocytes. It was considered as the 
predominant isoform of PPARγ in murine adipose tissue, as 5’-end cDNA 
sequence showed that all five tested samples contained the PPARγ2 specific 
sequence (Tontonoz et al., 1994a). Further differentiation experiments 
suggested PPARγ2 was an early adipocyte specific regulator in both 3T3-F442A 
and 3T3-L1 cells, as the transcript of PPARγ2 was up-regulated dramatically on 
day 2 and plateaued on day 9. Two other downstream genes LPL (lipoprotein 
lipase) and ap2 (adipocyte p2, exclusively expressed in adipose cells) were up-
regulated following the time course and showed abundant expression on day 9 
(Tontonoz et al., 1994a). By over expression of PPARγ2 in NIH3T3 cells, the 
entire differentiation programme was activated, as late differentiation genes 
such as adipsin and ap2 were up-regulated, the effect of which was not 
achievable by over-expressing either PPARα or RXRα (Tontonoz et al., 1994b). 
However, no data regarding over-expression of PPARγ1 or total PPARγ was 
shown, possibly because of previous demonstrated results of specific PPARγ2 
transcript expression in murine adipose tissue (Tontonoz et al., 1994a). The 
differentiation process initiated by over-expression of PPARγ2 was more 
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dependent on the entirety of the DNA binding domain rather than the N-
terminal domain of PPARγ2. Deletion of the N-terminal domain containing but 
not confined to the first 30 amino acids (the difference between PPARγ1 and 
PPARγ2), even increased the production of lipid, indicating advanced 
functional differentiation. By contrast, replacement of two conserved cysteine 
residues to serine in the DNA binding domain abolished the lipid 
accumulation, which suggested that interaction with other transcription factors 
and binding to the DNA sequence of target genes were required and essential 
for PPARγ2-induced adipogenesis (Tontonoz et al., 1994b).  
5.1.4 Isoforms of PPARγ proteins in urothelium and other tissues 
The protein isoforms of PPARγ have been studied in different types of tissues. 
In adipose tissues that predominantly express PPARγ2 (Tontonoz et al., 1994a), 
a 67kDa PPARγ2 band was observed in induced adipocytes on day2 by using a 
PPARγ2 antibody binding to the N-terminal of protein obtained from Santa 
Cruz (Aprile et al., 2014). 
In mouse prostate cells (Strand et al., 2012) and benign human prostate 
epithelial cells (Strand et al., 2013), two PPARγ bands identified as PPARγ1 and 
PPARγ2 were reported by western blotting using antibody from Santa Cruz. 
Knock down of PPARγ2 was suggested as a key event for prostate cells to 
transdifferentiate to urothelial cells. However, details of PPARγ antibody used 
in this paper were not sufficient (Strand et al., 2013).  
In NHU cells, only one band was observed consistently with the molecular 
weight same as PPARγ1 (Kawakami et al., 2002; Varley et al., 2004a). 
Information regarding the PPARγ antibody can only be found from Varley et 
al. paper, which was PPARγ E-8 from Santa Cruz. This PPARγ isoform was 
also detected in UC cell lines by Western blots using the same Santa Cruz 
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antibody (sc7273, PPARγ E-8), and the amounts of protein expressed in 
different UC lines were different (Mansure et al., 2013).  
5.1.5 Summary 
There are at least seven PPARγ transcript variants with different promoters 
reported and these transcripts may have different roles in regulating 
differentiation. PPARγ2 has been demonstrated as the most significant isoform 
regulating adipogenesis. 
Two main PPARγ protein isoforms have been described as present in different 
tissues. But controversy in recognising different PPARγ isoforms using 
different antibodies or insufficient information of antibodies used in paper 
limited the understanding of PPARγ isoforms. The role of individual isoforms 
may be important, but analysis using consistent PPARγ antibody will be 
critical.   
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5.2 Rationale and aims  
Results shown in the previous chapter suggested that transcript expression of 
PPARγ2 was related to the extent of differentiated phenotype in UC cell lines. 
Due to the complex splicing mechanism, there are multiple PPARγ transcript 
variants present. To understand the roles of different PPARγ transcript 
variants, it was essential to know the difference among them. Thus, examining 
the expression of individual exons may inform us of the splicing variants that 
exist and their expression in urothelial cells related to different phenotypes 
(proliferative or differentiated). By using primers designed to bind within 
different exons, with various combinations, RT-PCR can be performed to 
determine whether one or more exons were missing in PPARγ transcripts. 
Expression of PPARγ transcripts in UC lines showing different phenotype may 
provide additional information about links between UC and expression pattern 
of different PPARγ variants.   
The differential expression of PPARγ protein isoforms in different UC cell lines 
suggested that the distinct isoforms may regulate different phenotypes. To 
explore whether there was a difference in localisation of different PPARγ 
isoforms, proteins were extracted using different concentrations of salt and/or 
DNAse I to extract proteins from different cellular or nuclear compartments. 
Higher concentration of salt or digestion with DNAse I has been shown to 
disaggregate the binding between proteins and nuclear matrix (Ainscough et 
al., 2007; Stenoien et al., 2000). Therefore, with increased salt concentration or 
incubation with DNAse I, proteins expressed in different cellular compartments 
were extracted differentially. After the extraction, different PPARγ isoform 
proteins were detected by western blotting using protein lysates generated 
from different cytoplasmic or nuclear compartments, which would suggest the 
localisation of different PPARγ isoforms in urothelial cells.  
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The aims for this chapter were to 
 Explore the expression pattern of PPARγ transcript variants in NHU 
cells and UC cell lines. 
 Examine the expression and compartmentalisation of different PPARγ 
protein isoforms in NHU cells. 
 Investigate whether this differential expression was related to 
differentiated phenotypes displayed by NHU cells and UC cell lines. 
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5.3 Experimental approach 
5.3.1 Expression of different PPARγ transcripts 
The first coding exon is specific to PPARγ2, the rest of the exons are common to 
PPARγ1 and PPARγ2. Fig 5.3.1 shows the binding sites of primers for 
individual exons.  
 
Fig 5.3.1 Schematic diagram showing the 7 coding exons and the positions of primer binding 
sites. Diagram was drawn to display the exons proportional to the length of individual exons. 
The 7 exons in PPARγ2 are shown with distinct colours. Primers are indicated as arrows 
heading to opposite direction. Arrows heading right indicate forward primers (F), whereas 
arrows heading left imply reverse primers (R). 
As the primers were designed against coding sequence, the limitation was the 
impossibility to identify whether the 1st and 7th exon was absent. There is a start 
codon in the 2nd exon, acting as the first exon in PPARγ1. Thus, experiments 
were designed to identify the possibility of missing other exons. The following 
table showed the primers used to detect combinations of exons missing (Table 
5.3.1). To start with, two main PPARγ transcript variants labelled as PPARγ1 
and PPARγ2 were also examined. 
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Combination 
Regions amplified/Missing 
Exons 
Primer sets 
Size (bp) of 
missing exons 
Normal transcripts 
PPARγ1 2F 7R NA 
PPARγ2 1F 7R NA 
Single exon missing 
3rd 2F 4R 170 
4th 3F 5R 139 
5th 4F 6R 200 
6th 5F 7R 451 
Double exons missing 
3rd and 4th 2F 5R 309 
4th and 5th 3F 6R 339 
5th and 6th 4F 7R 651 
Triple exons missing 
3rd, 4th and 5th 2F 6R 509 
4th, 5th and 6th 3F 7R 790 
Table 5.3.1 Combination and primer sets for determination of the missing exons. Possibilities 
of missing one or more exons were grouped separately. Primer sets were listed to show the 
primers utilised to determine the missing exons. F or R indicates the forward or reverse primers, 
respectively. The size of potential missing exon(s) was calculated and displayed. For double or 
triple exons missing, only the maximal size was listed, as smaller ones were listed in single or 
double exon missing rows. 
Primers were either obtained from lab or designed to identify whether certain 
exons were present in PPARγ transcript variants. Sequence of the primers is 
shown in Table 5.3.2. 
Name Sequence 5’-3’ 
PPARG2_Ex1F TCCTTCACTGATACACTGTCTGC 
PPARG2_Ex2F ACTTTGGGATCAGCTCCGTG 
PPARG2_Ex3F GCAATCAAAGTGGAGCCTGC 
PPARG2 Ex 4F CTTGCAGTGGGGATGTCTCAT 
PPARG2 Ex 5F AGGGCGATCTTGACAGGAAAG 
PPARG2_EX1-2 R CAAAGGAGTGGGAGTGGTCT 
PPARG2_EX3-4 R(4R) TTATGAGACATCCCCACTGC 
PPARG2 Ex 5R AGGTCAGCGGACTCTGGATT 
PPARG2 Ex 6R CCCTCGGATATGAGAACCCC 
PPARG2_Ex7R GGGCTTGTAGCAGGTTGTCT 
Table 5.3.2 Sequence of primers binding to different exons of PPARγ. Ex represents exon. 
Exon counting was based on coding sequence of PPARγ2. F or R indicates forward or reverse 
primer, respectively. Sequence was displayed from 5’ to 3’. All primers were designed with 
annealing temperature at 60°C.  
To understand whether there was any relationship between exons missing and 
urothelial differentiation, PPARγ transcript variants were examined in both 
proliferating and 7 days TZ/PD differentiated NHU cells (Y1289). One well-
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differentiated UC cell line and one poorly differentiated UC cell line were 
included to inform the expression of exons in UC cell lines. PCR was performed 
using same amount of cDNA from different samples. In order to calculate the 
potentially missing exons, all PCR reactions were performed for 40 cycles to 
obtain sufficient transcript products and have all potential splice variants 
amplified. 
5.3.2 Expression of different PPARγ protein isoforms assessed by 
CSK extraction and western blotting 
To examine the compartmentalisation of individual PPARγ isoforms in NHU 
cells, cytoskeletal extraction was performed. 0.5 M salt with 0.1% TX-100 was 
added to extract the cytoplasmic proteins or nuclear proteins not binding to 
nuclear matrix. DNase I was utilised to treat the pellet after salt wash, after 
which both supernatant and pellet were harvested. Mock digestion was 
included using digestion buffer alone (See section 2.6.2 for detailed method). 
Lysates from whole cell extracts, supernatants or pellet from every step were 
collected. 
In this experiment, antibody against histone H2A was applied on the blot 
following western blot to demonstrate whether proteins harvested were 
binding to the chromatin. The blot was afterwards incubated with PPARγ E8 
antibody to elucidate the expression of distinct isoforms in different cellular 
compartments. 
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5.4 Results  
5.4.1 Transcript variants of PPARγ 
To determine the transcript expression of PPARγ isoforms and investigate 
whether exons were missed when transcripts were spliced before translation, 
two main PPARγ isoforms were analysed by PCR. Proliferating and 
differentiated NHU cells were both examined to display whether the expression 
was different when differentiation was induced. UMUC9 cells were selected as 
well-differentiated UC cells, whereas T24 cells were poorly differentiated. These 
two cell lines were examined to show the expression of PPARγ in cancer cell 
lines. 
PPARγ1 was amplified using primer sets 2F&7R, and abundantly expressed in 
both NHU cell lines and UC cell lines (Fig 5.4.1 left panel, pointed with an 
arrow). The extent of differentiation did not show any difference in terms of the 
expression of the full length band in all cell lines (Fig 5.4.1 left panel). There was 
more PPARγ1 expression in UMUC9 cells. However, multiple bands smaller 
than the full length PPARγ1 band in all cell lines were detected, some of which 
were present in NHU cells and cancer cell lines, whereas some other bands 
were unique to certain cell lines (Fig 5.4.1 left panel, arrow head). However, 
with such complicated splicing combination among 7 exons, it was not possible 
to define the bands. 
Using primer sets 1F&7R, PPARγ2 was detected and shown in Fig 5.4.1 (right 
panel, pointed with an arrow). The full length PPARγ2 band was weakly 
detected in NHU cell lines and T24 cell line, whereas the expression was 
extremely robust in UMUC9 cells which was consistent with the RT-QPCR 
result shown in Fig 4.3.2. Smaller bands were still detectable in UMUC9 cells, 
but not in NHU cell lines, which may be due to the low abundance of PPARγ2 
in NHU cell lines. 
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Fig 5.4.1 Transcript expression of PPARγ1 and PPARγ2. PPARγ1 was amplified using primer 
sets 2F 7R; PPARγ2 was amplified using 1F 7R. Extension step was 2 min. The full length band 
was 1209bp for PPARγ1 (left arrow) and 1288bp for PPARγ2 (right arrow). The Arrow head 
indicates a specific band expressed in T24 cell line. P or D indicates proliferating or 
differentiated NHU cells (Y1289), respectively. UMUC9 or T24 cells were cultured in medium 
with addition of serum, and labelled as U or T, respectively. The no template water control was 
shown as (-). Equal amount of cDNA was used as template. 
To distinguish among the PPARγ splice variants, further PCR was performed. 
However, the band was so weak using forward primer binding to PPARγ2 
specific exon, which is the 1st exon, that it was hardly detectable at 572bp even 
in the most abundant PPARγ2 expressing UMUC9 cell line (Fig. 5.4.2 left 
panel). Thus, further experiments mainly focused on investigating whether 
exons were missing in PPARγ1 transcript variants. 
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Whether the 3rd exon was missing was detected using primer set 2F and 4R. In 
all tested cell lines, a robust band at 493bp was detected. Missing 3rd exon may 
result in a smaller band at 323bp. The band shown in the image was at about 
the size or slightly smaller, which could be the product of missing the 3rd exon. 
Also, the smaller band demonstrated less expression in both differentiated 
NHU cells and the well-differentiated UMUC9 cancer cell line, whereas the 
expression was more abundant in proliferating and T24 cells (Fig. 5.4.2 middle 
panel). The finding was repeated in other two NHU cell lines, but one of which 
was not the same as shown in Fig 5.4.2 (See appendix, Fig 7.1.3).  
Primer set 3F and 7R was utilised to detect the possibility of missing exons of 
4th, 5th or 6th. Multiple bands were still present in all cell lines with slight 
different expression pattern. The expression of full length band with size of 
1021bp was the most abundant in UMUC9 cells. The band at the size of 231bp 
could be missing of triple exons (4th, 5th and 6th). But the other bands were hard 
to determine as the information shown by the DNA ladder was not enough (Fig 
5.4.2 right panel). Thus, to simplify the experiment, the possibility of missing 
exons was investigated from individual missing exons. 
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Fig 5.4.2 Missing exons in PPARγ1 and PPARγ2. Primer sets for detecting of missing different 
exons are shown. 1F and 4R was specific for PPARγ2 with a product of 572bp. The full length 
band for primer 2F and 4R was 493bp. Primer set 3F and 7R was utilised to amplify a band of 
1021bp. P or D indicates proliferating or differentiated NHU cells (Y1289), respectively. UMUC9 
or T24 cells were cultured in medium with addition of serum, and labelled as U or T, 
respectively. The no template water control was shown as (-). Equal amount of cDNA was used 
as template. 
To determine whether a single exon was missing, primer sets across the 
potential missing exon was used. Only full length band for primers 3F and 5R 
was amplified with the size of 404bp. No detectable band smaller than the full 
length one was observed, indicating that exon 4 was mostly present when exons 
3 and 5 expressed (Fig 5.4.3 left panel). 
Full length band for primers 4F and 6R was visible at 521bp. With 5th exon 
missing, a band at 321bp was present in NHU cells and UMUC9 cells. The full 
length band was not as abundant in T24 cells as in the others, whereas the 
smaller band was even not visible (Fig 5.4.3 middle panel). 
For primers 5F and 7R, both the full length band at 550bp and the smaller band 
at 99bp indicating the absent of exon 6 were present in all the cell lines. No 
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obvious difference was detected except that the two bands were most abundant 
in UMUC9 cells (Fig 5.4.3 right panel). 
 
Fig 5.4.3 Detecting the possibility of missing single exon. Size of full length bands for each 
primer set was 404bp, 521bp and 550bp, respectively. P or D indicates proliferating or 
differentiated NHU cells (Y1289), respectively. UMUC9 or T24 cells were cultured in medium 
with serum, and labelled as U or T, respectively. Equal amount of cDNA was used as template. 
The no template water control was shown as (-).  
PCR result for testing of single exon missing showed the possibility of missing 
the 3rd and the 6th exon. To further determine the potential of double exon 
missing, primer sets across 4 exons were utilised. 
A full length band of 592bp for primers 2F and 5R was present in all cell lines. 
Even if the 3rd and the 4th exon were double missed, the size (283bp) would still 
be larger than any detectable bands, which were between 100bp and 200bp (Fig 
5.4.4 left panel). This result may suggest the presence of other unknown spliced 
products. 
For primers binding to 3rd and 6th exons, the full length band with the size of 
803bp was detected. Missing the 4th or the 5th exon would result in a band with 
the size of 664bp or 603bp, which was detectable in all four cell lines but 
without dramatic expression. The double exons missing resulted in a band at 
464bp, and was present in the proliferating, differentiated NHU cell lines and 
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UMUC9 cell line, but not visible in T24 cell line. Smaller bands between 100bp 
and 300bp were present in NHU cells and UMUC9 cells (Fig 5.4.4 right panel). 
 
Fig 5.4.4 Examination the possibility of missing double exons. Full length bands for 2F5R and 
3F6R were at 592bp and 803bp, respectively. P or D indicates proliferating or differentiated 
NHU cells (Y1289), respectively. UMUC9 or T24 cells were cultured in medium with serum, 
and labelled as U or T, respectively. The no template water control was shown as (-). Equal 
amount of cDNA was used as template. 
To find out whether the 5th or the 6th exon was missing, primers binding to 4th 
and 7th exons were utilised. The full length band was present at 739bp. If the 5th 
exon was missed, the band would be 539bp, whereas missing of 6th exon would 
result in a band at 288bp. The missing of double exons would show a band at 
88bp. The 288bp band was abundant in all four cell lines with the most 
abundance in UMUC9 cells. The 88bp band was prominent in UMUC9 cells but 
still detectable in the others. But the 539bp band was not obvious in all four cell 
lines (Fig 5.4.5 left panel). 
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To determine the possibility of missing triple exons, primers 2F and 6R were 
utilised. The visible band at 482bp could be the product of missing 3rd, 4th and 
5th exon in proliferating NHU cells. Bands at about 800bp were detected and 
could be missing of either the 3rd or the 4th exon (Fig 5.4.5 right panel). 
 
Fig 5.4.5 Detecting the possibility of missing double or triple exons. Size of full length bands 
was 739bp for primers 4F7R and 991bp for primers 2F6R. P or D indicates proliferating or 
differentiated NHU cells (Y1289), respectively. UMUC9 or T24 cells were cultured in medium 
with serum, and labelled as U or T, respectively. The no template water control was shown as (-
). Equal amount of cDNA was used as template. 
The RT-PCR results suggested that there are different PPARγ splicing variants 
expressed in NHU cells and UC cell lines. There might be relationship between 
splicing of exons and differentiated phenotype, but it was not yet understood. 
5.4.2 Protein expression of different PPARγ isoforms following 
cytoskeletal extraction  
To explore whether different PPARγ isoforms were expressed in different 
cellular compartments, differential extraction was performed followed by 
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western blotting. The blots below showed the expression of PPARγ isoforms in 
different cellular compartments (Fig 5.4.6). With PPARγ E8 antibody binding to 
C-terminus of PPARγ protein, both of the two main PPARγ isoforms were 
detectable on the blot. Histone H2A band indicates whether the proteins 
extracted were associated with chromatin.  
Salt solution at 0.5M was not high enough to disturb the DNA-protein 
interaction, as histone H2A was not detectable in the supernatant after the salt 
wash. After digestion with DNase I, the interaction was broken, which released 
some amount of histone H2A protein. But there were still H2A proteins left, 
suggesting the salt and DNA enzyme extractions performed were not sufficient 
to release tightly binding proteins. The buffer-only lysates showed that without 
interruption of DNA-histone interaction, no chromatin proteins were extracted. 
PPARγ isoform A was only detected in the pellet, even after the DNA 
digestion, implying its close interaction with the nuclear matrix. By contrast, 
PPARγ isoform B was mostly present in the supernatant after salt wash, 
suggesting the binding of isoform B to nuclear matrix was not as strong as 
chromatin proteins, which resulted in extraction of PPARγ isoform B before the 
binding of chromatin proteins was interrupted. Thus, isoform B was 
predominantly expressed in the cytoplasm and might be partially present in the 
nucleus with weak binding to the chromatin. In spite of that, small amount of 
isoform B was still detectable after enzyme digestion in the pellet. Other PPARγ 
bands with different molecular weight were detected in whole cell extracts and 
supernatant after salt wash, though the expression was not abundant. 
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Fig 5.4.6 Blot of proteins extracted using CSK method. Proliferating NHU cells (Y1314) were 
extracted using cytoskeletal extraction. Whole cell extracts (WCE) showed the total proteins 
harvested. After washing with 0.5M NaCl solution, supernatant was collected (S). Pellet (P) was 
either treated with DNase I or the digesting buffer (Mock). Supernatant and pellet were 
collected from all groups after digestion. Two main PPARγ isoforms were detected using 
PPARγ E8 antibody, and labelled as A and B. Histone H2A antibody was applied to 
demonstrate the solubility of chromatin proteins. 
The cytoskeletal extraction and western blot afterwards demonstrated that the 
two main PPARγ isoforms were mainly expressed in different compartments in 
NHU cells. However, whether it was related to differentiated phenotype needs 
further investigation.  
5.4.3 Summary 
 There was strong evidence supporting the missing exons of the 3rd, 5th 
and the 6th in PPARγ splice variants. In some cases, the possibility of 
missing more than two exons was considerable. 
 The splicing pattern was not clear, but might be involved in urothelial 
cancer or differentiation of urothelial cells, as the expression pattern was 
distinct for missing of certain exons in different urothelial cell lines. One 
speculation is that missing exon 3 might be associated with a more 
differentiated phenotype. 
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 Missing of certain exons are detectable. But the size of some exons is not 
divisible by three. Detailed information regarding the expression of 
different PPARγ transcripts is listed in Table 5.4.1. 
Absence of exons 
tested 
Possibility of 
missing 
Comments 
3rd Yes Not divisible by 3 
4th Not detectable  
5th May be yes Bands were faint 
6th Yes 
Not divisible by 3, might be spliced 
together with 5th exon 
Table 5.4.1 Possibility of missing certain exons. 
 PPARγ protein isoforms were detectable by western blotting after 
cytoskeletal extraction. The 50kDa band was mostly expressed in either 
cytoplasm or weakly present in the nucleus, whereas the 58kDa one was 
only detectable in proteins binding to the nuclear matrix. However, the 
antibody used in the experiment showed inconsistency in other blots (see 
chapter 3 and chapter 4) and needs further evidence. 
  
 Chapter 6 
173 
 
Chapter 6 Discussion 
 
Major findings of the current study are listed and further discussed in following 
sections. 
 Transcript expression of ELF3 was mainly up-regulated by activated 
PPARγ pathway, but evidence also suggests the influence by other 
pathways (section 6.1.1). 
 Regulation of some widely studied genes by ELF3 was observed at 
transcript level (section 6.1.2). 
 Transcription factors may affect each other through negative feedback 
(section 6.1.3). 
 UC cell lines demonstrated different expression pattern of differentiation-
associated markers compared to NHU cells (section 6.2.1). 
 UMUC9 cells showed a differentiated phenotype and were not able to 
proliferate in serum-free medium (section 6.2.2). 
 5637 cells demonstrated a less differentiated phenotype assessed by 
reduced expression of differentiation-associated markers.  When adapted to 
serum-free medium, cells were shown to be dependent on GSK3β and 
PPARγ pathway for growth (section 6.2.3). 
 Transcript expression and protein isoforms of PPARγ were different in UC 
cells from NHU cells (section 6.3). 
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6.1 The impact of ELF3 in urothelial differentiation 
6.1.1 Pathways involved in regulating ELF3 expression 
In this study, ELF3 was shown to be up-regulated by TZPD. This regulation 
was demonstrated to be mediated through the PPARγ signalling pathway, as 
previous results have shown that the PPARγ antagonist T0070907 reversed the 
increased expression of ELF3 (Bock et al., 2013).  
Other pathways may also be involved. Firstly, the result of this study indicated 
that expression of ELF3 was elevated slightly in long term (96h) control 
cultures. But it was suggested that in vitro cultured urothelial cells were unable 
to switch to a differentiated phenotype without specific induction of 
differentiation, as no terminal differentiation features such as expression of 
uroplakins was observed only by reaching confluence (Lobban et al., 1998; 
Southgate et al., 1994).  
When cells become confluent, the expression of EGFR and HB-EGF was not 
affected evidently, whereas the expression of ERBB2 (HER2) was up-regulated 
upon confluence (Varley et al., 2005). ERBB2 is one of the four EGFR gene 
family members, and found to be highly involved in human cancer, especially 
breast cancer. In human epithelial cell lines, it has been demonstrated that with 
endogenous expression of both ERBB2 and ELF3 proteins, ELF3 promoter 
exogenously transfected could be activated, suggesting possible regulation of 
ELF3 promoter activity by ERBB2. The activity of the ELF3 promoter was 
inhibited by the ERBB2 inhibitor AG1478 in the SKBR3 breast cancer cell line, 
which expresses a high amount of ERBB2 (Neve et al., 2002). Therefore, this up-
regulation of ELF3 observed in the current study could be caused by enhanced 
ERBB2 expression, which resulted from the NHU cells obtaining confluence. 
Also, there might be crosstalk between pathways to regulate ELF3 expression. 
The ELF3 transcript study demonstrated that treatment with PD153035 alone 
 Chapter 6 
175 
 
increased the expression of ELF3, but not statistically significant. PPARγ has 
been shown to translocate to the nuclei of NHU cells by PD153035, regardless of 
addition of TZ (Varley et al., 2004a). In non-invasive MCF10A mammary cells, a 
more invasive phenotype could be induced by over-expression of ELF3 and 
presence of EGF signal. But with ERBB2 over-expression, the presence of EGF 
was no longer indispensable for the cells to be invasive (Coppe et al., 2010). As 
the enhanced ELF3 transcript expression was more dramatic when the NHU 
cells were treated with PD153035 than the DMSO control and further increased 
at late time point, the result could be the combination of PPARγ nuclear 
translocation and increased ERBB2 expression generated by the confluence of 
cells at late time point, which would need to be confirmed experimentally. 
Furthermore, Alamar blue assay suggested the proliferation of both ELF3 knock 
down and ELF3 over expressing cells was reduced. The reduced proliferation 
rate in ELF3 over-expressing cells at late time point may be due to growth 
regulation through the PI3K/AKT pathway that resembled the growth of NHU 
cells cultured in physiological concentration of calcium on day 7 (Georgopoulos 
et al., 2010). The promoter of ELF3 showed the lowest activity when inhibited 
by PI3K inhibitor LY294002 compared to other inhibitors like PD98089 in breast 
cancer cell line SKBR3 present with high amount of ERBB2 expression, 
suggesting an essential role of PI3K pathway in regulating ELF3 transcriptional 
activity (Neve et al., 2002). There might be a negative feedback to ERBB2 or 
PI3K pathway by over-expression of ELF3 in NHU cells, which further 
inhibited the proliferation of ELF3 over-expressing NHU cells. But the low 
growth rate may also result from the senescence of transduced cells, as they 
have gone through many passages to be selected by antibiotics.  
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6.1.2 Possible downstream targets 
6.1.2.1 CLDN7 as an ELF3 downstream target gene 
The result in this study demonstrated that the knock down of ELF3 
compromised the formation of functional barrier. This indicates an essential 
role of ELF3 in urothelial differentiation in terms of formation of functional 
barrier either directly or through the regulation of other factors required to 
form a functional barrier, such as tight junction proteins. 
In urothelial cells, expression of CLDN7 was relatively stable (Varley et al., 
2006). The up-regulation of CLDN7 observed in this study by induction of 
PPARγ using TZPD may suggest it a downstream target gene of PPARγ, and 
knock down of ELF3 also resulted in the reduction of CLDN7 transcripts but 
not the proteins.  
CLDN7 was reported as a downstream gene regulated by ELF3 in synovial 
sarcoma cells (Kohno et al., 2006). ELF3 knock down in the SW480 cell line 
(human colon cancer; ELF3 and CLDN7 positive) resulted in decreased CLDN7 
gene expression consistent with the reduction of ELF3 expression (Kohno et al., 
2006). De novo expression of CLDN7 transcript could be induced by exogenous 
ELF3 expression in HT1080 (human fibrosarcoma; ELF3 and CLDN7 negative) 
and SYO-1 (human synovial sarcoma cell line; ELF3 and CLDN7 negative), but 
CLDN7 protein expression could not be detected following exogenous 
expression of ELF3 in these two cell lines (Kohno et al., 2006). This may indicate 
that ELF3 was not the only factor regulating expression of CLDN7, which could 
explain the inconsistency of CLDN7 transcript and protein expression in ELF3 
knock down cells observed in this study. 
6.1.2.2 Relationship of ELF3 and TGFβRII 
Knockout of ELF3 in mice demonstrated its role in intestinal development (Ng 
et al., 2002). The formation of functional enterocytes can be rescued by 
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exogenous expression of TGFβRII in ELF3 knockout mice, suggesting 
regulation of TGFβRII by ELF3 and importance of TGFβRII in intestinal 
development (Flentjar et al., 2007).  
In urothelial differentiation, ELF3 was identified as a transcription factor 
involved in urothelial differentiation in vitro (Bock et al., 2013). As exogenous 
addition of TGFβ1 accelerated the wound healing process by activation of p-
SMAD3 (Fleming et al., 2012), it was hypothesised that knock down of ELF3 
may have affected the TGFβ signalling pathway, which led to an inefficient 
repair of wounded cultures. In the current study, there appeared to be a 
reduction in the activation of the TGFβRII pathway downstream factor p-
SMAD3. However, transcript expression of TGFβRII was demonstrated to be 
down-regulated in differentiated  NHU cells (Fleming et al., 2012). Therefore, 
conclusions regarding the effect of ELF3 on TGFβRII should only be made with 
confirmation of further experiments. 
6.1.3 Hierarchy of transcription factors 
6.1.3.1 PPARγ and its downstream transcription network 
The up-regulation of PPARγ2 transcript found at 6h by TZPD in this study 
suggested its role as a transcription factor mediating early differentiation in 
urothelial cells. The low transcript expression in proliferating and late 
differentiated NHU cells detected in the current study also indicated that 
PPARγ2 might be degraded after the differentiation programme has been 
initiated. However, a more complicated mechanism involving the production of 
transcript variants by alternative splicing may need to be taken into 
consideration, which will be discussed in section 6.3. 
Knock down of ELF3 resulted in reduction of ELF3 transcripts and proteins (by 
western blotting only). The expression change of ELF3 knock down cell sheets 
by IHC was not obvious, which could be caused by the non-specific binding of 
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this antibody (blots with two different ELF3 antibodies were included in 
Appendix 7.1.4). 
This study showed that apart from ELF3, the PPARγ downstream transcription 
factor FOXA1 was up-regulated significantly by TZ treatment alone, though it 
was not as dramatic as the treatment of TZPD, which blocked the 
phosphorylated PPARγ entirely and further activated the PPARγ pathway. 
Most importantly, this effect can only be observed on FOXA1 transcript but not 
on other transcription factors tested. Such an effect on FOXA1 was reported 
previously, and by using PPARγ antagonist T0070907 or GW9662, the increased 
FOXA1 protein was reduced, suggesting the direct regulation of FOXA1 by 
PPARγ pathway (Varley et al., 2009). 
6.1.3.2 Feedback on other transcription factors by alteration of ELF3 
expression 
As ELF3 was inducible by TZPD, it is considered downstream of the PPARγ 
signalling pathway (Bock et al., 2013). However, the preliminary IHC result on 
ELF3 knock down cells in this study suggested possible knock down of nuclear 
PPARγ expression. The regulation of ELF3 by PPARγ was supported by 
demonstrating a reduced ELF3 expression using the PPARγ antagonist 
T0070907 (Bock et al., 2013). Therefore, the down-regulation of total PPARγ in 
ELF3 knock down cells may suggest a negative feedback, which would need 
further experiment to confirm. 
The over-expression of ELF3 in this study demonstrated the dramatic up-
regulation of ELF3 at transcript level. But the transcripts of other transcription 
factors such as FOXA1 and GRHL3 did not show any obvious alteration by 
ELF3 over-expression. One possible reason was that these factors were 
regulated by PPARγ directly, as the PPRE site was identified upstream of 
FOXA1 promoter (Varley et al., 2009). Alternatively, the over-expression of 
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ELF3 was only achieved at transcript level and not sufficient to initiate the 
differentiation program, so that the expression of other differentiation-
associated transcription factors was not induced. 
6.1.3.3 Transcription factor involved in early stage of differentiation 
RT-qPCR using ELF3 knock down cells in this study showed that knock down 
of ELF3 reduced the amount of KLF5. But the amount of KLF5 transcripts was 
the most abundant among transcription factors. It has been previously 
demonstrated that KLF5 was essential in mouse urothelial development (Bell et 
al., 2011). Knock out of KLF5 compromised the maturation of mouse bladder 
and reduced the protein expression of transcription factors such as FOXA1. RT-
qPCR also showed the statistically significant knock down of transcription 
factors including PPARγ, ELF3 and GRHL3 (Bell et al., 2011). Reduced KLF5 
transcripts by ELF3 knock down demonstrated in the current study may be 
caused by feedback of ELF3 knock down. Thus, the hierarchy of these 
transcription factors may be more complicated and would require further work 
to be unravelled. 
6.1.4 Other transcript variant/protein isoform of ELF3 
A 25kDa band was observed by western blotting using the ELF3 antibody in 
NHU cells. It is potentially the product of a 3’ incomplete CDS, with truncation 
at the 3’ ending of ELF3 coding sequence. This transcript is displayed both in 
Ensembl (ENST00000446188) and Havana database (OTTHUMT00000087361) 
but without further information. Both the knock down and over-expression of 
ELF3 in the current study showed visible effects on this 25kDa ELF3 protein, 
however, there is no apparent evidence suggesting the function of this 
truncated ELF3 isoform. 
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6.1.5 Summary 
ELF3 is up-regulated by PPARγ signalling pathway and there is possibility that 
ELF3 is regulated by other pathway, such as ERBB2. As one of the transcription 
factors involved in urothelial differentiation, the regulation by other factors or 
the feedback after alteration of gene expression was present with preliminary 
evidence and might indicate the importance of their roles. Other genes 
including CLDN7 and TGFβRII were reported to be regulated by ELF3, but the 
regulation on them in NHU cells was not apparent, which might be due to the 
involvement of other factors or a different mechanism in different species/tissue 
types.   
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6.2 Signalling pathways associated with UC cell 
proliferation 
6.2.1 Expression pattern of differentiation markers  
6.2.1.1 Comparison of expression pattern of genes/proteins between UC lines 
to NHU cells 
RTqPCR results in this study demonstrated that UC cell lines have different 
phenotypes in terms of the expression of differentiation-associated genes and 
transcription factors. Expression pattern of markers in UC cell lines was 
compared to the pattern of NHU cells and listed in Table 6.1. 
Cell line UMUC9 5637 5637 RT4 RT112 T24 
NHU 
(pro) 
NHU 
(dif) 
Medium 
DMEM 
(10%) 
KSFM 
RPMI 
(5%) 
D:R 
(5%) 
D:R 
(5%) 
D:R 
(5%) 
KSFMc KSFMc 
ELF3 
transcripts 
++ - ++ ++ + - - +++ 
FOXA1 
transcripts 
+++ - + +++ + + - +++ 
PPARG2 
transcripts 
+++ + + + + - - + 
PPARγ 
52kDa 
protein band 
++ - + + + + - + 
PPARγ 
58kDa 
protein band 
- + + - - - + + 
UPK2 
transcripts 
+++ - - ++ + - - +++ 
CK20 
transcripts 
+++ - - + ++ - - ++ 
CK20 
proteins 
++ - - NT NT NT - + 
CK13 
proteins 
- - - - + - - + 
CK14 
proteins 
- + - - + - + + 
Table 6.2.1 Transcript/protein expression of differentiation-associated markers. Transcripts in 
NHU cells and UC cell lines were compared according to the amount of transcript or protein 
assessed qualitatively. Transcripts were assessed by RT-qPCR; protein expression was assessed 
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by western blots or IF. Differentiated transcripts of NHU cultures were induced by TZ/PD; 
differentiated protein lysates of NHU cells were induced by ABS/Ca2+. NT indicates the protein 
was not tested. Symbols indicate the amount of transcripts/proteins (- for negative, + for low, ++ 
for moderate and +++ for high). D:R indicates the medium comprised with 50% DMEM and 50% 
RPMI. 
The acquisition of a squamous phenotype in 5637 cells when cultured in KSFM 
was similar to the phenotype observed in NHU cells cultured in vitro in serum-
free low calcium medium (Southgate et al., 1994; Varley et al., 2004b). As 5637 
cells were able to be maintained in KSFM without exogenous growth factors, it 
appeared that the 5637 cells were able to maintain their growth by autocrine 
activity, possibly via the EGFR pathway similarly as the NHU cells 
(Georgopoulos et al., 2014; Varley et al., 2005). 
UMUC9 cells demonstrated dependence on serum for growth, whereas NHU 
cells would be induced to differentiate if cultured in medium supplemented 
with serum (Cross et al., 2005). This suggested that the differentiated phenotype 
maintained by UMUC9 cells might be related to the proliferation of cells. The 
acquisition of CK14 protein expression in UMUC9 cells treated with EGF or 
TGFβ suggested a switch to a more squamous phenotype that resembled the 
proliferating NHU cells (Harnden and Southgate, 1997), alteration of other 
features were also observed and will be discussed in following sections.   
6.2.1.2 Indication of grade of UC and UMUC9 cell lines 
Compared to RT4 cells, which was extensively studied and described as a grade 
1 tumour-derived cell line, UMUC9 cells demonstrated more abundant UPK2 
transcripts typical of a more differentiated phenotype. Nevertheless, it was 
suggested that features similar to normal superficial urothelial cells were 
present in some high grade NMIBC, as in carcinoma in situ (CIS) tissues (19 
cases), 83.3% were positive for UPK2 expression and 84.2% were positive for 
CK20 expression (Jia et al., 2013). Another study also showed that the samples 
having most abundant expression of differentiation-associated genes were 
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tumours of high grade (G3) (Biton et al., 2014). Thus, the expression of 
differentiation-associated genes may not be associated with histopathological 
grade of UC. 
UMUC9 cells was first reported in 1988 and found to be able to produce tumour 
in nude mice (Grossman et al., 1988). Tumours of 1-1.5 cm diameter were 
produced less than three weeks (17 days) in athymic nude mice after injection 
of trypsinised UMUC9 cells (Sabichi et al., 2006). UMUC9 was characterised as 
a grade III high stage carcinoma (Liebert et al., 1994; Liebert et al., 1989; Zou et 
al., 2001). A recent study about high grade MIBC demonstrated the expression 
of differentiation-associated transcripts in luminal subtype (Choi et al., 2014). 
After treatment with PPARγ selective agonist rosiglitazone, UMUC9 cell line 
demonstrated PPARγ downstream signalling pathway gene expression, which 
was analysed using Ingenuity Pathway Analysis (IPA, Ingenuity Systems) 
(Choi et al., 2014). UMUC9 was also characterised to be resistant to 
chemotherapy and was grouped as a p53-like MIBC, as incubation with 
cisplatin for 48h did not demonstrate as high apoptosis rate as the other UC cell 
lines (Choi et al., 2014). Sequencing data suggested exon 7 of TP53 was mutated 
in the UMUC9 cell line, and this mutation resulted in overexpression of P53 
protein displayed as strong nuclear P53 staining by immunohistochemistry 
(Sabichi et al., 2006). Whether this mutation was related to cell survival is not 
clear, but may help further investigation.  
6.2.1.3 The expression pattern of PPARγ transcripts and proteins 
A dramatic expression of PPARγ2 transcripts was detected in UMUC9 cells in 
the current study. Another study also showed that knock down of PPARγ in 
some of the bladder cancer cell lines (for example, UMUC9, SD48 and RT112) 
significantly reduced the viability of cells. Formation of colonies was 
significantly affected in UMUC9 and SD48 cell lines as well (Biton et al., 2014). 
They also demonstrated a correlation between decreased PPARγ transcripts 
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and inhibition of proliferation by PPARγ siRNA, which indicated that in cell 
lines like UMUC9 that expressed the most PPARγ transcripts, proliferation was 
affected most effectively by knock down of PPARγ, suggesting dependency on 
PPARγ or the differentiated phenotype for survival (Biton et al., 2014). 
PPARγ protein was also investigated in various cell lines in this study. Loss of 
the 52kDa band was observed in 5637 cells cultured in serum-free, whereas in 
medium with serum, this 52kDa band was present and was the same situation 
in differentiated NHU cells. Medium with serum combined with physiological 
concentration of calcium was used to differentiate NHU cells (Cross et al., 
2005), so the band at 52kDa could be related to a more differentiated phenotype 
of 5637 cells in medium with serum and calcium. These bands were observed in 
other reports in human adipocytes but without detailed interpretation 
(Visweswaran et al., 2015), whereas another group claimed the 52kDa band as 
PPARγ2 (Liu et al., 2014). To identify the difference between PPARγ bands in 
UC lines with lysates generated from other tissues or species, a comparison was 
performed with UC cells, buccal epithelial cells and 3T3-L1 cells (See appendix, 
Fig 7.1.2). It appeared that 3T3-L1 cells showed distinct pattern of PPARγ 
protein isoforms. One band was present in both the UC lines and 3T3-L1 cells 
using PPARγ E8 antibody for detection of total PPARγ. 
Given that UMUC9 cells showed the most abundant expression of PPARγ2 
transcripts, compared to RT4 and RT112 cell lines, the similar height of the 
PPARγ bands in UMUC9 cells might be due to the post-transcriptional 
modification of PPARγ, such as sumoylation (Diezko and Suske, 2013), protein 
degradation mediated via activated MAPK pathway (Hedvat et al., 2004) or 
ligand induced ubiquitination followed by protein degradation (Hauser et al., 
2000). Different isoforms of PPARγ and reports related to possible degradation 
mechanism will be discussed in section 6.3.  
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6.2.2 EMT process and possible growth pathways of UMUC9 cells 
6.2.2.1 Possibly involved EMT process 
The elongated morphology of UMUC9 cells treated with EGF and TGFβ in 
KSFM suggested that the cells might have undergone an EMT process. 
Although expression of vimentin was detectable after EGF/TGFβ treatment in 
the current study, the expression of E-cadherin was still visible, which was not 
consistent with reports demonstrating loss of E-cadherin in cells undergone 
EMT process (Chen et al., 2012). But another study showed that loss of E-
cadherin was not necessary for EMT (specified by positive expression of 
Caveolin-1 as EMT marker) in breast cancer cells, as 50% samples (34 in total) 
had E-cadherin expression (Hollestelle et al., 2013). Therefore, whether it was 
an EMT or alteration to a more basal-like phenotype of the UMUC9 cells 
cultured in KSFM with EGF or TGFβ requires further investigation to assess.  
6.2.2.2 Signalling pathways related to EMT and speculated mechanisms 
It was reviewed that exogenous TGFβ was the most important growth factor in 
induction of the EMT process (reviewed by Xu et al., 2009), but EGF pathway 
was also suggested to be essential. In normal murine mammary gland epithelial 
cells, the EMT process was demonstrated to occur only with activated ERK 
pathway, without which the cuboidal shape of cells was still observable with 
expression of differentiation-associated protein like ZO1 (Lu et al., 2004). 
Similarly, the addition of EGF in current study altered the morphology of 
UMUC9 cells in KSFM and promoted proliferation at the same time. 
Another study in intestinal cells demonstrated the essential role of PPARγ in 
promoting EMT by activating the Rho family, as block of MEK pathway 
inhibited ligand-activated PPARγ-induced EMT (Chen et al., 2006a). Although 
in the current study the growth of UMUC9 cells with TGFβ alone was similar to 
control cells, the increase of PPARγ expression was obvious. Treatment with 
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TGFβ has been shown to increase protein expression of β-catenin and its 
nuclear accumulation in human fibroblasts (Akhmetshina et al., 2012). 
Therefore, the up-regulation of PPARγ protein could be due to the increased β-
catenin expression, as the up-regulation of PPARγ was reported as the result of 
over-expression of β-catenin in colon cancer cells (Jansson et al., 2005). 
However, the negative regulation of PPARγ by exogenous TGFβ was reported 
in hepatic stellate cells via up-regulation of β-catenin, which was contrary to the 
speculation (Qian et al., 2012). Importantly, in NHU cells, TGFβ pathway-
associated transcripts such as TGFβRII were down-regulated in TZ/PD or 
ABS/Calcium induced differentiated cultures compared to control cultures 
(Fleming et al., 2012). Exogenous TGFβ1 inhibited the differentiation of NHU 
cells as transcript expression of UPK2 decreased significantly, suggesting a 
negative effect of TGFβ on differentiated NHU cultures (Fleming et al., 2012). 
But an accelerated wound repair in differentiated cultures and decelerated cell 
migration in non-differentiated cultures were observed (Fleming et al., 2012). 
Therefore, it is currently difficult to interpret whether TGFβ pathway was 
involved in the morphology alteration of UMUC9 cells cultured in KSFM. 
Coincidentally, one report demonstrated an interrelationship between vimentin 
expression and PPARγ degradation and suggested that vimentin might be 
essential in preventing ubiquitination and degradation of PPARγ upon ligand-
induced adipocyte differentiation. They showed that knock down of vimentin 
accelerated the degradation of PPARγ protein when 3T3-L1 cells were induced 
to differentiate by BRH49653 (Tsai et al., 2013). Therefore, the de novo 
expression of vimentin in UMUC9 cells grown in KSFM with EGF supplement 
in the current study may decelerate the degradation of PPARγ, which might 
further indicate that expression of PPARγ was essential for proliferation of 
UMUC9 cells. But further experiments are needed to verify this speculation. 
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6.2.3 Involvement of GSK3β in regulating cell proliferation 
6.2.3.1 Role of activated β-catenin in cell growth  
The growth inhibition of 5637 cancer cells in KSFM resulting from inactivation 
of the GSK3β pathway by SB415286 observed in the current study was 
reversible by inhibition of PI3K/AKT pathway with LY294002. Other reports 
also demonstrated that inhibition of the AKT pathway with down-regulation of 
phosphorylated AKT led to reduced p-GSK3β (Gan et al., 2010; Wu et al., 2012). 
In GSK3β-inactivated prostate cancer cells, increased expression of β-catenin 
eventually resulted in the up-regulation of the EGFR pathway. CHIP assay and 
promoter analysis suggested that after being activated (dephosphorylated), β-
catenin was able to bind to the promoter of the EGFR gene and increased its 
expression. Downstream target pathways such as ERK1/2 were also activated 
following the binding of β-catenin to EGFR promoter (Guturi et al., 2012). In 
NHU cells, down-regulated phosphorylated-ERK expression in β-catenin-knock 
down NHU cells was observed, suggesting β-catenin might be able to regulate 
the expression of EGFR pathway (Georgopoulos et al., 2014).  
However, in the current study with bladder cancer line 5637 cells cultured in 
KSFM, the inactivation of GSK3β led to reduced cell proliferation, which was in 
disagreement with the reports mentioned above.  In NHU cell cultured in 
physiological concentration of calcium (2mM), β-catenin was located to 
membrane and interacted with E-cadherin (Georgopoulos et al., 2010), which 
was also observed in 5637 cells maintained in KSFM. This might be part of the 
reason of reduced growth in 5637 cells cultured in KSFM after inactivation of 
GSK3β.  
6.2.3.2 Growth inhibition by inactivated GSK3β signalling pathway 
There is controversy between different studies demonstrating roles of GSK3β 
pathways on proliferation. One report suggested that decreased cell 
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proliferation was observed in neuroblastoma B65 cells after treatment of either 
lithium or SB415286, both are GSK3β inhibitors, and this growth inhibition was 
associated with G2/M cell cycle arrest. This might have resulted from increased 
phosphorylated GSK3β on Ser9, which further enhanced phosphorylation of 
CDC2 (CDK1) on Tyr15 (inactive form) (Pizarro et al., 2009). Nevertheless, 
another report in human myeloid leukemia cells suggested that 
pharmacological inhibition or knock down of GSK3α/β decreased apoptosis 
(Rahmani et al., 2013). 
In the current study, the growth rate of 5637 cells cultured in KSFM appeared to 
be associated with localisation of PPARγ protein, and may further affected the 
expression of active β-catenin (Table 4.3.4).  
6.2.3.3 Influence on GSK3β-mediated growth inhibition by PPARγ signalling 
pathway 
The decreased proliferation by GSK3β inhibition was further enhanced after 
inhibition of PPARγ signalling pathway using T0070907. In agreement with this 
result, GSK3β-mediated growth inhibition has been reported to be related to 
PPARγ. One report in mouse adipocytes suggested that protein expression and 
function of PPARγ was regulated indirectly by GSK3β and directly by Snail 
(Lee et al., 2013). The transcript and protein expression of PPARγ was 
negatively correlated with Snail. E-box-707 and E-box-154 on the promoter of 
mouse PPARγ2 were the binding sites of Snail, as the promoter activity 
investigated by luciferase assay suggested that PPARγ2 promoter activity was 
down-regulated after transfection of Snail in 3T3-L1 cells, whereas mutation on 
either E-box on PPARγ2 promoter abolished the Snail-induced down-
regulation (Lee et al., 2013). By contrast, induced adipogenesis inhibited the 
protein expression of Snail. Furthermore, expression of Snail was up-regulated 
by treatment of Wnt10b or LiCl, which resulted in inactivation of GSK3β, 
decreased protein expression of adipocyte differentiation-associated proteins 
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and reduction of oil red staining (Lee et al., 2013). Whether the Snail pathway 
was involved in inhibited growth of 5637 cells in KSFM was not clear in the 
current study and would need further investigation. 
Other reports demonstrated a PPARγ regulated growth control, which may 
help interpret the reversed GSK3β-mediated growth inhibition by LY294002 
and enhanced inhibition by T0070907. Firstly, one report showed that PPARγ 
antagonist GW9662 could inhibit the expression of p-AKT and p-GSK3. In 
neurons, decreased expression of p-AKT and p-GSK3 could lead to apoptosis. 
They demonstrated that nutrient deprivation-induced apoptosis can be 
inhibited by addition of Telmisartan, which is an angiotensin II receptor 
antagonist and also activates PPARγ (Pang et al., 2014). In NIH3T3 cells, 
however, Telmisartan as a PPARγ ligand was able to inhibit p-AKT (Yamamoto 
et al., 2009). This PPARγ ligand-mediated p-AKT down-regulation was also 
observed in myofibroblast differentiation (Kulkarni et al., 2011). Therefore, 
inhibition of PPARγ by T0070907 may reverse the inhibition of p-AKT, which 
resulted in the enhanced growth inhibition in the current study on 5637 cells 
treated with SB415286 and T0070907. This growth inhibition might be due to 
increased p-AKT and p-GSK3β expression via both GSK3β and PPARγ 
pathways, which would need further experiments to investigate. The proposed 
signalling pathways affecting proliferation in NHU cells and 5637 cells were 
summarised in Fig 6.1. 
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Fig 6.2.1 Diagram to show the proposed relationship of signalling pathways involved in 
proliferation. Red rectangular indicates the destruction complex which can be destroyed by 
SB415286. Then, GSK3β was phosphorylated and β-catenin was released. 
6.2.3.4 Relationship of PPARγ and β-catenin 
Contrary findings of the relationship between PPARγ and β-catenin were 
reported in different cell lines. The up-regulation of β-catenin was suggested to 
induce PPARγ protein expression, which has been reported in colon cancer 
cells (Jansson et al., 2005).  
Nevertheless, relationship between PPARγ and β-catenin seems to be more 
complicated, as another report showed that PPARγ functioned as a suppressor 
of β-catenin by targeting phosphorylated β-catenin to the proteasome, whereas 
oncogenic expression of β-catenin demonstrated resistance to PPARγ-mediated 
degradation, which required the TCF/LEF binding domain of β-catenin (Liu et 
al., 2006). During adipogenesis from mouse fibroblasts, β-catenin protein was 
negatively correlated with differentiation-associated proteins. Addition of 
troglitazone activated PPARγ and decreased the amount of β-catenin protein 
(Liu and Farmer, 2004). In mouse adipocytes, where the only activated and 
functional PPARγ form is PPARγ2 (Ren et al., 2002), this negative regulation of 
β-catenin protein expression was suggested to be controlled by PPARγ2 
(Rahman et al., 2012).  
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6.3 Regulating the expression of PPARγ  
The differential PPARγ transcript expression pattern between NHU cells and 
cancer cell lines and different PPARγ protein isoforms observed may suggest 
that the different PPARγ transcripts and proteins have specific roles in 
regulating downstream genes.  
6.3.1 Splicing variants 
RT-PCR analysis suggested that missing certain exons (e.g., exon3) might be 
associated with a more differentiated phenotype. However, length of the 
coding nucleotides of exon3 is 170bp, which is not divisible by three, suggesting 
that theoretically it could not be the only missing part. Thus, there might be a 
more complicated splicing event that has been reported by several groups in 
different tissues/cell lines (see below). These truncated PPARγ variants may be 
involved in regulating expression and function of the principal PPARγ isoforms 
in differentiated tissues and/or carcinomas. 
One case was associated with the 4th intron. A novel PPARγ isoform which 
contained part of the 4th intron was identified in an human ovary fibrothecoma 
and an adenocarcinoma using human genome sequencing data and was named 
γORF4 (Sabatino et al., 2005). The majority of the LBD domain present in the 
other PPARγ isoforms was truncated, leaving 22 amino acids followed by 21 
amino acids of the 4th intron. Reporter assay suggested that this isoform 
functioned as a dominant-negative protein of PPARγ in regulating PPRE 
reporter activity in COS7 cells (Sabatino et al., 2005). This truncated variant was 
found in PPARγ1, 2 and 3, showing similar functions as dominant negative 
proteins. Adipocyte differentiation using human MSC (mesenchymal stem 
cells) demonstrated that both transcripts and proteins of γ2ORF4 were up-
regulated after differentiation for 2 days and decreased gradually, the pattern of 
which matched the expression of PPARγ2. Such matched expressing pattern, 
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however, was neither detectable for PPARγ1, which showed a consistently high 
amount of transcript in undifferentiated and differentiated MSC cells, nor 
γ1ORF4, which demonstrated no obvious expression pattern (Aprile et al., 
2014). This result confirmed a differentiation-associated role of PPARγ2, and 
may also suggest a role in regulation of PPARγ2 expression by γ2ORF4. 
However, another research report claimed that the γ1ORF4 comprised less than 
10% of PPARγ transcripts and existed in general (Bouancheau et al., 2007). 
Thus, whether a read-through of introns and truncation of following exons are 
cases present in NHU cells needs further investigation.  
Another similar case suggested a truncated PPARγ1 isoform was expressed in 
human lung cancer tissues, whereas full length PPARγ1 was expressed in the 
normal tissue surrounding the cancer area (Kim et al., 2007). The truncated 
variant was the N-terminal sequence of wild type human PPARγ1 lacking part 
of the hinge domain and the entire Ligand Binding Domain, which resulted 
from an extra 143bp in the hinge domain  as a novel exon (exon 3’). The 
additional 143bp resulted in a frameshift in the ORF, creating 8 alternative 
amino acids and a premature stop codon. The splice variant showed sequence 
that conformed to the GT-donor/ AG-acceptor rule for exon splicing (Kim et al., 
2006). As the majority of exons are not divisible by three, containing of intron 
and frameshift might be involved in the splicing events of PPARγ variants 
found in NHU cells. 
The truncated variant did not show activity in a transactivated PPRE luciferase 
reporter, and acted as a dominant negative protein that decreased the activity of 
full length PPARγ1. It also significantly increased CHO cell viability to 
oxidative stress or cisplatin. Reduction of tumour suppressor proteins was 
associated with over-expression of PPARγ truncated proteins, suggesting that 
expression of truncated PPARγ was related to resistance to tumour therapy and 
might be involved in regulating pathways associated with PPARγ in tumour 
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tissues (Kim et al., 2007).  Some evidence also suggested that an isoform switch 
of PPARγ was found in human lung squamous cell carcinoma among the nine 
tested cancer types. The switch of isoforms affected pathways regarding gene 
expression, development and metabolism. By comparing normal and tumour 
samples from the same patient, the amino acid sequence of PPARγ was found 
to be different (Sebestyen et al., 2015). Further experiments regarding the 
function of PPARγ transcript variants are needed to find out whether there is a 
link between expression of different variants and phenotype of NHU cells 
(proliferating or differentiated) and role in UC. 
6.3.2 Post-translational modification and protein degradation 
6.3.2.1 SUMOylation 
One report using in vitro transcription/translation system suggested that 
PPARγ2 was able to be SUMOylated after addition of SUMOylation pathway 
proteins, as extra bands at about 75kDa were observed and considered as single 
SUMOylated PPARγ. Some other higher bands were considered as double 
SUMOylated PPARγ. Lysine 107 on PPARγ2 could be a potential site of 
SUMOylation; mutation on this amino acid resulted in reduced SUMOylation 
of PPARγ (Floyd and Stephens, 2004). 
Another report also demonstrated that exogenous SUMOylation of PPARγ in 
HEK293 cells was impaired when cells were treated with PPARγ ligands like 
GW1929 or rosiglitazone. The SUMOylation site affected by binding of ligands 
was lysine 33 but not lysine 77 on PPARγ1 protein (lysine 107 on PPARγ2) 
(Diezko and Suske, 2013). 
6.3.2.2 Ubiquitination 
The stable expression of PPARγ was also reported to be regulated by HAUSP 
(herpes virus-associated ubiquitin-specific protease). This regulation 
deubiquitinated PPARγ proteins and was detectable for both endogenous and 
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exogenous expression of PPARγ. Deubiquitination of PPARγ resulted in the 
expression of more stable PPARγ proteins at protein level, whereas the 
transcripts of PPARγ were stable and not affected by HAUSP expression (Lee et 
al., 2013). Most importantly, deubiquitination of PPARγ by HAUSP increased 
the transcriptional activity of PPARγ independent of the presence of PPARγ 
ligand (e.g., rosiglitazone). This enhanced transcription of PPARγ was reversed 
by siRNA knockdown of HAUSP or mutation on C223 of HAUSP, which 
confirmed the role of deubiquitination of PPARγ by HAUSP in maintaining the 
PPARγ transcriptional activity. In vivo experiments in mouse liver also verified 
the regulation on PPARγ by HAUSP, as oil red stain increased along with 
enhanced protein expression of PPARγ. Downstream adipogenesis-associated 
transcripts were up-regulated significantly (Lee et al., 2013). 
6.4 Ideas for future work 
 To test whether ELF3 was regulated by ERBB2 in NHU cells, ERBB2 
inhibitor could be used on nearly confluent cultures. 
 Whether PI3K/AKT pathway affected growth of ELF3 over-expressed NHU 
cells might be examined by checking the p-AKT and E-cadherin in the cells.  
 The growth inhibition induced by SB415286 in 5637 cells may be controlled 
by p-AKT (Fig 6.1.1), and could be examined by IF or western blotting. 
 If the alteration of PPARγ localisation in 5637 cells is reproducible by IF, 
cytoskeletal extraction can be performed to check the result and understand 
whether the protein has interaction with the nuclear matrix. 
 PPARγ protein might be modified and not detectable. Sumoylated or 
ubiquitinated isoforms might be alternative forms and appear at different 
height on the blot.  
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Appendix A Transcript and protein expression of 
differentiation-associated markers 
Appendix A1 Transcript of KRT20 in UC cell line (log scale) 
 
Fig Appendix A1 Transcript expression of CK20 (KRT20) in UC cells using log scale. RNA 
samples were obtained from cancer cells cultured in medium with serum or adapted to KSFM 
(5637 cells and T24 cells). 5637RPMI indicated RNA sample of 5637 cells cultured in RPMI with 
serum; T24DR indicated RNA sample of T24 cells cultured in DMEM& RPMI with serum. 
Proliferating (NHU pro) and 7 days TZ/PD differentiated (NHU dif) NHU cells (Y1289) were 
included as control. RT-QPCR was performed. Gene expression of KRT20 was normalized to 
GAPDH. Fold change of each sample was obtained by comparing to the proliferating NHU cell 
sample. Log scale was used to demonstrate the difference between cell lines showing low 
KRT20 transcript. Error bars indicate standard deviation of three technical replicates.  
  
 
Appendix A2 Comparisons of PPARγ protein isoforms between UC cells and 3T3-L1 cells 
 
Fig Appendix A2 Blots showing the different PPARγ isoforms in various UC lines, two buccal epithelial cell lines and 3T3-L1 cells. All UC cell lines were 
cultured in growth media supplemented with serum. 3T3-L1 lysate was obtained using nuclear protein preparation by Jonathan Fleming. Buccal cell lysates were 
proliferative cultures generated by Arianna Hustler. The left blot was immunolabelled with PPARγ2 antibody (Abcam), whereas the right one was labelled with 
PPARγ E8 antibody (Santa Cruz) for total PPARγ protein isoforms. Dotted red line showed the upper band present in the majority of UC cell lines at 52kDa using 
total PPARγ antibody and not detectable in 3T3-L1 cells using γ2 antibody. The distinguished band present in 3T3-L1 cells noted with yellow dotted line was not 
obvious in UC cells but was at about the height of the bands detected in buccal cell lines and NHU cells (Fig 4.3.3). The work was done together with Dr. Carl 
Fishwick and Han Yang. 
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Appendix A3 Repeat of interested RT-PCR showing expression of 
PPARγ transcripts 
A                                                                                           B  
    
Fig Appendix A3 Expressing pattern of PPARγ transcripts. Primers targeting different exons 
were used. Primer sets demonstrating difference between proliferating and differentiated NHU 
cells in chapter 5 were used in other two different NHU cell lines (A, Y1194; B, Y1529) to verify 
the previous identified expressing trend.  The enhanced expression of band smaller than 300bp 
detected using primer sets 2F4R was speculated to be relevant with a more proliferative 
phenotype observed in Fig 5.4.2 and panel B. However, the difference of PPARγ transcript 
amount showed no consistency compared to previous data, which might be dependent on 
different cell lines. 
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 Appendix A4 Comparison of ELF3 antibodies by western blots 
Fig Appendix A4 Comparison of two ELF3 rabbit antibodies. A, ab97310; B, ab133621. Arrows 
indicate the ELF3 full length protein band that is absent in the proliferating (Pro) control. 
Detailed information regarding these two antibodies is listed in Table 2.6.1. Ab97310 was the 
antibody used for IHC showing positive staining in urothelial tissue, whereas ab133621 does 
not work by IHC. 
Appendix B Primer efficiency test 
Newly designed primer sets for RT-qPCR were optimised before use in 
experiments. Results of optimised primers are shown. 
 
A 
Day 2 Day 4 Day 6 
S S S ELF3 k/d ELF3 k/d ELF3 k/d 
Pro     Dif 
B 
Day 2 Day 4 Day 6 
S S S ELF3 k/d ELF3 k/d ELF3 k/d 
Pro     Dif 
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Fig Appendix B Primer efficiency test for KLF5, GRHL3, IRF1 and CLDN7. Primer sets for 
RT-qPCR were tested using relative standard curve program. Samples known for expression of 
target primers were diluted gradually (1, 1/10, 1/100, 1/1000). Standard process was performed 
including melt curve cycle. Acceptable optimised primers are supposed to demonstrate a 
unique peak with slope of -3.333 (±10% deviation) and R square of 0.999 (±10% deviation).  
  
 
Appendix C Example of analysing IHC slides using HistoQuest Software 
 
Fig Appendix C1 Analysis of IHC slides using HistoQuest. ELF3 knock down cell sheet was used as an example to show the workflow of the analysing process. 
  
 
 
Fig Appendix C2 Creation of ROI (region of interest). ROI was created to set up parameters of analysis. 
  
 
 
Fig Appendix C3 Magnification of ROI. ROI was magnified and indicated by a rectangular. 
  
 
 
Fig Appendix C4 Autodetection of nuclei. Haematoxylin and DAB staining were used as markers of nuclear labelling. After defining size of nuclei, staining 
background and setting of the threshold, nuclei were picked up by the software (surrounded by green circles). 
  
 
 
Fig Appendix C5 Manual correction. Manual corrections were applied if the nuclei were not selected correctly. 
  
 
 
Fig Appendix C6 Corrected nuclei. Nuclei were labelled with green circles. 
  
 
 
Fig Appendix C7 Backward gating and set up of cut-off value. Cut-off value was set based on the DAB staining of positive/negative cell population. Individual cells 
were linked with corresponding data points and can be visualized by backward gating.  
  
 
 
Fig Appendix C8 Percentage of positive staining cells. By viewing of backward data in upper quadrant, positive PPARγ staining cells were indicated by red circles. 
Percentage of positive cells was shown (bottom right corner, red oval). 
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Fig Appendix C9 Positive staining of nuclear PPARγ in control and ELF3 knock down cell 
sheets. Percentage of positive staining cells was demonstrated by upper quadrant cell 
population and noted by red arrow.A and B, scramble control; C and D, ELF3 knock down.   
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Appendix D Buffer recipe 
 
 0.1% EDTA 
1 g EDTA disodium salt in 1000 mL of PBS (made from 10x DPBS (Gibco) in 
Elga distilled water). 
 
 Trypsin Inhibitor (TI):  
Trypsin Inhibitor- Sigma T6522 100 mg stored at 4 °C (1 mg TI inhibits 1.94 mg 
trypsin)  
Dissolve 100 mg vial in 5 mL D-PBS, aspirate into a syringe and filter sterilise 
with 0.2 µm filter.  
Aliquot 100 µL into Universal tubes, store at -20 °C.  
One aliquot inhibits 1 mL of TV  
 
 Trypsin in Versene (TV):  
Trypsin - Sigma T4549 100 mL (10 x solution)  
On arrival thaw and aliquot into 20 mL -store at -20 °C  
20 mL Trypsin  
4 mL 1% EDTA  
176 mL HBSS (without Ca2+ and Mg2+)  
Aliquot into 5 mL and store at -20 °C  
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 10% (v/v) Formalin in PBSc  
100 mL 37% Formalin  
900 mL PBSc  
PBSc 0.5 mM MgCl2 , 0.9 mM CaCl2  
998.6 mL PBS  
900 L 1M CaCl2  
500 L 1M MgCl2 
 
 10xTris Borate EDTA (TBE) 
108 g of Tris 
55 g boric acid 
9.1 g EDTA 
 
 2x SDS Sample Buffer: 
10 mL Glycerol (20% v/v) 
1 g SDS (2% w/v) 
6.25 mL Tris-HCl (pH 6.8)  
0.42 g Sodium fluoride (NaF) 
18.4 mg Sodium orthovanadate (Na3PO4) 
0.446 g tetra-Sodium pyrophosphate 
dH2O up to 50 mL 
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Store at –20 °C in 5 mL aliquots 
 
 Transfer Buffer (1x): 
Tris   1.45 g (12 mM) 
Glycine 7.2 g (96 mM) 
Methanol 200 mL (20%) 
dH2O  to 1 L 
  
 Ponceau red (10X): 
5 g Ponceau 
10 mL glacial acetic acid 
dH2O up to 100 mL 
 
 TBS for western blotting 
Tris  1.21 g (10 mM) 
NaCl  8.18 g (140 mM) 
dH2O  to 1L 
pH 7.4 
 
 TBS-Tween 20 for western blotting 
Tris  1.21 g  10 mM 
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NaCl  8.18 g  140 mM 
Tween 20  0.1% 
dH2O to 1L 
pH 7.4 
 
 TBS for IF: 
50 mM Tris-HCl (pH 7.6) & 150 mM NaCl 
25 mL 2M Tris (pH 7.6)  
50 mL 3M NaCl  
10 mL 10% (w/v) NaN3 solution  
10 mL 10% (w/v) BSA in TBS  
Make to 1L with dH2O and store at 4 °C.  
 
 Antifade mountant  
0.1% (w/v) p-Phenylendiamino Dihydrochloride (Sigma) in 90% Glycerol.  
Dissolve 100 mg of p-Phenylendiamino Dihydrochloride in 10 mL PBS.  
Adjust to pH 8.0 with carbonate-bicarbonate buffer pH 9.6 (0.42 g NaHCO3 in 
10 mL H2O, adjust pH to 9.6 with NaOH).  
Add 90 mL Glycerol, mix well, store in the dark bottle at -20 °C.  
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 TBS for IHC 
0.05 M Tris-HCl + 0.15 M NaCl pH 7.6  
Stock solutions:  
3 M NaCl 175.32 g/L  
2 M Tris pH 7.6 242.28 g/L  
To make 1 L of TBS buffer  
25 mL of 2 M Tris pH 7.6  
50 mL of 3 M NaCl  
Make up to 1 L with dH2O  
 
 Citric Acid Buffer pH6.0  
0.8 g Citric Acid per 350 mL of water+ several pellets of NaOH, adjust pH to 6.0  
 
 0.1% Calcium Chloride (CaCl2) pH 7.8  
Dissolve 1 g of CaCl2 in 900 mL of dH2O, pH to 7.8 with NaOH, make up to a 
final volume of 1 L.  
 
 CSK buffer:  
 For 1 litre; 
Make 200 mL 50 mM PIPES (final 10 mM after dilution) and pH to 6.8 with 
KOH before adding any other reagents  
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Dilute to ~ 700 mL and add; 1 mM EGTA, 300 mM sucrose, 1 mM MgCl2 
(sufficient for 1 L). 
Make aliquots with: 
(500 mL) 0.1 M NaCl and No TX-100 
(400 mL) 0.5 M NaCl and 0.1% TX-100 
(100 mL) 1 M NaCl and 0.2 % TX-100 
On day of experiment add ATP to 0.1 mM, 1/1000 protease inhibitors, DTT 
to 1 mM and PMSF to 1mM  
Add PMSF immediately before harvesting /incubations as it has a lifetime 
in aqueous solution of < 5 min 
 
 1X DNaseI buffer: 
10 mM Tris pH 7.5, 10 mM MgCl2, 5 mM CaCl2.  
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Appendix E List of suppliers 
Abcam 332 Cambridge Science Park 
Milton Road 
Cambridge 
CB14 0WN 
 
Ambion Supplied by fisher Scientific 
  
Applied Biosystems Supplied by Life technology 
  
Becton-Dickinson The Danby BuildingEdmund Halley 
Road 
Oxford Science Park 
Oxford 
OX4 4DQ 
 
Bioline Bioline Reagents Limited, Unit 16 
The Edge Business Centre Humber 
Road 
London 
NW2 6EW 
 
BioRad Maxted Road 
Hemel Hempstead 
Hertfordshire  
HP2 7DX 
 
Calbiochem Supplied by Millipore 
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Cell Signaling New England Biolabs (UK) Ltd. 
75-77 Knowl Piece 
Wilbury Way 
Hitchin, Hertfordshire 
SG4 0TY 
 
Clontech 2 Avenue du President Kennedy 
78100 Saint-Germain-en-Laye 
France 
 
Corning Elwy House 
Lakeside Business Village 
St. David's Park 
Flintshire 
CH5 3XD 
 
Cymbus Unit J Eagle Close 
Southampton 
Hampshire 
 
Dako Cambridge House 
St Thomas Place, Ely 
Cambridgeshire 
CB7 4EX 
 
Dynex Yeoman Gate, Yeoman Way 
Worthing 
West Sussex 
BN13 3QZ 
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Eurofins Eurofins Genomics 
Anzinger Str. 7a 
85560 Ebersberg 
Germany 
 
Fisher Scientific Bishop Meadow Road  
Loughborough  
LE11 5RG 
 
GraphPad 7825 Fay Avenue, Suite 230 
La Jolla, CA 92037 USA 
 
Greiner Bio-One Brunel Way 
Stroudwater Business Park 
Stonehouse 
 
GSK Harmire Road 
Barnard Castle, County Durham 
DL12 8DT 
 
Harlan Sera-Lab 1 Westminster Way 
Oxford 
OX2 0PZ 
 
Invitrogen Supplied by Life technology 
  
Li-CoR St. John's Innovation Centre 
Cowley Road 
Cambridge 
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CB4 0WS 
 
Life Technologies 3 Fountain Drive 
Inchinnan Business Park 
Paisley  
PA4 9RF 
 
Media Cybernetics Beech House 
27 Little Marlow Road 
Marlow 
Buckinghamshire 
SL7 1HA 
 
Millipore Croxley Green Business Park 
Watford 
Hertfordshire  
WD18 8YH 
 
Molecular Probes Supplied by Life technology 
 
Novocastra Larch House, Woodlands Business 
Park, Breckland, Linford Wood 
Milton Keynes 
MK14 6FG 
 
Pierce Supplied by Life technology 
 
Promega 
 
Delta House 
Southampton Science Park 
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Southampton  
SO16 7NS 
 
Qiagen 
 
Skelton House 
Lloyd Street North 
Manchester 
M15 6SH 
 
RA Lamb 
 
Supplied by fisher Scientific 
 
Roche 
 
Charles Avenue 
Burgess Hill 
West Sussex 
RH15 9RY 
 
Santa Cruz 
 
10410 Finnell Street 
Dallas, Texas 75220 
U.S.A. 
 
Scientific Laboratory Supplies 
 
Orchard House, The Square, Hessle 
East Riding of Yorkshire 
HU13 0AE 
 
Serotec 
 
Endeavour House 
Langford Lane 
Kidlington 
OX5 1GE 
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Sigma Aldrich 
 
The Old Brickyard 
New Road Gillingham 
Dorset 
SP8 4XT  
 
Source Bioscience 
 
1 Orchard Place 
Nottingham Business Park 
Nottingham 
NG8 6PX 
 
Starlab 
 
5 Tanners Drive 
Blakelands 
Milton Keynes  
MK14 5BU 
 
Syngene 
 
Beacon House 
Nuffield Road 
Cambridge 
CB4 1TF 
 
Thermo Scientific 
 
Unit 5/Ringway Centre 
Edison Road 
Basingstoke 
RG21 6YH 
 
TissueGnostics 
 
TissueGnostics GmbH 
Taborstraße 10/2/8 
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1020 Vienna 
Austria 
 
 
Veolia Water Technologies Windsor Court 
Kingsmead Business Park 
High Wycombe 
HP11 1JU 
 
VWR Hunter Boulevard 
Magna Park 
Lutterworth, Leicestershire 
LE17 4XN 
 
Zeiss 509 Coldhams Lane 
Cambridge 
CB1 3JS 
 
Zymed Supplied by Life technology 
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Glossary 
 
AUM asymmetric unit membrane 
CSK Cytoskeleton 
CK Cytokeratin 
EGFR Epidermal growth factor receptor 
EMT Epithelial–mesenchymal transition 
GSK3β Glycogen synthase kinase-3β  
KSFM Keratinocyte serum-free medium  
MIBC muscle invasive bladder cancer 
NHU Normal human urothelium 
PD PD153035, EGFR inhibor 
TER transepithelial electrical resistance 
TJ Tight junction 
TZ troglitazone, PPARγ activator 
UC Urothelial cancer 
UPEC Uropathogenic Escherichia coli 
UPK Uroplakin 
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